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ABSTRACT 
 
  
Many successful initiatives have been employed to stem the spread of the diseases such as 
malaria and trichomoniasis. However, in cases where infection has occurred, pharmaceutical 
treatments are required. A problem seen across the board is the development of resistance to 
known treatments. An even bigger problem has been the development of resistance to 
promising compounds during the clinical trial phase. This has led to the need for effective 
treatments which are able to overcome the resistance problem.  
 
This study investigated the synthesis, characterisation and pharmacological evaluation of new 
bioorganometallic organosilane‒containing compounds based on thiosemicarbazone (TSC), 
quinoline and benzothiazole scaffolds. Selected thiosemicarbazone‒containing ruthenium(II), 
rhodium(III) and palladium(II) metal complexes were also studied. The compounds were 
screened for antiplasmodial and antitrichomonal activity, along with their activity against 
A2780 human ovarian carcinoma and WHCO1 oesophageal cancer cell‒lines.  
 
A series of ferrocenyl‒ and aryl‒derived organosilane thiosemicarbazones were synthesised, 
along with an aryl‒derived carbon analogue. Coordination of these thiosemicarbazones with 
[Ru(η6-p-iPrC6H4Me)Cl2]2 and [Rh(Cp*)Cl2]2 yielded N,S‒chelated heterobimetallic 
ferrocenyl‒derived TSC and mononuclear aryl‒derived TSC complexes. Furthermore, ortho‒ 
cyclopalladated complexes were prepared via C‒H activation of selected thiosemicarbazones 
by cis‒[Pd(PTA)2Cl2]. These compounds were fully characterised using NMR (1H, 13C{1H}, 
31P{1H}, COSY, HSQC) spectroscopy, infrared spectroscopy and mass spectrometry [electron 
impact, electrospray ionisation]. 
 
The thiosemicarbazone‒based compounds were evaluated for their antiplasmodial activity 
against the NF54 chloroquine−sensitive (CQS) and Dd2 chloroquine−resistant (CQR) strains 
of Plasmodium falciparum. The aryl‒derived cyclopalladated complexes were found to be the 
most potent, displaying activity below 1 μM against both strains. Furthermore, the 
organosilane‒containing compounds were generally less toxic when screened against the 
Chinese Hamster Ovarian (CHO) cell‒line. One of the biological targets of antimalarial 
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compounds is haemozoin. Therefore, a metal−free TSC and selected rhodium(III) complexes 
were screened to investigate their ability to inhibit β‒haematin formation (synthetic 
haemozoin). The rhodium complexes displayed inhibitory effects on the formation of 
β‒haematin. Subsequent to the in vitro studies mentioned above, an aryl‒derived 
organosilane‒containing cyclopalladated complex was further evaluated in an in vivo P. 
berghei infected mouse model. No significant effect on percentage parasitaemia was observed.  
 
The thiosemicarbazone compounds were also screened against the metronidazole−sensitive G3 
strain of Trichomonas vaginalis to establish if thiosemicarbazones are selective towards 
particular parasites. The ruthenium and rhodium complexes were the most effective growth 
inhibitors of T. vaginalis parasites, generally displaying inhibition above 90 %. Following on 
from the screening against parasites, selected ferrocenyl‒derived thiosemicarbazone 
compounds were evaluated against cisplatin‒sensitive (A2780) and cisplatin‒resistant 
(A2780cisR) tumourigenic cell‒lines, where the ruthenium complex exhibited the highest 
cytotoxicity against both cell‒lines (IC50 = 12.4 and 18.9 µM, respectively). The tested 
compounds were further tested against the non−tumourigenic KMST-6 human fibroblast cells 
and displayed similar activities compared to the cancer cell‒lines.   
 
A series of ferrocenyl‒containing aminoquinolines, consisting of both organosilane and carbon 
analogues, were prepared and fully characterised using NMR (1H; 13C{1H}; COSY; HSQC) 
spectroscopy, infrared spectroscopy and electron impact mass spectrometry. The structure of 
the ferrocenyl‒containing aminoquinolines were further confirmed by the molecular structures 
of two compounds which were determined using single−crystal X−ray diffraction. Both 
compounds crystallise in a folded conformation due to intramolecular hydrogen bonding 
between the nitrogen atoms on opposite sides of the ferrocenyl moiety. 
 
Following on from the aminoquinoline compounds, a series of ferrocenyl‒containing 
aminobenzothiazoles, consisting of both organosilane and carbon analogues, were synthesised 
and fully characterised using NMR (1H; 13C{1H}; COSY) spectroscopy, infrared spectroscopy 
and mass spectrometry (Electron Impact; Electrospray Ionisation). 
  
The ferrocenyl‒containing aminoquinolines and aminobenzothiazoles were screened for their 
activity against NF54 and Dd2 strains of P. falciparum. The aminoquinolines were generally 
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more effective than the aminobenzothiazoles. However, the aminobenzothiazoles were more 
selective towards the resistant strain than the sensitive. Additionally, the aminoquinolines were 
effective inhibitors of β‒haematin formation, as opposed to the aminobenzothiazole compound 
which displayed no inhibitory effects. Metabolic stability studies of the aminoquinolines 
revealed that the compounds metabolise more quickly than ferroquine. When evaluated against 
the T. vaginalis, the ferrocenyl−containing aminoquinolines and aminobenzothiazoles 
displayed inhibitory effects of parasite growth with moderate IC50 values. Further studies 
against the WHCO1 oesophageal cancer cell‒line revealed that the aminoquinoline and 
aminobenzothiazole compounds displayed cytotoxicity, with the aminobenzothiazole (IC50 = 
1.74 µM) displaying good potency.      
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SEM Scanning Electron Microscope 
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CHAPTER 1 
Literature review 
 
 
1.1  Introduction  
Parasites can inhabit organisms such as insects, plants, animals and humans. Parasites may either 
use the host organism only as a breeding ground (carrier) while waiting for the opportunity to 
infect another organism, or the organism can be infected as well as affected by the parasite. 
Overlooking the impact on food supplies when animals such as cattle are infected by parasites, 
another major concern is the effect parasites have on human beings. The effects of parasitic 
diseases may range from a simple cold to death, therefore the management and treatment of 
parasitic diseases is crucial.   
 
1.2  Malaria 
Malaria, a disease caused by the Plasmodium protozoan parasite, is transmitted by certain types 
of female Anopheles mosquitoes which function as carrier organisms. Five species of 
plasmodium are reported to infect humans, namely Plasmodium falciparum, P. vivax, P. 
malariae, P. ovale and P. knowlesi (originally an ape strain).1 P. falciparum and P. vivax are the 
most prevalent, with P. falciparum being the most deadly species.  
 
 
Figure 1.1  A world map illustrating the different regions affected by malaria.2  
 
In areas such as the tropical and subtropical regions (Figure 1.1) with ideal climate conditions 
for parasite reproduction (e.g. humidity), as well as densely populated areas which allow for the 
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easy transmission from mosquito to human and vice versa, the survival of the parasite is ensured. 
Therefore, areas which meet these conditions, such as Africa, are affected with 90 % of the 198 
million clinical cases reported in 2013.3 Treatments may aid in reducing the number of reported 
cases. Therefore, understanding how the parasite reproduces, particularly identifying the stages 
which can be targeted by potential drugs, is an important aspect to be familiar with.  
 
1.2.1  Life cycle of the parasite 
The first step in the life cycle of the malaria parasite involves infection of the human host by a 
female Anopheles mosquito carrying the malaria-causing parasites, in the form of sporozoites, 
into the bloodstream (Figure 1.2). The sporozoites travel to the liver via the bloodstream and 
invade liver cells where sporozoites develop into merozoites. However, some malaria parasite 
species do not immediately start the conversion process from sporozoites to merozoites and 
instead remain dormant in the liver, causing patient relapses weeks or months later.4    
 
 
Figure 1.2  Life cycle of the malaria parasite.5 
 
Merozoites enter the bloodstream where the red blood cells are invaded, and over the course of 
1−3 days of asexual replication, leads to the formation and release of thousands of merozoites 
which in turn leads to illness if not treated (Figure 1.2). A portion of the merozoite−infected 
blood cells are involved in the development of the parasite into gametocytes (male and female 
sexual forms). These merozoite−infected blood cells circulate in the bloodstream and are 
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available for ingestion by the next mosquito, which bites the infected host, thereby facilitating 
transmission of the parasite.4 Further development of the parasite occurs within the gut of the 
mosquito. Following the bursting of infected blood cells, gametocytes are released and develop 
into mature sex cells called gametes. The fusing of male and female gametes leads to the 
formation of diploid zygotes which develop into ookinetes. Further development to oocytes 
occurs in the midgut wall.  After replication of oocytes, sporozoites are formed which are 
available to be transferred to the next host.4    
 
1.2.2  Survival and defence mechanism of the malaria parasite    
Infection of the host organism by plasmodium initiates a series of events allowing for parasite 
survival (Figure 1.3). The first step involves ingestion and transportation of haemoglobin to the 
parasite’s digestive vacuole where various proteases such as the cysteine proteases (falcipains II 
and III)6, metalloprotease falcilysin7 and aspartic proteases plasmepsin8 are employed in the 
digestion of haemoglobin to short peptides. These peptides are transported out of the digestive 
vacuole and converted to amino acids which are the parasite’s food source.  
 
 
Figure 1.3  The proposed sequence of events following haemoglobin degradation.  
 
Upon degradation of haemoglobin, free haem is released. Oxidation of the iron in free haem, 
from Fe(II) to Fe(III), by molecular dioxygen produces ferriprotoporphyrin IX (Fe(III)PPIX) and 
reactive oxygen species (ROS), namely hydroxyl radicals.  Hydroxyl radicals are known to be 
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disruptive to lipid membranes; leading to the death of the parasites.9 However, the parasite has 
developed a defence mechanism whereby the cytotoxic haematin is converted to non-toxic 
haemozoin via biomineralisation. Haematin dimers, linked via hydrogen bonds between the iron 
and the propionic acid side chain of the adjacent haem, are able to form chains. The chains, 
which exist due to the hydrogen bonded propionic acid side chains, form low solubility 
haemozoin crystals (β−haematin) which accumulate in the food vacuole.10 
 
1.2.3  Current and previously used antimalarial treatments 
Throughout the years, various compounds have been synthesised and evaluated as 
antiplasmodial agents, with a select few compounds becoming successful antimalarial drugs. The 
treatment of malaria using quinoline−based compounds such as quinine and chloroquine became 
a popular route. However, despite the success of these antimalarial drugs, other classes of 
compounds were explored to circumvent the parasite developing resistance to the treatments. A 
method to prevent resistance development is through treatment with compounds which operate 
via a variety of mechanisms. One class of compounds evaluated were artemisinin and its 
analogues.  
 
Artemisinin and its analogues operate via the formation of ROS. Reactive oxygen species are 
generated by the cleavage of the peroxide bond in the 1,2,4-trioxane core of artemisinin−type 
compounds (1.1; Figure 1.4).11 In an attempt to slow down the emergence of resistance, 
artemisinin−based combination therapies (ACTs) were developed.12 ACTs comprise of two 
antimalarial drugs, which act via different mechanisms, and at different rates, are used in 
combination to combat resistant strains. The combination involves the use of a fast acting 
artemisinin derivative and a compound with a longer half−life.13 Therefore, artemisinin 
derivatives such as artemether (1.2; Figure 1.4) are marketed as combination therapies such as 
CoartemTM [artemether/lumefantrine (1.3; Figure 1.4)].13 Artemether has a short half−life (t½ = 
3‒7 hr) and quickly kills off a majority of the parasitaemia. Lumefantrine (t½  = 4‒6 days) on the 
other hand, has a longer half−life, allowing for removal of any remaining parasites.13 Other 
combinations are dihydro-artemisinin/piperaquine and artesunate with either amodiaquine or 
mefloquine. 
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1.1 
 
1.2     
 
1.3 
Figure 1.4  Endoperoxide compounds artemisinin (1.1) and artemether (1.2) [in combination with lumefantrine 
(1.3)] were evaluated as antimalarial agents.11,13,14 
 
Additionally, antifolates and protease inhibitors (e.g. cysteine proteases) have also been of 
interest. Antifolates, for example, target the folic acid cycle (involves the transfer of one−carbon 
unit during the synthesis of DNA components such as amino acids, nucleotides and other 
biomolecules). Therefore antifolates such as pyrimethamine [1.4, in combination with 
sulfadoxine (1.5); Figure 1.5] inhibit enzymes such as dihydrofolate reductase (DHFR) and 
dihydropteroate synthase (DHPS), which are involved in parasite folate biosynthesis.15  
 
 
                                                        1.4 
 
1.5 
Figure 1.5  The antimalarial combination treatment Fansidar [pyrimethamine (1.4)/sulfadoxine (1.5)].15 
 
As previously mentioned, drug resistance is a major problem. Due to this, there is a continuous 
search for new drugs, which has led to the development of a wide range of compounds displaying 
promising activities in vitro and in vivo. However, the main difficulty in drug discovery is finding 
a potential drug which satisfies the requirements for both pre−clinical and clinical trials. 
Furthermore, malaria is not the only parasitic disease affected by drug resistance. Other parasitic 
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disease such as leishmaniasis, schistosomiasis and trichomoniasis, to name a few, are also 
plagued by drug resistance. In particular, the reported number of trichomoniasis cases has 
steadily been on the rise. 
 
1.3  Trichomoniasis 
Trichomoniasis is a parasitic disease, caused by the protozoan Trichomonas vaginalis, which is 
one of the most prevalent sexually transmitted parasitic diseases. The major concern with regard 
to trichomoniasis is the increased risk of acquiring HIV, cervical cancer and aggressive prostate 
cancer.16–18 It is estimated that in 2008, there were 187.0 million people infected with T. vaginalis 
globally, of which 42.8 million were located in Africa.19 
  
1.3.1  Life cycle of the parasite  
The life cycle of the Trichomonas vaginalis parasite is not well understood. The trophozoite 
(lacking a cystic stage) of the parasite is transferred during sexual intercourse and divides by 
longitudinal binary fission (cytoplasmic division along the longitudinal axis of the individual). 
This gives rise to a parasite population in the lumen and on the mucosal surfaces of the urogenital 
tracts of humans.20 
 
1.3.2  Survival and defence mechanism of the T. vaginalis parasite    
It is evident from previous studies that the parasite obtains its nutrients via the phagocytosis of 
various host cells (e.g. leucocytes, vaginal epithelial cells).21 The mechanism by which the 
parasite evades the host immune system is of significance. It is believed that leucocytes (white 
blood cells) are phagocytosed to circumvent any immune responses, which is illustrated in Figure 
1.6.21,22 Furthermore, the parasite contains proteases which degrade immunogenic cytokines and 
antibodies, preventing an immune response.23,24  
 
 
a 
 
b 
Figure 1.6  SEM photos illustrating the idea that the T. vaginalis (green) ingests the cells via phagocytosis. (a) 
Trichomonad phagocytosing yeast (yellow) and bacteria (pink) cells. (b) Cells completely internalised by the 
parasite.22 
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1.3.3  Current and previously used antitrichomonal treatments  
The current treatment of T. vaginalis is limited to 5-nitroimidazole compounds, such as 
metronidazole (1.6; Figure 1.7), tinidazole (1.7; Figure 1.7), ornidazole, secnidazole and 
nimorazole to name a few, which are effective drugs against protozoal infections.16,25–28 
Metronidazole, a derivative of azomycin (1.8, 2-nitroimidazole; Figure 1.7) which was one of 
the first antiprotozoal agents, was introduced in 1959 and became one of the first and most 
successful antitrichomonal drugs. This drug is believed to diffuse into the hydrogenosomes of 
the parasite, where the nitro group is reduced by the flavin enzyme thioredoxin reductase, 
resulting in the formation of cytotoxic nitro radical−ion intermediates which are able to interact 
with DNA.29 This interaction cleaves the DNA, disrupting mitosis and resulting in cell death. 
The other end−products are inactive and excreted.29 However, as mentioned for antimalarial 
drugs, there is evidence for the emergence of metronidazole−resistant T. vaginalis strains. 
 
 
                     1.6  R = CH2CH2OH 
 1.7  R = CH2CH2SO2CH2CH3 
 
           
1.8 
Figure 1.7  5-Nitroimidazole compounds metronidazole (1.6), tinidazole (1.7) and azomycin (1.8) which are 
active against T. vaginalis.16  
 
This led to the synthesis of tinidazole, a derivative of metronidazole. It is proposed that the drug 
works in a similar manner to metronidazole, though tinidazole (t½ = 12‒14 hr) has a longer 
half−life than metronidazole (t½ = 6‒7 hr) making it more favourable as it reduces the 
administered dosage.20 Tinidazole has also exhibited good tissue penetration and with the 
reduction of tinidazole, a gradient is created which allows for the influx of more tinidazole, 
providing more prodrug to be reduced and increasing bioavailability.30 As is the case with 
malaria, new antitrichomonal compounds based on a scaffold other than nitroimidazole are 
required in an attempt to overcome the resistance problem. 
 
1.4  The application of metals in the medical field    
Metals have been recognised for their medicinal properties and used for the treatment of various 
diseases.31–33 Gold compounds have been used for centuries; however the 20th century brought 
about their use in the treatment of rheumatoid arthritis.34 Research into the synthesis and 
Chapter 1: Literature review 
 
8 
 
biological evaluation of inorganic and organometallic complexes have significantly increased 
since the success of complexes such as cisplatin (1.9; Figure 1.8).4,35–41  
   
 
1.9 
           
1.12 
 
1.10 
 
1.11 
Figure 1.8  Clinically approved platinum−based complexes cisplatin (1.9), carboplatin (1.10), oxaliplatin (1.11) 
and the ruthenium complex (N)KP1339 (1.12) which is currently in clinical trials.42 
 
However, due to the cytotoxicity of cisplatin, second generation platinum compounds 
carboplatin and oxaliplatin (1.10 and 1.11, respectively; Figure 1.8) were investigated to 
overcome the drawbacks of cisplatin. As seen with malaria and trichomoniasis, drug resistance 
gradually develops and the anticancer drug loses its potency. Therefore, researchers began 
studies with other platinum group metals, such as ruthenium, which have displayed promising 
results. (N)KP1339 [1.12, sodium trans-tetrachlorobis-(1H-indazole)ruthenate(III); Figure 1.8] 
is an example of a ruthenium complex currently in clinical trials. (N)KP1339 was initially 
designed to mimic the DNA binding ability of platinum complexes, the mode of action appears 
to be DNA−independent. Especially the transport through serum protein binding and the 
activation by reduction only in cancer cells, may contribute to the low side−effects of this 
compound type.43 
 
Hydroxynaphthoquinones, such as atovaquone, have displayed antiplasmodial activities through 
the altering of mitochondrial membrane potentials.44 Therefore, Padhye and co−workers 
prepared transition metal (Cu, Ni, Co, Fe, Mn) complexes of the hydroxynaphthoquinone, 
buparvaquone, and evaluated them in vitro for biological activity against 3D7 (CQS) and K1 
(CQR) strains of P. falciparum.45 All the tested complexes displayed activity against the P. 
falciparum strains, with the Cu complex (1.13, Figure 1.9) displaying the highest activity [ED50 
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= 0.0002 (3D7) and 0.01 (K1) μg/mL]. Compound 1.13 exhibited a 1000−fold increase in 
activity compared to that of the uncoordinated buparvaquone [ED50 = 0.18 (3D7) and 0.03 (K1) 
μg/mL], as well as improved activity over chloroquine and atovaquone.45 Compound 1.13 was 
further evaluated in vivo in a Peter’s four−day suppression test against female mice infected with 
P. berghei. The results of the antimalarial study was promising as compound 1.13 cleared 90 % 
parasitaemia at a 15 mg/kg dose per day, while chloroquine cleared the parasite at a dose of 10 
mg/kg per day.45 
 
 
1.13 
 
 
1.14 
 
1.15 
Figure 1.9  Examples of complexes (1.13−1.15) evaluated as antiparasitics.45–47 
 
The clinically proven antiarthritic drug Auranofin (1.14, Figure 1.9) has also been evaluated as 
an antiplasmodial agent.46 Auranofin was tested against the 3D7 strain of P. falciparum and 
displayed nearly complete inhibition of P. falciparum growth at concentrations in the nanomolar 
range (IC50 = 142 nM).46 
 
In terms of antitrichomonal agents, one of the earliest known drugs was the organoarsenic 
Carbarsone (1.15, Figure 1.9).47 Nevertheless, the evaluation of metal complexes as treatments 
for other diseases is an ongoing challenge. 
 
1.4.1  The use of organosilanes 
Silicon chemistry has attracted a lot of interest due to the ability of silicon to favourably alter the 
chemical properties of a compound compared to the carbon analogue. Silicon has previously 
been incorporated into the scaffold of known drugs to either enhance the potency of the drug or 
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to remodel the drug to treat other diseases. Silicon−containing compounds generally exhibit 
enhanced pharmacological activity, and reduced cytotoxicity against non−infected cells, when 
compared to their corresponding non−silicon analogues.48–51 In cases where a compound enters 
the cell via membrane crossing, silicon−containing compounds have been associated with 
enhanced cell and tissue penetration. 
   
 
1.16 
 
1.17 
 
1.18 
Figure 1.10  Organosilicon compounds 1.16‒1.18 evaluated as biological agents.50–52 
 
Compounds 1.16‒1.18 (Figure 1.10) are examples of silicon−containing compounds which have 
exhibited significant biological activities. Compound 1.16, a silanediol protease inhibitor, has 
exhibited activity as an angiotensin converting enzyme inhibitor (IC50 = 3.8 nM), while 
compounds 1.17 (Zifrosilone) and 1.18 (Karenitecin) have been evaluated as treatment for 
Alzheimer’s disease and as an anticancer drug, respectively.48 Organosilane 1.18 was designed 
as the lipophilic analogue of camptothecin and intended to reduce toxicity. Compound 1.18 is 
currently undergoing phase III clinical trials in advanced ovarian cancer patients.51,53 
 
Organosilicon compounds have displayed not only activities in the nanomolar range, but also 
favourable pharmacokinetic properties. Coupled with the limited number of compounds which 
have been tested as antiparasitic agents, the evaluation of organosilanes and their complexes is 
a viable avenue to explore. Furthermore, the incorporation of pharmacophores, in combination 
with silane moieties, may further improve the biological properties of the proposed compounds. 
A pharmacophore is defined as the ensemble of steric and electronic features which are necessary 
to ensure optimal interactions with a specific biological target and to trigger (or block) its 
biological response. Therefore, the design of potential drugs would contain one or more 
pharmacophores. 
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1.5  Thiosemicarbazones 
Schiff base compounds such as thiosemicarbazones (TSCs, Figure 1.11) are formed via a 
condensation reaction between a carbonyl group and an amine group. Thiosemicarbazone 
systems contain donor atoms which allow for binding or chelation to various metals depending 
on the softness [Pd(II), Pt(II)] or hardness [Fe(III), Mg(II)] of the metal.54 The compounds can 
act as a monodentate (binding via the S atom)55, bidentate (chelate in a N,S fashion)56,57, or 
tridentate (N,N,S58,59, O,N,S60–62 or C,N,S63–65) ligands which allows for the formation of a wide 
range of complexes. Thiosemicarbazones have been tested for biological applications, and 
displayed pharmacological properties as antitumoural,56,60,61,64,66–68 antibacterial,69,70 
antiviral71,72 and antiparasitic60,63,64,73–77 agents.  
 
 
 = H, alkyl, aryl or heteroaromatic group 
Figure 1.11  The general structure of a thiosemicarbazone compound. 
 
Organic thiosemicarbazone compounds 
Studies focused on the evaluation of thiosemicarbazones as antiplasmodial and antitrichomonal 
agents are scarce in literature.73–75,78–80 Thiosemicarbazones were first regarded as 
antiplasmodial agents by Barrett and co-workers in 1965, and then in 1979 by Klayman and co-
workers who sought to reintroduce thiosemicarbazones with derivatives of 2-acetylpyridine 4-
phenyl-3-thiosemicarbazone.79–83 They expanded upon their initial work by evaluating the 
antimalarial activity of 2-acetylpyridine 1-oxide thiosemicarbazone.84 Compound 1.19 (Figure 
1.12) was the only active compound curing one out of five animals at 640 mg/kg. The pyridyl 
oxides were generally found to be less active than the parent pyridyl compounds.84  
 
 
1.19 
Figure 1.12  Thiosemicarbazone compound (1.19) evaluated as antiplasmodial agent.84 
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More recent work on thiosemicarbazones also focused on testing potential modes of action such 
as inhibition of cysteine proteases.75,78 Chiyanzu et al. have investigated potential cysteine 
protease inhibitors in the form of thiosemicarbazone derivatives of isatins.78 Previous studies on 
isatins revealed that these compounds inhibit cysteine and serine proteases.85,86 As mentioned 
before, inhibition of cysteine proteases has also been suggested as the mode of action for 
thiosemicarbazones. Therefore, the compounds were evaluated against three parasitic cysteine 
proteases namely cruzain, falcipain−2 and rhodesain. Compound 1.20 (Figure 1.13) exhibited 
good activity (IC50 = 10.5, 9.4 and 3 μM, respectively) against all three proteases.78   
 
Phenolic Mannich bases of benzaldehyde and thiosemicarbazone derivatives were synthesised 
by Chipeleme et al. as potential inhibitors of the cysteine protease falcipain−2, and tested against 
the CQ−resistant W2 strain of P. falciparum.75 Of the thiosemicarbazone−containing Mannich 
base compounds, compound 1.21 (Figure 1.13) showed the best overall inhibition of falcipain−2 
(IC50 value = 2.25 µM) and antiplasmodial activity against W2 (IC50 value = 3.75 µM).75 The 
presence of the quinoline suggests that the activity is related to haem−binding and the ability of 
the thiosemicarbazones to chelate endogenous iron in the cell.75  
 
 
1.20 
 
1.21 
 
1.22 
Figure 1.13  Thiosemicarbazone compounds (1.20‒1.22) evaluated as antiplasmodial agents.75,78,87 
 
Duan and Zhang explored the activity of aromatic iodide thiosemicarbazone compounds in vivo 
(mice) against P. falciparum.87 Work previously done on iodine containing compounds 
prompted this work as the compounds exhibited higher activity and lower toxicity than the 
corresponding chloro compounds. Compound 1.22 [4-(p-Iodophenyl)-3-thiosemicarbazone; 
Figure 1.13] exhibited the best activity with suppression percentages of 88.1, 90.7 and 92.6 at 
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concentrations of 3, 9 and 27 mg/kg, respectively. The authors concluded that the hydroxyl group 
was important for antimalarial activity and the iodine analogues were slightly more active than 
the chloro analogue.87  
 
 
1.23 
 
 
 
 
 
 
1.24 
Figure 1.14  Thiosemicarbazone compounds (1.23 & 1.24) evaluated as antitrichomonal agents.88,89 
 
Very limited research has focussed on the investigation of thiosemicarbazones as 
antitrichomonal agents.88,89 Michaels et al. investigated the use of bis(thiosemicarbazones) in 
vitro and in vivo as antitrichomonal agents. The in vitro tests revealed that the 
bis(thiosemicarbazone) with the terminal amine methylated is more active than the unsubstituted 
analogue. Pyruvaldehyde-bis(4-methythiosemicarbazone) [1.23; Figure 1.14] displayed 90 % 
inhibition at 3 ng/mL. In vivo tests were conducted on mice and hamsters, which were treated 
with the compounds orally, via injection and applied locally. However, these compounds were 
not able to cure chronically infected hamsters or the intravaginally infected mice. The authors 
believed this was due to the lack of local absorption of the compounds.89   
 
5-Nitrothiophene-2-carboxaldehyde thiosemicarbazone was evaluated as an antiprotozoal agent 
by Bharti et al. due to the antiprotozoal activity exhibited by previously evaluated 
thiophene−containing compounds.88,90,91 As antitrichomonal agents, compound 1.24 (Figure 
1.14) was the most active with an IC50 value of 1.49 μM (Metronidazole: 1.92 μM).88  
 
Metal−based thiosemicarbazone compounds 
Thiosemicarbazone complexes containing metals, such as copper92, nickel92, iron92, ruthenium93–
95 , gold55,57, palladium60–63,70,96 and platinum59,64,70,97,98 to name a few, have been investigated 
for their biological properties.  
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Some of the first thiosemicarbazone−based complexes evaluated as antimalarials were 
synthesised in the 1980’s. Scovill et al. prepared Cu(II), Ni(II), Fe(II) and Mn(II) complexes 
with 2-acetylpyridine thio− and selenosemicarbazones.92 The Cu(II), Ni(II) and Fe(II) complexes 
prepared using 2-acetylpyridine thiosemicarbazone ligands were evaluated in vivo against P. 
berghei infected mice. The thiosemicarbazone ligands exhibited activity at dosage levels of 40 
to 160 mg/kg, whereby 3/5 infected mice were cured. Upon complexation, the Cu(II) complexes, 
which includes compound 1.25 (Figure 1.15), were found to be the most active curing 5/5 
infected mice at a dose of 160 mg/kg. The Ni(II) complexes were inactive and the Fe(II) 
complexes were less active than the Cu(II) complexes.92 
 
 
1.25 
 
1.26 
 
 
 
 
 
 
 
 
1.27  R = H  
1.28  R = CH3 
 
Figure 1.15  Thiosemicarbazone complexes (1.25‒1.28) evaluated as antiparasitic agents.57,92,99 
 
Work by Khanye et al. focused on the use of Au(I) and Au(III) complexes as antiplasmodial 
agents.55,57 The Au(III) compound 1.26 (Figure 1.14) displayed activity (IC50 = 3.04 μM) in the 
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low micromolar range against the CQR W2 strain of P. falciparum.57 Khanye also worked on 
incorporating ferrocenyl thiosemicarbazones onto a poly(propyleneimine) dendrimer scaffold 
(Figure 1.15) and evaluated the antiplasmodial activity.99 There is a significant increase in 
activity when comparing compounds 1.27 and 1.28, which contains four ferrocenyl moieties, to 
the ferrocenyl dithiocarbamates (one ferrocenyl moiety). Compounds 1.27 and 1.28 were tested 
in vitro against the W2 strain of P. falciparum, and exhibited activity with IC50 values of 6.59 
and 1.79 μM, respectively. The other compounds were inactive at the highest tested 
concentration (20 μM).99 Compound 1.27 was further evaluated for its antitrichomonal properties 
against the metronidazole−sensitive G3 strain of T. vaginalis.100 Compound 1.27 displayed 
moderate inhibition (61.5 %) of parasite growth. 
 
Therefore, due to the potential of these compounds as antiparasitic agents, TSCs are a class of 
compounds which can further be explored. Other pharmacophores, including heterocycles, may 
prove to be a useful addition to potential antiplasmodial agents.  
 
1.6  Heterocyclic compounds 
1.6.1  Quinoline−based compounds 
Quinolines are heterocyclic compounds comprised of a benzene ring fused to a pyridine ring at 
two adjacent carbons (Figure 1.16). Quinolines have garnered significant attention due to their 
presence in a large number of natural products, as well as their prevalence in biologically active 
compounds displaying properties such as antimalarial14,101–103, antitumoural104–107  and 
antimycobacterial108 activity. 
 
    
    = H, NH, Halide, Aryl, etc. 
Figure 1.16  The general structure of a quinoline compound. 
 
Organic quinoline compounds  
As mentioned in section 1.2, quinine (1.29; Figure 1.17) was one of the first quinoline−based 
compounds used in the treatment of malaria. Quinine−containing materials were used since the 
17th century up until the 1940’s.14 The cost effectiveness of chloroquine (CQ, 1.30; Figure 1.17), 
and its success against various plasmodium strains, allowed for the world−wide use of the drug 
and the phasing out of quinine. Chloroquine is believed to act by binding to α−haematin through 
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π−π complexation to slow the rate of conversion to haemozoin, which is a non−toxic crystallised 
form of haematin.109 Despite the emergence of resistant strains, chloroquine is still being used to 
treat the sensitive strains, or in combination therapies, especially in developing countries. 
However, as chloroquine resistance increased, other quinoline−based compounds such as 
mefloquine (1.31) and amodiaquine (1.32) were evaluated with the prospect of different 
mechanisms of action (Figure 1.17).14 As with chloroquine, various other quinoline‒based 
compounds such as piperaquine (1.33) and naphthoquine (1.34) to name a few have been utilised 
in combination therapies.110,111 These quinoline based compounds generally inhibit β−haematin 
formation, while other functional groups either help with other properties such as changing the 
lipophilicity of the compound and assisting with accumulation in the vacuole.  
 
 
Figure 1.17  Quinoline based antimalarial drugs quinine (1.29), chloroquine (1.30), mefloquine (1.31), 
amodiaquine (1.32), piperaquine (1.33), naphthoquine (1.34) and trioxane (1.35).14,101,112,113 
 
Extensive work has been done to derivatise known quinoline-based drugs to afford new effective 
compounds which may overcome drug resistance.14,114,115 A method researchers have employed 
is to focus studies towards the synthesis of hybrid compounds. Coslédan et al. developed a series 
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of compounds which contain the 7-chloro-4-aminoquinoline base for inhibition of haemozoin 
formation, as well as the 1,2,4-trioxane motif present in artemisinin derivatives. Trioxaquine 
(1.35, PA1103/SAR116242; Figure 1.17) exhibited the best activity against D6 (CQS) and 
FcM29 (CQR) malaria strains in vitro with IC50 values of 7 and 10 nM, respectively.112 In vivo 
studies carried out on mice infected with rodent strains P. vinckei petteri (CQS strain) and P. 
vinckei vinckei (CQR strain) demonstrated that the antimalarial activity was similar. Therefore, 
due to the high antimalarial activity and the low toxicity of the compound, trioxaquine is 
currently in preclinical trials.112,116   
 
 
1.36 
 
 
 
 
1.37 
 
1.38 
Figure 1.18 Quinoline−based compounds (1.36‒1.38) evaluated as antitrichomonal agents.100,117,118 
 
Not many quinoline−based compounds have been investigated as potential treatment for 
trichomoniasis.100,117–119 The work by Nava−Zuazo et al. sought to derivatise chloroquine by 
synthesising hybrids containing the ethylenediamine spacer and phenylurea from ethambutol 
(first−line TB drug) and isoxyl (displays antimycobacterial activity), respectively.117 These 
compounds were tested against parasitic strains such as G. Intestinalis and T. cruzi to name a 
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few, but in terms of T. vaginalis the tested compounds exhibited moderate activity with 
compound 1.36 (Figure 1.18) exhibiting the best activity. Compound 1.36 exhibited an IC50 value 
of 8.44 μM, which is more active than chloroquine (30.0 μM) while compared to metronidazole 
(0.29 μM) the activity was approximately 30−fold less.117 
 
2-Alkenylquinoline compounds have exhibited a variety of biological properties and were thus 
exploited by Martinez−Grueiro et al. The observed inhibition of T. vaginalis growth was 
generally above 50 % for the tested compounds at the highest tested concentration (100 μM).118 
Compound 1.37 (Figure 1.18) exhibited the highest inhibition of 99.7 %. However, it was 
observed for all compounds that the percentage inhibition decreased as the concentration 
decreased.118  
 
Stringer et al. prepared a series of quinoline−based compounds conjugated onto a thiourea 
polyamine scaffold.100 These compounds were evaluated for their antiparasitic properties as 
antiplasmodial and antitrichomonal agents.100 The compounds, which includes the tetrameric 
1.38 (Figure 1.18), displayed moderate percentage inhibitions (< 60 %) against the T. vaginalis 
G3 strain.  
 
Metal−based quinoline compounds 
In terms of quinoline−based complexes evaluated as antiparasitic agents, research is primarily 
focused on antimalarial studies. One of the first organometallic complexes evaluated as an 
antimalarial agent was RhCl(COD)(CQ) [1.39, COD = cyclooctadiene; Figure 1.19] which was 
synthesised by Sánchez−Delgado et al.120 In addition to the rhodium complex, a binuclear 
ruthenium(II)−chloroquine complex (1.40; Figure 1.19) was also synthesised by the 
Sánchez−Delgado group.120  
 
Due to the low toxicity exhibited by ruthenium complexes, further research has gone into the 
synthesis of ruthenium−chloroquine complexes.120,121 In the case of the rhodium complex, 
chloroquine binds to the metal via the quinoline nitrogen atom, whilst for 1.40, the ruthenium is 
coordinated to two chloroquines, through the quinoline N of one chloroquine molecule and the 
diethylamine N of another, to form a dimer.120 Compounds 1.39 and 1.40 exhibited in vitro and 
in vivo activity against the rodent strain P. berghei. However, the ruthenium complex 1.40 
exhibited better activity than 1.39, as well as chloroquine diphosphate, with IC50 = 18 nM (in 
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vitro) and a 94 % reduction of parasitaemia (in vivo). Therefore, 1.40 was also evaluated against 
two chloroquine−resistant strains FcB1 and FcB2 (IC50 = 10.5 and 46.5 nM, respectively). The 
structure and basicity of the complex, as well as the presence of the Ru(II), contributed to the 
enhanced activity of the complex.120 
 
 
1.39 
 
1.40 
 
1.41 
 
1.42 
 
1.43 
Figure 1.19  Quinoline based metal complexes (1.39‒1.43) evaluated as antiplasmodial agents.120–123 
 
Ruthenium is able to access the oxidation states Ru(II), Ru(III) and Ru(IV) under physiological 
conditions. Ruthenium(II) complexes are generally more biologically active and lower in toxicity 
due to their ability to mimic iron. Iron(II) is able to bind to biological molecules and be excreted. 
Thus, ruthenium is able to reduce its concentration in the body in a similar manner as Fe(II), and 
is therefore less toxic.124 Ruthenium(II) ions can also be oxidised in a similar manner to Fe(II), 
allowing for electron transfer, and generation of reactive oxygen species which may play a role 
in parasite death. 
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Following on from the previously mentioned work, Sánchez−Delgado group investigated the 
activity of half−sandwich ruthenium(II)−chloroquine complexes containing arene moieties.121 
The arene ring is present in order to stabilise the metal, as well as possibly alter the lipophilicity 
of chloroquine, thus enabling transport of the complex to the active site. The 
ruthenium(II)−complexes were tested in vitro, and showed significant activity against resistant 
strains. Compound 1.41 (Figure 1.19) exhibited the highest activity with IC50 values (234 nM 
for Dd2) which were significantly lower than chloroquine diphosphate (1184 nM for Dd2).121  
 
Due to the medicinal uses of gold, Au(III)−chloroquine complexes were synthesised by Navarro 
et al. and their antiplasmodial activities evaluated.122 With the coordination of Au(III) to 
chloroquine, there is a change in the electronic properties of the 7-chloro-4-aminoquinoline base. 
The complex [Au(PPh3)(CQ)]PF6 (1.42; Figure 1.19) showed good activity against FcB1 and 
FcB2, with IC50 values of 5 and 23 nM, respectively,122 which was significantly lower than 
CQDP (47 nM for FcB1120 and 104.5 nM for FcB2120). Derivatives of compound 1.42, such as 
[Au(PEt3)(CQ)]PF6, displayed the highest activity against FcB1 with an IC50 value of 10 nM 
when compared to the activity of chloroquine diphosphate (IC50 = 50 nM).122 
 
Ferrocene, an iron−containing sandwich structure, has garnered significant interest despite 
having no inherent cytotoxic activity. The lipophilic properties of ferrocene allow for the 
effective penetration of cellular membranes and it is believed to act in the same way as the iron 
in haematin, which produces reactive oxygen species when oxidised from Fe(II) to Fe(III).123 
There has been a significant interest in ferrocenyl−containing compounds especially with the 
synthesis of ferroquine (1.43; Figure 1.19) by the Brocard group.123 Ferroquine, a chloroquine 
(1.30; Figure 1.17) derivative with a ferrocenyl moiety incorporated into the side chain, has not 
only shown higher activity against P. falciparum than chloroquine, but has also displayed activity 
against chloroquine−resistant strains.123 Ferroquine is currently in phase IIb clinical trials.125      
 
Further studies were conducted on a variety of ferrocene-containing analogues of other known 
antimalarials to determine if the incorporation of ferrocene could favourably alter the properties 
of those antimalarial drugs in a similar manner as seen with ferroquine.4,126,127 As mentioned in 
section 1.2, artemisinin compounds contain a 1,2,4-trioxane motif which is largely responsible 
for the observed antimalarial activity. Ferrocenyl artemisinin derivatives prepared by Delhaes et 
al. were evaluated for their antiplasmodial activity against CQS (HB2, SGE2) and CQR (Dd2) 
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strains of P. falciparum.126 The activities were compared to that of the parent artemisinin 
compounds. Compound 1.44 (Figure 1.20) displayed the highest activity with IC50 values of 12, 
11 and 14 nM against the tested strains HB3, SGE2 and Dd2, respectively. A loss of activity was 
observed for the ferrocenyl compounds; however, the compounds still displayed significant 
cytotoxic effects.126     
 
 
 
1.44 
 
1.45 
 
1.46 
 
1.47 
Figure 1.20  Sandwich (1.44‒1.46) and half−sandwich (1.47) quinoline complexes evaluated as antiplasmodial 
agents.126–129 
 
A similar study was carried out by Biot et al. who synthesised ferrocenyl analogues of 
mefloquine (1.31; Figure 1.17) and quinine (1.29; Figure 1.17), and tested the compounds against 
CQS (HB2) and CQR (Dd2) strains of P. falciparum.127 Of the tested compounds, compound 
1.45 (Figure 1.20) displayed the highest activity. As seen with the artemisinin derivatives, the 
ferrocenyl analogues were less active than the parent compound.127   
 
Similarly trioxaferroquine (1.46; Figure 1.20), a ferrocenyl analogue of trioxane (1.35; Figure 
1.17), was prepared by Bellot et al.128 The trioxaferroquines and trioxaferrocenes (compounds 
which lack the 7-chloro-4-aminoquinoline) were tested against the FcB1 and FcM29 strains.128 
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The authors reported that all the trioxaferroquines displayed activity similar to that of artemisinin 
and ferroquine, whilst they were more active than chloroquine. The trioxaferroquines displayed 
significantly higher activity than trioxaferrocenes, which suggests that in this instance the 7-
chloro-4-aminoquinoline is required for activity. Trioxaferroquine 1.46 displayed the highest 
activity with IC50 values 20 and 17 nM against FcB1 and FcM29, respectively.128  
 
On the other hand, half−sandwich rhenium and chromium compounds have been prepared to 
determine if the oxidation of the ferrocenyl moiety is partially responsible for the antimalarial 
activity.129,130 The tricarbonylchromium complex 1.47 (Figure 1.20) along with the organic 
ligand, and the dimethylaminomethyl tricarbonylchromium intermediate compounds prepared 
by Glans et al. were evaluated for their antiplasmodial activity against CQS (D10) and CQR 
(Dd2) strains of P. falciparum.129 The two intermediates were also tested to determine if the 
tricarbonylchromium fragment possessed any inherent antiplasmodial activity. The 
intermediates had no significant effect on the parasites [> 1000 nM (D10)], which led the authors 
to conclude that any activity observed for compound 1.47 is not related to chromium toxicity. 
IC50 values of 3.8 and 33.9 nM were recorded for compound 1.47 against D10 and Dd2, 
respectively. Compound 1.47 displayed enhanced activity compared to chloroquine [IC50 = 22 
nM (D10)], especially against the chloroquine−resistant Dd2 strain, where an IC50 value of 109.5 
nM was observed for chloroquine.129  
 
1.6.2  Benzothiazole−based compounds 
Benzothiazoles are heterocyclic compounds comprised of a thiazole ring fused onto a benzene 
ring at two adjacent carbons (Figure 1.21). Benzothiazoles have extensively been used as 
biological agents since the 1950’s, initially as muscle relaxants, and since then as antitumour131–
134, antimicrobial133,134, antifungal135 and antiparasitic134,136–138 agents to name a few.  
 
 
 
 
    = H, halide, alkyl, aryl 
Figure 1.21  The general structure of a benzothiazole compound. 
 
Organic benzothiazole compounds 
Hout et al. tested three series of compounds in vitro against healthy human cells and the W2 
strain of P. falciparum.137 Compounds 1.48 and 1.49 (Figure 1.22) exhibited the highest activity 
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against the parasite with IC50 values of 0.7 and 1.8 μM, respectively, and displayed the lowest 
cytotoxicity against the healthy cells. Compounds 1.48 and 1.49 were further evaluated against 
the 3D7 strain, as well as clinical isolates. Compound 1.48 (IC50 = 1 μM) was more active than 
compound 1.49 (IC50 = 4.1 μM) against 3D7, as well as against the clinical isolates.137 The 
mechanism of action for these compounds was evaluated using a range of tests and assays. The 
compounds were found to have an effect on the mitochondrial membrane potential; dropping the 
potential resulted in changes in the respiratory chain length and ultimately parasite death. Only 
compound 1.49 had a slight effect on the inhibition of haem crystallisation. Compound 1.49 had 
no effect on free radical production, and appeared to have no effect on DNA as no changes in 
structure were observed.137 
   
 
1.48 
 
1.49 
 
1.50 
Figure 1.22  Benzothiazole−based compounds (1.48‒1.50) exhibiting antimalarial properties.137,138 
 
The derivatisation of known antimalarials continued in work done by Ongarora et al. whereby 
amodiaquine was altered by replacing the phenyl group with heteroaromatic ring systems, as 
well as altering the attached amine groups.138 The tested compounds generally exhibited good 
activity against the W2 and K1 strains of P. falciparum. Compound 1.50 (Figure 1.22), a 
benzothiazole−containing compound, was one of the compounds which exhibited the best 
activity with IC50 values of 0.013 (W2) and 0.007 (K1) μM. The cytotoxicity of the compounds 
was also determined and found to be moderate against the rat mycoplast L6 cells.138  
 
Delmas et al. prepared and evaluated 6-nitro-, 6-amino and anthranilic benzothiazole derivatives 
as antitrichomonal agents. Compounds 1.51 and 1.52 (Figure 1.23) were the only compounds in 
Chapter 1: Literature review 
 
24 
 
the three series which displayed activity below 10 μM. Compound 1.51 and 1.52 gave IC50 values 
of 1.6 and 2.9 μM, respectively, which was also more active than metronidazole (3.2 μM).136  
 
 
1.51 
 
1.52 
Figure 1.23  Benzothiazole compounds (1.51 & 1.52) exhibiting antitrichomonal properties.136 
 
Platinum group metal benzothiazole−containing complexes have been tested against tumoural 
cell−lines and bacterial strains.95,139,140 However, no benzothiazole−containing complexes have 
been tested as antiplasmodial or antitrichomonal agents. 
 
1.7  Aims and objectives 
1.7.1 General aims 
Identifying potential lead compounds based on pharmacophores such as thiourea, quinoline and 
benzothiazole are of interest for the development of new bioorganometallic antiparasitic agents. 
Therefore, the overall aims of the project were as follows: 
i. To prepare organosilane−containing thiosemicarbazones, which were further reacted 
with metal precursors, to prepare mono− and binuclear complexes (Figure 1.24). 
ii. To prepare organosilane−based ferrocenyl−containing compounds comprised of 
aminoquinolines (Figure 1.25) or aminobenzothiazoles (Figure 1.26). 
iii. To evaluate the prepared compounds for their pharmacological activity as antiparasitic 
agents.  
iv. To investigate potential mechanisms of action responsible for any observed 
pharmacological activity. 
 
1.7.2  Specific objectives     
a) Synthetic objectives 
 Ferrocenyl− and aryl−derived organosilane thiosemicarbazones (Figure 1.24a) were 
prepared via a nucleophilic acyl substitution reaction between Schiff base compounds 
(dithiocarbamates) and amine−terminated silanes. Groups R1−R3 of the 
thiosemicarbazones were modified as listed in Figure 1.24. The organosilicon TSC 
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compounds were used to prepare mono− or heterobimetallic N,S−chelated TSC 
ruthenium(II) and rhodium(III) complexes containing arenes as the ancillary ligands 
(Figure 1.24b). The presence of the arene assists in stabilising the metal centre. 
Additionally, selected cyclopalladated C,N,S−chelated thiosemicarbazone complexes were 
also prepared which contained the water soluble 1,3,5-triaza-7-phosphaadamantane (PTA) 
ligand in the fourth position around the Pd(II) metal ion. 
 
       
a  
 
 
 
= Si(CH3)3; C(CH3)3 
 
b 
R1 = Ferrocenyl; 3,4-Dichlorobenzene 
R2 = H; CH3 
M = Ru, Rh, Pd 
 L = Cl, iPrC6H4CH3, Cp*, PTA 
Figure 1.24  Representation of the organosilane thiosemicarbazones and corresponding complexes. 
 
 Ferrocenyl−containing aminoquinolines (Figure 1.25) were synthesised via the 
nucleophilic substitution of the trimethylammonium group of quaternised ferroquine141 by 
amine−terminated organosilanes, and the corresponding carbon analogue. 
 
 
 
= organosilane‒containing amine side‒chain; carbon analogue 
Figure 1.25  Representation of ferrocenyl−containing quinoline−based compounds. 
 
 Ferrocenyl−containing aminobenzothiazoles (Figure 1.26) were prepared in a similar 
manner to the aminoquinolines illustrated in Figure 1.25, which began with the 
nucleophilic substitution of a halide  (6-chloro-2-iodobenzothiazole) by 2-[(N,N-
dimethylamino)methyl]-ferrocenylmethylamine. Quaternisation of the resulting 
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compound was followed by the nucleophilic substitution of the trimethylammonium group 
by amine−terminated organosilanes, and the corresponding carbon analogue. 
 
 = organosilane‒containing amine side‒chain; carbon analogue 
Figure 1.26  Representation of ferrocenyl−containing benzothiazole−based compounds. 
 
b) Characterisation 
The compounds were fully characterised using the required techniques such as Nuclear Magnetic 
Resonance (NMR) [1H, 13C{1H}, 31P{1H}, COSY (correlation spectroscopy), HSQC 
(Heteronuclear Single Quantum Coherence)] spectroscopy, Infrared (IR) spectroscopy and mass 
spectrometry [electron impact (EI), electrospray ionisation (ESI)]. The molecular structure of 
selected compounds was confirmed using single−crystal X−ray diffraction. 
 
c) Pharmacological studies 
Following the preparation of the desired compounds, in vitro screening against parasitic strains 
of Plasmodium falciparum and Trichomonas vaginalis was carried out, along with cytotoxicity 
studies. As a potential mechanism of action, selected compounds were evaluated for their ability 
to inhibit the formation of β−haematin. Furthermore, based on promising in vitro data, a complex 
was selected for in vivo evaluation in a P. berghei infected mouse model. Another important 
aspect to consider when identifying potential lead compounds, is how long it takes the compound 
of interest to metabolise and what it metabolises to. Therefore, the metabolic stability of 
ferrocenyl−containing aminoquinoline compounds were assessed in liver microsomes.  
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CHAPTER 2 
Synthesis and Characterisation of Mono‒ and Binuclear Organosilane 
 Thiosemicarbazone Metal Complexes 
 
  
2.1  Introduction  
Thiosemicarbazones (TSC), are thiourea‒based compounds known for their ability to chelate to 
metals by means of electron‒rich donor atoms. The thiourea moiety is found in biologically 
active compounds,1–4 making TSCs attractive systems to work with in terms of metal complex 
preparation and biological evaluation thereof.   
 
Several bonding modes such as monodentate, bidentate or tridentate modes (Figure 2.1) have 
been observed for thiosemicarbazones.5–8 In the case of monodentate complexes, the metal ion 
generally coordinates via the thione sulfur atom. The metal ion coordinates via the imine 
nitrogen atom and the thione/thiolate sulfur atom when the TSC chelates in a bidentate manner. 
Tridentate complexes are formed via the coordination of the metal ion to the imine nitrogen 
atom, the thiolate/thione sulfur atom and an additional atom which is usually either part of a 
ring system (e.g. pyridyl, thiophene, phenyl) or attached to the ring system (e.g., deprotonated 
hydroxyl group).5–8     
 
 
                      I                     II              III 
Figure 2.1  Monodentate (I), bidentate (II) and tridentate (III) coordination modes.5 
 
Thiosemicarbazones and their complexes have previously been evaluated within our research 
group for their biological activities.9–16 Smith and co‒workers investigated cycloplatinated, 
cyclopalladated, palladium(II) salicylaldiminato and ruthenium−arene TSC complexes in vitro 
as antiplasmodial and/or antitrichomonal agents.9,10,16,17 It was found that the compounds 
containing chlorines on the aromatic ring generally displayed better activity against the 
Plasmodium falciparum and Trichomonas vaginalis parasitic strains than the compounds with 
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unsubstituted aromatic rings.16 In the studies involving the cycloplatinated and cyclopalladated 
TSC complexes, the incorporation of a 1,3,5-triaza-7-phosphaadamantane (PTA) ligand 
generally led to improved activity.9,17 The cycloplatinated complex IV displayed moderate 
biological activities against P. falciparum strains, giving IC50 values of 21.42 (D10) and 24.90 
μM (Dd2). Against the parasite T. vaginalis (T1 strain), compound IV displayed 92.5 % 
inhibition of parasite growth at 100 μM and an IC50 value of 21.1 μM (Metronidazole: IC50 = 
0.72 μM).9 The cyclopalladated complexes V was screened against the NF54 and Dd2 strains 
and displayed low micromolar IC50 values of 1.93 and 2.69 μM, respectively.17 Compound V 
was not tested against the parasite T. vaginalis. 
 
 
IV: M = Pt; V: M = Pd  
 
VI 
 
VII 
 
VIII: n = 1; IX: n = 3 
Figure 2.2  Compounds IV‒IX were evaluated as antiparasitic agents. 9,10,16–18 
 
In another study, the palladium(II) salicylaldiminato TSC complexes were evaluated against 
the T1 strain of T. vaginalis.10 The tested complexes displayed varying percentages of parasite 
growth inhibition ranging from 14–97 %, with compound VI (Figure 2.2), the most potent 
inhibitor, displaying the lowest IC50 values of 17 μM (Metronidazole: IC50 = 0.72 μM).10  
 
Another metal of interest in antiparasitic research has been ruthenium, which led to the 
evaluation of ruthenium(II)−arene complexes such as compound VII (Figure 2.2) which 
displayed IC50 values of 2.9 μM (NF54) and 3.8 μM (Dd2). Moderate activity was observed 
against the G3 strain of T. vaginalis, with an IC50 value of 7.56 μM.16 Additionally, the 
compounds containing a ferrocenyl moiety displayed moderate potency which may be 
improved upon. 
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In addition to the pharmacologically active thiourea‒containing compounds, organosilanes are 
of significant interest. As mentioned in Chapter 1 (Section 1.4.1), the idea of enhancing the 
pharmacological properties of a drug, or the repurposing of the drug for treatment of an 
alternate disease may be achieved through incorporation of organosilanes.19–21 
Silicon‒containing compounds have been associated with enhanced cell and tissue penetration, 
provided a suitable balance between hydrophilicity and lipophilicity exists.19 Additionally, the 
lipophilicity, as well as electropositive nature of silicon, may alter the selectivity of the 
organosilane compounds compared to their carbon analogues. These properties of the 
silicon‒containing compounds have made organosilanes an attractive field to pursue. 
 
In terms of TSCs and silicon, coordination complexes involving the chelation of TSC to 
silicon(IV) are found in literature.22,23 None of the TSC compounds involve the formation of 
organosilane (C‒Si) bonds, which are then chelated to selected transition metals. As seen in 
Figure 2.2, TSCs previously evaluated as antiparasitic agents contained an unsubstituted 
terminal amine. This led to the idea of altering the structure of previously evaluated TSC 
compounds through incorporation of organosilanes in order to improve pharmacological 
effects. 
 
In another study, non‒TSC compounds containing organosilanes of interest were synthesised. 
Li et al. prepared silicon‒containing 7-chloro-4-aminoquinoline compounds which were 
evaluated as antitumour, antimycobacterial and antiplasmodial agents.18 In terms of the in vitro 
P. falciparum studies, compounds VIII and IX (Figure 2.2) displayed activities in the 
nanomolar range, with IC50 values of 248 and 98 nM, respectively, against the NF54 strain. 
Additionally, compound IX also exhibited higher activity against the Dd2 (270 nM) strain of 
P. falciparum.18 
 
For this study, compounds with increased potency and an ability to circumvent antiparasitic 
drug resistance are of interest. The scarcity of research on organosilicon TSCs as antiparasitic 
agents provides an avenue worthy of exploration. In this project, organosilane TSCs with 
bidentate [N,S (thione)] and tridentate [C,N,S (thiolate)] systems were studied. 
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2.2  Results and Discussion 
2.2.1  Synthesis and Characterisation of Schiff base Dithiocarbamates and Organosilane 
Thiosemicarbazones    
Synthesis 
Methyl hydrazinecarbodithioate was synthesised by means of a published method.24 Schiff 
base dithiocarbamates (2.1 and 2.2) were prepared by the procedure illustrated in Scheme 2.1. 
The dithiocarbamates were synthesised via a Schiff base condensation reaction between the 
respective aldehyde (ferrocenecarboxaldehyde and 3,4-dichlorobenzaldehyde) or ketone 
(acetylferrocene and 3,4-dichoroacetophenone) and methyl hydrazinecarbodithioate. 
   
 
Scheme 2.1  The synthesis of the Schiff base dithiocarbamates (2.1a‒b and 2.2a‒b) and the corresponding 
thiosemicarbazones (2.3a‒b, 2.4a‒b and 2.5).  
Reagents and conditions: (i) 2-Propanol, 70 ˚C, 24 hr; (ii) (aminomethyl)trimethylsilane (2.3, 2.4) or 2,2’-
dimethylpropan-1-amine (2.5), Ethanol, 70 ˚C, 22 hr (2.3a); 7 hr (2.3b); 24 hr (2.4a, 2.4b, 2.5). 
  
Motivation for the choice of the R1 group  
Cohen and co‒workers screened a wide range of thiosemicarbazones for their ability to inhibit 
cysteine proteases.25 The thiosemicarbazones which contained a 3,4-dichloroaryl group were 
amongst the most active compounds. In addition to this, TSCs prepared within our group, 
which contained the above mentioned 3,4-dichloro-substituted aryl group, have displayed good 
antiplasmodial activities.12 Furthermore, as mentioned in Chapter 1 (Section 1.6.1), the 
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incorporation of ferrocenyl moieties is believed to assist with membrane penetration and redox 
properties.   
 
Compounds 2.1a‒b and 2.2b have previously been synthesised.26–28 Compound 2.2a is a new 
compound, which was isolated as an off‒white powder in moderate yield (68 %) with a 
melting point range of 200.9‒201.4 ˚C. The compound is soluble in most organic solvents and 
insoluble in water and non‒polar organic solvents. 
 
Five new thiosemicarbazones were synthesised following the procedure described in Scheme 
2.1. The organosilane compounds were prepared via a nucleophilic acyl substitution reaction 
between the Schiff base dithiocarbamates and an amine, as illustrated in Figure 2.3. The 
nucleophilic amine attacks the electrophilic thiocarbonyl carbon of the dithiocarbamate to form 
an unstable tetrahedral intermediate. Reforming the thiocarbonyl double bond and proton 
transfer (PT) results in the elimination of methanethiol gas and formation of the desired TSC. 
Additionally, a carbon analogue of compound 2.4b was synthesised, using 2,2’-
dimethylpropan-1-amine, to determine if the Si atom is significant for biological activity.  
 
 
Figure 2.3  Formation of organosilane thiosemicarbazones via a nucleophilic acyl substitution reaction. 
 
Compounds 2.3a‒b were isolated as brown powders and compounds 2.4a‒b and 2.5 were 
isolated as white powders in low to high yields (34‒83 %). Compounds 2.3‒2.5 are soluble in 
most organic solvents such as dichloromethane, chloroform, diethyl ether and dimethyl 
sulfoxide. Not surprisingly, the compounds are not soluble in water or non-polar solvents such 
as hexane and pentane.   
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Characterisation 
Compounds 2.2a, 2.3a‒b, 2.4a‒b and 2.5 were fully characterised using NMR (1H; 13C{1H}) 
spectroscopy, infrared (IR) spectroscopy and electron impact mass spectrometry (EI‒MS). 
 
NMR Spectroscopy 
The 1H NMR spectrum of compound 2.2a was recorded in DMSO‒d6. The compound displays 
a singlet corresponding to the imine proton at 8.21 ppm. Formation of the Schiff base shields 
the SCH3 protons, resulting in a small upfield shift of the peak (2.53 ppm) compared to that 
observed for methyl hydrazinecarbodithioate (2.63 ppm). The peak corresponding to the 
hydrazinic proton is observed downfield at 13.4 ppm. The peaks for the aromatic protons H‒5 
and H‒6 overlap, while a broad signal is observed for H‒2. 
       
 
Figure 2.4  1H NMR spectrum of 3,4-dichlorophenylethylidene-((trimethylsilyl)methyl) TSC (2.4b). 
 
Compounds 2.3a, 2.4a and 2.5 were recorded in CDCl3 and compounds 2.3b and 2.4b in 
DMSO‒d6. It was evident from the 1H NMR spectra that the organosilane TSCs had been 
synthesised. The absence of a singlet for the methanethiol protons and the appearance of a 
signal for the newly incorporated amine confirm this. In addition to the presence of a singlet in 
the range 0.10‒0.18 ppm for the Si(CH3)3 protons18, it was also observed that the CH2 protons 
couple to the proton of the adjacent secondary amine. A doublet is observed at approximately 
3.30 ppm (3JHH ~ 5.90 Hz) for the CH2 protons of the TSC compounds. For the carbon 
analogue 2.5, the C(CH3)3 protons resonate as a singlet at 1.04 ppm. 
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The hydrazinic proton is more deshielded than the other secondary amine proton, and resonates 
in the range 8.46‒10.1 ppm. In CDCl3, the peak for the second amine proton is observed as a 
broad signal in the range 7.31‒7.74 ppm. However, in DMSO‒d6 (2.3b, 2.4b) the peak for the 
amine proton is observed as a triplet (3JHH = 5.70 Hz; Figure 2.4) at 7.95 and 8.41 ppm, 
respectively. As mentioned before, the amine proton couples to the adjacent CH2 protons 
resulting in the observed triplet. For compounds 2.3a and 2.4a, the peak associated with the 
imine proton is observed at 7.65 and 7.78 ppm, respectively. The protons of the methyl group 
situated on the azomethine carbon atom resonate as a singlet between 2.14–2.26 ppm for 
compounds 2.3b, 2.4b and 2.5.  
 
Similar trends are seen for the ferrocenyl (2.3a−b) and aromatic (2.4a‒b, 2.5) TSC 
compounds. Three peaks corresponding to the ferrocenyl protons are observed between 4.15 
and 4.74 ppm. Two triplets (3JHH = 2.00 Hz) corresponding to the protons on the substituted 
cyclopentadienyl (Cp) ring and one singlet associated with the unsubstituted Cp ring are 
observed.29 The H‒2, H‒5 and H‒6 protons of the aryl ring resonate as a doublet, doublet and 
doublet of doublets, respectively, in the range 7.41‒8.13 ppm. 
 
The 13C{1H} NMR spectrum of compound 2.2a was recorded in DMSO‒d6. The 13C{1H} 
NMR spectrum of compound 2.2a displays peaks at 199.0 and 143.4 ppm which correspond to 
the thiocarbonyl and azomethine carbon atoms, respectively. The aromatic carbon atoms 
resonate in the range 127‒134 ppm and the carbon atom of the methyl group (SCH3) resonates 
upfield at 16.7 ppm. 
 
The 13C{1H} NMR spectra of compounds 2.3a‒b, 2.4a and 2.5 were recorded in CDCl3 and 
compound 2.4b in DMSO‒d6. With the formation of the organosilane TSCs (2.3a‒b, 2.4a‒b), 
two additional peaks are observed in the 13C{1H} NMR spectra. The CH2 carbon atom 
resonates at around 35.0 ppm, while the methyl carbon atoms of the Si(CH3)3 group resonates 
as a singlet in the range ‒1.84 to ‒2.50 ppm for organosilane TSCs (2.3a‒b, 2.4a‒b).18 In 
addition to the CH2 carbon atom (55.8 ppm), and the methyl carbon atom of the C(CH3)3 group 
(27.4 ppm), the carbon analogue displays an additional peak at 32.2 ppm which correspond to 
the quaternary carbon atom of the C(CH3)3 group.   
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Formation of the thiosemicarbazones (2.3‒2.5) occurs via the substitution of the methanethiol 
group with the amine. This resulted in a more shielded thiocarbonyl carbon atom which 
resonates at ~178 ppm [199.0 ppm (2.2a)]. Amines are stronger bases than thiols, and thus the 
newly incorporated amine group has a larger electron donating effect, resulting in a more 
shielded thiocarbonyl carbon atom. No significant shift is observed for the peak of the imine 
carbon atom, which resonates between 143.1 and 148.0 ppm. As with the imine carbon, no 
significant change is observed for the peak associated with the CH3 carbon atom (CH3C=N) 
upon formation of the TSC compounds (2.3‒2.5). The ferrocenyl carbon atoms resonate 
between 66.8 and 82.5 ppm, with the quaternary carbon atoms being the most deshielded. The 
peaks for the aromatic carbon atoms are observed in the range 125.1‒138.4 ppm.  
 
Infrared Spectroscopy 
Infrared analysis of compounds 2.3a, 2.4a‒b and 2.5 was carried out using KBr pellets, while 
ATR was used for 2.2a and 2.3b. In the infrared spectrum of compound 2.2a, the absorption 
bands observed at 1586 and 812 cm-1 corresponds to C=N imine and C=S bond, respectively.  
 
Table 2.1  The C=N and C=S stretching vibrations for compounds 2.2‒2.5. 
Compound C=N ν (cm-1) C=S ν (cm-1) Si-CH3 ν (cm-1) 
2.2a 1586 812 − 
2.3a 1606 856 1245 
2.3b 1600 851 1243 
2.4a 1602 854 1250 
2.4b 1616 846 1252 
2.5 1615 858 − 
 
A comparison of the infrared spectra of the dithiocarbamates and TSCs (2.3‒2.5) reveals a 
significant shift, which is expected for the absorption band of the C=S bond. An absorption 
band is observed in the range 846−858 cm-1 (Table 2.1), which is at a higher wavenumber than 
the Schiff base dithiocarbamates. As mentioned before, the incorporation of the amine results 
in a higher electron density on the carbon of the new C−N bond, shifting the absorption band to 
a lower wavenumber. The absorption bands for the imine bond are observed in the range 
1600‒1616 cm-1. Furthermore, incorporation of the organosilane is confirmed by the presence 
of the absorption band between 1243 and 1252 cm-1, which corresponds to the Si−CH3 bond. 
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Mass Spectrometry 
Compounds 2.2a and 2.3−2.5 were analysed using electron impact mass spectrometry. The 
mass spectrum of compound 2.2a displays the molecular ion peak at m/z 277.94 (Theoretical: 
277.9504 g.mol-1), once again confirming formation of the desired dithiocarbamate. For 
compounds 2.3−2.5, the estimated molecular masses were calculated to be 373.0724, 387.07, 
333.00, 347.04 and 331.0672 g.mol-1, which is consistent with the molecular ion peaks 
observed at m/z 373.07, 387.04, 333.00, 347.02 and 330.98, respectively.   
 
2.2.2  Synthesis and Characterisation of Organosilane Thiosemicarbazone Half‒Sandwich 
Ruthenium(II) Complexes    
As previously discussed in Chapter 1, a strategy to improve the biological activity of a 
compound involves the incorporation of transition metals. Therefore, in this project we sought 
to prepare organosilane TSC ruthenium(II) complexes for evaluation as antiparasitic agents. 
 
Synthesis 
The bridge‒splitting reaction of the ruthenium dimer [Ru(η6-p-iPrC6H4Me)Cl2]2 by two  
equivalents of TSC (2.3a‒b, 2.4a‒b, 2.5) was used to prepare five new chiral ruthenium(II) 
complexes, as outlined in Scheme 2.2.  
 
 
 
Scheme 2.2  The synthesis of organosilane thiosemicarbazone ruthenium(II) complexes 2.6‒2.8.  
Reagents and conditions: (i) Dichloromethane, r.t., 4 hr. 
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Compounds 2.6‒2.8 were isolated as orange to red solids in moderate yields (61−84 %), and 
relatively stable to temperatures above 100 ˚C. The complexes are soluble in most polar 
organic solvents (e.g. chlorinated solvents, alcoholic solvents, etc.), and as expected insoluble 
in non-polar solvents and water. 
 
Characterisation 
The racemic mixtures of the ruthenium complexes were characterised using NMR (1H, 
13C{1H}, COSY, HSQC) spectroscopy, infrared (IR) spectroscopy and high resolution 
electrospray ionisation (ESI) mass spectrometry.  
 
NMR Spectroscopy 
The 1H NMR spectra of the ruthenium(II) complexes (2.6‒2.8) were recorded in CDCl3. Due to 
the orientation around the ruthenium centre, the arene ring losses its two‒fold symmetry, 
resulting in protons being observed in different environments.14,16,30 The aromatic p‒cymene 
protons (Figure 2.5) are observed in the range 4.10‒5.52 ppm (3JHH ~ 6.00 Hz) as a set of four 
doublets each accounting for one aromatic proton, as opposed to the two doublets observed for 
the starting material. Additionally, the two methyl groups (isopropyl) are observed as two 
doublets between 1.08‒1.21 ppm (3JHH ~ 6.80 Hz). The remaining p‒cymene protons, CH 
(multiplet) and CH3 (singlet) are observed between 2.57‒2.66 and 2.06−2.15 ppm, 
respectively.  
 
The ruthenium metal coordinates to the imine nitrogen, and due to back‒donation, the 
environment of the imine proton and the methyl protons (CH3C=N) are altered. The peak 
associated with the methyl protons (CH3C=N) of TSC compounds 2.6b, 2.7b and 2.8 have 
shifted downfield upon complexation, from around 2.20 to approximately 3.00 ppm. Similarly, 
the imine proton is also more deshielded upon complexation, resonating at 8.60 and 8.79 ppm 
(ligands: ~7.70 ppm), respectively, for 2.6a and 2.7a. 
 
While the Si(CH3)3 protons have been deshielded (shift from ~0.13 to ~0.22 ppm), the CH2 
protons have been slightly shielded (from ~3.23 to ~3.05 ppm). The same effect is observed for 
compound 2.8, where the C(CH3)3 protons are slightly deshielded upon formation of the 
complex [1.04 (2.5) to 1.08 ppm], while the CH2 protons are more shielded [3.60 (2.5) to 3.41 
ppm]. Binding of the ruthenium arene fragment has also had a deshielding effect on the amine 
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protons. Both the hydrazinic proton and the other secondary amine proton resonate downfield 
in comparison with the free TSC. As seen with other ruthenium arene complexes containing a 
ferrocenyl ligand, one of the protons of the substituted Cp ring is significantly more deshielded 
than the other three protons on the ring.16 The proton resonates at approximately 6.10 ppm, 
whilst the remaining ferrocenyl protons resonate in the expected region between 4.00 and 5.00 
ppm. 
 
 
 
Figure 2.5  1H NMR spectrum of the ruthenium(II) complex 2.6b. 
 
The 13C{1H} NMR spectra of compounds 2.6a‒b, 2.7a‒b and 2.8 were recorded in CDCl3. No 
significant change is observed for the thiocarbonyl carbon (~178 ppm). As previously 
mentioned, coordination of the ruthenium metal ion to the imine nitrogen affects the 
environment around the imine bond due to back‒donation. Therefore, the imine carbon atom is 
more deshielded as it resonates at approximately 163 ppm (ligand: ~144 ppm). 
 
Similarly, the carbon of the CH3 attached to the imine carbon atom of compounds 2.6b, 2.7b 
and 2.8 is also significantly deshielded and observed at ~27.0 ppm (ligand: ~14.0 ppm). The 
presence of the newly incorporated p‒cymene ring carbon atoms are also observed in the 
13C{1H} NMR spectra. Decomposition of 2.6a is observed after 2 hours, which may explain 
why the peaks for the ferrocenyl carbon atoms were not resolved (broad hump). 
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Infrared Spectroscopy 
Infrared analysis of compounds 2.6a, 2.6b and 2.7b were carried out using KBr pellets, while 
2.7a and 2.8 was analysed using ATR. As seen in the infrared spectra of similar cationic 
complexes, upon chelation of the TSC to the ruthenium centre, a high energy shift was 
expected for the absorption band of the C=N bond.14 The absorption band for the imine bond is 
observed as a weak shoulder in the range 1624−1633 cm-1, which was at a higher wavenumber 
than found for the TSCs (1600−1616 cm-1). 
 
Mass Spectrometry 
The ruthenium complexes 2.6−2.8 were analysed using high resolution electrospray ionisation 
mass spectrometry. Complexes 2.6−2.8 were calculated to have theoretical molecular masses 
of 678.9866, 693.0392, 638.9808, 654.0042 and 638.0242 g.mol-1, respectively. The mass 
spectra of the ruthenium complexes (2.6a‒b, 2.7a‒b, 2.8) revealed a peak at m/z 304.5437, 
311.5522, 284.5207, 291.5291 and 284.5441, respectively. These peaks correspond to the 
fragment [M‒Cl]2+ (M refers to the complex cation excluding the Cl counter-ion). A peak 
corresponding to the fragment [M‒H‒Cl]+ has also been observed for the compounds (2.6a‒b, 
2.7a‒b, 2.8) at m/z 608.0793, 622.0960, 568.0345, 582.0500 and 568.0828, respectively. The 
mass spectra further confirm the successful preparation of the desired ruthenium complexes.  
 
Molecular Structure        
Crystals suitable for single−crystal X−ray diffraction were grown by slowly diffusing pentane 
into a solution of compound 2.6b dissolved in chloroform. The compound crystallised as red 
blocks with a molecule of chloroform in a monoclinic crystal system with space group P21/c. 
Selected bond lengths and angles are listed in Table 2.2 and selected crystallographic data in 
Table 2.3.   
 
As seen in Figure 2.6, as well as bond angles around the metal centre, the complex has a 
pseudo−tetrahedral geometry around the ruthenium centre. The structure confirms that the 
thiosemicarbazone chelates to the ruthenium centre in a N,S−bidentate manner. The bond 
length of C(5)−S [1.701(4) Å] was compared to that of previously reported complexes, as well 
as similar thiosemicarbazone ligands, and found to be comparable. This suggest that the ligand 
chelates in the thione form (Table 2.2) and not the thiolate form.14,16,31–33 This is also confirmed 
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by the bond length of N(2)−C(5) [1.346 Å] which is longer than the imine bond N(3)−C(6) 
[1.303 Å]. This implies that the single bond character of the N(2)−C(5) bond is retained. 
 
 
Figure 2.6  ORTEP representation of compound 2.6b with ellipsoids drawn at the 50 % probability level. 
 
Due to differences in atom sizes, the alkyl C‒Si σ‒bonds should be longer than alkyl C‒C 
σ‒bonds. This is evident from the crystal data, whereby C(3)‒Si(1) has an observed bond 
length of 1.859(9) Å, which is longer than that observed for C(25)-C(26) [1.530(8) Å]. As seen 
in Figure 2.6, and from the data listed in Table 2.2, a chlorido ligand occupies one of the sites 
around the ruthenium metal centre. Additionally, preparation of a N,S−chelated ruthenium (II) 
complex results in a cationic complex, which is confirmed by the presence of a chloride 
counter−ion (Figure 2.6). 
 
Table 2.2  Selected bond lengths (Å) and angles (˚). 
Bond lengths (Å) 
Ru‒N(3) 2.158(4) N(2)‒C(5) 1.346 
Ru‒S 2.3497(11) N(1)‒C(5) 1.333 
Ru‒Cl(1) 2.4134(12) C(5)‒S 1.701(4) 
Ru‒C(18) 2.273(4) C(3)‒Si(1) 1.859(9) 
N(3)‒C(6) 1.303 C(25)-C(26) 1.530(8) 
Bond angles (˚) 
N(3)‒Ru‒S 82.11(10) Cl(1)‒Ru‒S 86.07(4) 
N(3)‒Ru‒Cl(1) 88.04(11) Ru‒S‒C(5) 99.19(16) 
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Table 2.3  Tabulation of the crystal data of 2.6b 
 2.6b.CHCl3 
Chemical formula C27H39Cl2FeN3RuSSi.CHCl3 
Formula weight 812.96 
Crystal system Monoclinic 
Space group P21/c 
Crystal size (mm) 0.04 x  0.16 x  0.17 
a, b, c (Å) 13.8986(3), 22.6091(4), 11.4831(3) 
α, β, γ (°) 90, 103.4820(10), 90 
V/Å3 3508.95(13) 
Z 4 
T/K 173(2) 
Dc/g.cm−3 1.539 
μ/mm−1 1.341 
Scan range/° 3.5 < θ < 27.5 
Unique reflections 8016 
Reflections used [I > 2σ(I)] 6426 
Rint 0.061 
R indices (all data) 0.0519, wR2 0.1587, S 1.06 
Goodness-of-fit 1.012 
Max, Min Δρ/e Å −1.96, 2.26 
 
2.2.3  Synthesis and Characterisation of Organosilane Thiosemicarbazone Half−Sandwich 
Rhodium(III) Complexes 
As with the ruthenium complexes, it is believed that the activity of a compound may be 
enhanced with the incorporation of the rhodium. Additionally, the effect of a more 
electron−deficient metal centre was to be evaluated. Therefore, in this project we sought to 
prepare organosilane thiosemicarbazone rhodium(III) complexes to be evaluated as 
antiparasitic agents. 
 
Synthesis 
The rhodium dimer [Rh(Cp*)Cl2]2 was cleaved in a bridge−splitting reaction by two  
equivalents of the thiosemicarbazone (2.3a‒b, 2.4a‒b, 2.5) to prepare five new rhodium(III) 
complexes, as outlined in Scheme 2.3. The rhodium complexes were isolated in moderate to 
high yields (78−93 %) as orange or red powders. The compounds exhibit thermal stability 
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above 100 ˚C and are soluble in most polar organic solvents such as dichloromethane, ethanol, 
diethyl ether and dimethyl sulfoxide. 
 
 
Scheme 2.3  The synthesis of organosilane thiosemicarbazone rhodium(III) complexes 2.9‒2.11.  
Reagents and conditions: Dichloromethane, r.t., 4 hr. 
 
Characterisation 
The rhodium complexes were characterised using NMR (1H, 13C{1H}, COSY, HSQC) 
spectroscopy, infrared (IR) spectroscopy and high resolution electrospray ionisation (ESI) mass 
spectrometry.  
 
NMR Spectroscopy 
The 1H NMR spectra of compounds 2.9a, 2.10a‒b and 2.11 were recorded in CDCl3 and 
compound 2.9b was recorded in acetone‒d6. Formation of the rhodium complexes is confirmed 
by the appearance of a singlet in the region 1.51‒1.70 ppm. The signal corresponds to the 
methyl protons on the cyclopentadienyl ring coordinated to the rhodium centre. In addition to 
the appearance of the aforementioned singlet, a similar pattern is observed for the ferrocenyl 
protons of 2.9a as compounds 2.6a‒b (Section 2.2.2). The signal for one of the protons of the 
substituted ferrocenyl ring is observed downfield at 6.25 ppm due to the new orientation 
brought about by the incorporated metal fragment. The signals for the remaining ferrocenyl 
protons and the aromatic protons are observed in the expected regions.  
 
Chapter 2: Organosilane TSCs 
 
50 
 
A singlet for the azomethine proton is, as expected, observed downfield at 8.62 and 7.94 ppm 
for compounds 2.9a and 2.10a, respectively, when compared to the free ligand [7.68 ppm 
(2.3a); 7.78 ppm (2.4a)]. Additionally, a singlet in the range 2.40 and 2.53 ppm corresponds to 
the CH3 protons (attached to the imine carbon) of compounds 2.9b, 2.10b and 2.11, which is 
observed downfield compared to the ligands.  
 
The 13C{1H} NMR spectra of compounds 2.9a, 2.10a‒b and 2.11 were recorded in CDCl3, 
while 2.9b was recorded in acetone‒d6. The formation of the complexes is confirmed by the 
appearance of two additional peaks in the NMR spectra. A singlet at ~9.00 ppm, and a doublet 
(3JHH = 7.84 Hz) at approximately 96.0 ppm, corresponds to the carbon atoms of the 
cyclopentadienyl methyl groups and the quaternary carbons. The quaternary carbon atoms 
resonate as a doublet due to coupling with the spin active rhodium centre. The aromatic and 
ferrocenyl carbon atoms resonate in the expected regions.  
 
Infrared Spectroscopy 
Infrared analysis of compounds 2.9a‒b and 2.10a‒b were carried out using KBr pellets, while 
2.11 was analysed using ATR. As seen in the infrared spectra of the ruthenium complexes 
(Section 2.2.2) and similar cationic complexes, upon chelation of the TSC to the metal centre, a 
high energy shift is observed for the absorption band of the C=N bond.14 The absorption band 
for the imine bond of compounds 2.9‒2.11 is observed between 1624 and 1638 cm-1 (Table 
2.4), which is at a higher wavenumber than the rhodium‒free TSCs (1600‒1616 cm-1).   
 
Table 2.4  The C=N and C=S stretching vibrations for compounds 2.9‒2.11. 
Compound # C=N ν (cm-1) C=S ν (cm-1) 
2.9a 1636       856 
2.9b 1638 856 
2.10a 1638 856 
2.10b 1629 858 
2.11 1624 853 
 
Mass Spectrometry 
Complexes 2.9−2.11, which was further characterised using mass spectrometry, were estimated 
to have theoretical molecular masses of 681.0254, 695.0480, 640.9886, 655.0042 and 639.0272 
g.mol-1, respectively. In the mass spectra of the rhodium complexes (2.9a‒b, 2.10a‒b, 2.11), 
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peaks corresponding to the fragment [M‒Cl]2+ (M refers to the cationic portion excluding the 
Cl counter‒ion) are observed at m/z 305.5477, 312.5549, 285.5261, 292.5339 and 283.5399, 
respectively. A peak corresponding to the fragment [M‒H‒Cl]+ is also observed for 
compounds 2.9a‒b, 2.10a‒b and 2.11 at m/z 610.0873, 624.1039, 570.0446, 584.0607 and 
568.0739, respectively. 
 
2.2.4  Synthesis and Characterisation of Organosilane Thiosemicarbazone Cyclopalladated 
Complexes 
As seen in Section 2.1, previously synthesised C,N,S‒chelated cyclopalladated complexes have 
exhibited low to moderate antiplasmodial activities.12,17 Therefore, this study included the 
preparation of cyclopalladated complexes containing an organosilane moiety, in an attempt to 
improve on the previously observed biological activities. 
 
Synthesis 
The organosilane thiosemicarbazone can chelate in either a bidentate (N,S) or tridentate (C,N,S) 
manner to the palladium(II) metal ion. The cyclopalladated complexes were prepared by the 
procedure outlined in Scheme 2.4. The palladium complexes (2.12‒2.14) were synthesised by 
reacting the TSCs with the palladium precursor Pd(PTA)2Cl2 [PTA = 1,3,5-triaza-7-
phosphaadamantane] in the presence of triethylamine as the base. Compound 2.12 is a chiral 
compound; this is due to the planar chirality brought about by the 1,2−disubstitution of the 
cyclopentadienyl ring of the ferrocenyl moiety.   
  
 
Scheme 2.4  Synthesis of ortho‒cyclopalladated complexes 2.12‒2.14.  
Reagents and conditions: (i) Pd(PTA)2Cl2, Ethanol, Triethylamine, 85 ˚C, 24 hr. 
 
In the absence of a base, the direct reaction of the TSC with Pd(PTA)2Cl2 forms the N,S-
chelated palladium complex. Furthermore, formation of the N,S‒chelated palladium complexes 
are sluggish and resulted in low yields even after refluxing for 4 days. The ortho‒metallated 
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complexes (2.12‒2.14) were prepared via C‒H activation6,8,34,35, where the palladium(II) acts 
as a soft Lewis acid in an electrophilic substitution reaction (Figure 2.7). The substituted 
cyclopentadienyl ring (2.12) and the aromatic ring (2.13, 2.14) acts as the nucleophile which 
attacks the electrophilic palladium(II) metal centre. Incorporation of a methyl substituent on 
the imine carbon changes the electronic and steric properties of the aromatic ring, which in turn 
assists in bringing about cyclopalladation. In comparison to the direct method mentioned 
above, the presence of a base such as triethylamine facilitates deprotonation of the ring, which 
yields the desired C,N,S‒chelated complex (Figure 2.7). 
 
 
Figure 2.7  A proposed mechanism for the C−H activated formation of cyclopalladated complexes. 
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Compound 2.12 was isolated as a red powder, whereas compounds 2.13 and 2.14 were isolated 
as yellow powders, in moderate yields (45‒52 %). The compounds are thermally stable and 
decompose at temperatures above 240 ˚C. The silicon−containing compounds (2.12 and 2.13) 
are slightly more soluble than compound 2.14 in ethyl acetate and methanol. The compounds 
are soluble in dimethyl sulfoxide, chlorinated solvents, sparingly soluble in alcoholic solvents 
and insoluble in water. 
  
Characterisation 
The palladium complexes were characterised using NMR (1H, 13C{1H}, 31P{1H}, COSY, 
HSQC) spectroscopy, infrared (IR) spectroscopy and electron impact mass spectrometry 
(EI−MS).  
 
NMR Spectroscopy 
The 1H NMR spectra of compounds 2.12‒2.14 were recorded in DMSO‒d6. Synthesis of the 
cyclopalladated complexes is evident by the absence of a signal for a proton of the substituted 
cyclopentadienyl ring, as seen in Figure 2.8, and the C‒6 position on the aromatic ring. 
  
 
Figure 2.8  1H NMR spectrum of the cyclopalladated complex 2.12.  
 
In the 1H NMR spectrum of compound 2.12, there are only three signals for the protons of the 
substituted Cp ring observed in the range 4.32‒4.44 ppm. For compounds 2.13 and 2.14 a 
doublet (4JHP = 3.60 Hz) is observed for the aromatic proton H‒5, which experiences long-
range (four bond) coupling to phosphorus. The H‒2 proton of compounds 2.13 and 2.14 is now 
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observed as a singlet, as opposed to the doublet observed for the ligand when H‒2 coupled to 
the now absent H‒6. 
 
Formation of the palladacycle is further confirmed by the absence of the hydrazinic proton. 
The splitting pattern expected for the PTA ligand is observed. A singlet observed at ~4.26 ppm 
corresponds to the PCH2N protons (Figure 2.8). The NCH2N protons are in an AB spin system 
which should result in two doublets corresponding to the different environments experienced 
by the axial and equatorial NCH2N protons. In the 1H NMR spectra of 2.12‒2.14, a doublet 
(2JPH ~ 12.7 Hz) is observed for the equatorial protons (NCH2N). For compounds 2.13 and 2.14 
the axial protons are also observed as a doublet, whereas the signals for compound 2.12 
overlap with the signal for a proton of the substituted Cp ring resulting in a multiplet.  
 
The 13C{1H} NMR spectra of compounds 2.12 and 2.13 were recorded in DMSO-d6 and 
compound 2.14 was recorded in CDCl3. Coordination of the palladium metal to the imine 
nitrogen, deshields the imine carbon atom which resonates downfield at approximately 163 
ppm (Ligand: ~145 ppm). In the case of the aryl complexes (2.13, 2.14), the imine carbon atom 
resonates as a doublet (2JCP = 7.45 Hz). The quaternary ferrocenyl and aromatic carbon atoms 
to which the palladium metal is coordinated is also observed as a doublet due to coupling with 
phosphorus. The remaining aromatic and ferrocenyl carbon atoms resonate in the expected 
ranges 126–153 ppm and 66–100 ppm, respectively. 
 
As seen with similar complexes, the carbon atoms of the PTA ligand couples to phosphorus 
and resonate as doublets at approximately 52.0 (PCH2N) and 72.4 (NCH2N) ppm.  
 
The 31P{1H} NMR spectra displayed a singlet at ‒41.6, ‒49.6 and ‒49.6 ppm for compounds 
2.12‒2.14, respectively, which is upfield from ‒24.59 ppm for the precursor PdCl2(PTA)2. This 
corresponds to the expected chemical shift for the phosphorus (PTA) of the cyclopalladated 
complexes.12,17      
 
Infrared (IR) Spectroscopy and Mass Spectrometry 
Infrared spectral analyses of compounds 2.12‒2.14 were carried out using ATR. Upon 
formation of the cyclopalladated complexes 2.12–2.14, the absorption band for the imine bond 
chelated to the metal is found at a lower wavenumber (1530–1560 cm-1) when compared to the 
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thiosemicarbazones (Table 2.1). As previously mentioned, the thiosemicarbazone chelates in 
the thiolate form which is confirmed by the appearance of an absorption band for a C‒S bond, 
instead of the thione C=S bond, at a lower wavenumber (801‒807 cm-1). The shift to a lower 
wavenumber is indicative of the loss of double bond character and formation of a single bond. 
Additionally, chelation in the thiolate form is confirmed by the appearance of a second 
absorption band in the range 1570–1582  cm-1 for the newly formed C=N bond (Table 2.5).  
 
Table 2.5  The C=N and C=S stretching vibrations for 2.12‒2.14. 
Compound # C=N ν (cm-1) C‒S ν (cm-1) 
2.12 1570, 1530 807 
2.13 1578, 1560 807 
2.14 1582, 1558 801 
 
The mass spectra for compounds 2.12‒2.14, which have theoretical masses of 648.0520, 
608.0082 and 592.0312 g.mol-1, displayed molecular ion peaks at m/z 647.97, 607.99 and 
592.09, respectively.  
 
The ligands and complexes mentioned above were screened as potential antiparasitic agents 
against parasitic strains Plasmodium falciparum and Trichomonas vaginalis. The results of the 
biological studies are outlined in Chapter 3. 
 
2.3  Summary 
Thiosemicarbazone dithiocarbamates 2.1a‒b and 2.2a‒b were prepared via a Schiff base 
condensation reaction between methyl hydrazinecarbodithioate with either an aldehyde or 
ketone, respectively. The thiosemicarbazone dithiocarbamates were then reacted in a 
nucleophilic acyl substitution reaction with an amine‒terminated silane 
[(aminomethyl)trimethylsilane] to synthesise the organosilane thiosemicarbazones 2.3a‒b and 
2.4a‒b. Compound 2.2b was also reacted with 2,2’-dimethylpropanamine to prepare 
compound 2.5, the carbon analogue of 2.4b. These compounds were fully characterised using 
NMR (1H; 13C{1H}) spectroscopy, infrared (IR) spectroscopy and electron impact mass 
spectrometry (EI‒MS). 
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The aforementioned ligands (2.3a‒b, 2.4a‒b, 2.5) were then used in the preparation of a series 
of ruthenium(II)‒, rhodium(III)‒ and palladium(II) complexes. Two equivalents of the 
thiosemicarbazone was reacted in a bridge‒splitting reaction with the ruthenium dimer [Ru(η6-
p-iPrC6H4Me)Cl2]2 to yield heterobimetallic complexes 2.6a‒b and mononuclear complexes 
2.7a‒b and 2.8. The molecular structure of 2.6b was determined using single‒crystal X‒ray 
diffraction and shown to have a pseudo-tetrahedral geometry around the ruthenium metal 
centre. Following the ruthenium series, the rhodium series was synthesised in a similar manner 
by reacting the rhodium dimer [Rh(Cp*)Cl2]2 with the ligand to yield two heterobimetallic 
complexes 2.9a‒b as well as the mononuclear complexes 2.10a‒b and 2.11. These ruthenium 
and rhodium complexes were fully characterised using NMR (1H, 13C{1H}, COSY, HSQC) 
spectroscopy, infrared (IR) spectroscopy and electrospray ionisation mass spectrometry 
(ESI‒MS). 
  
Three C,N,S‒chelated cyclopalladated complexes (2.12‒2.14) were prepared via the C‒H 
activation of the thiosemicarbazones by the palladium precursor Pd(PTA)2Cl2, in the presence 
of triethylamine. These compounds were fully characterised using NMR (1H, 13C{1H}, 
31P{1H}, COSY, HSQC) spectroscopy, infrared (IR) spectroscopy and electron impact mass 
spectrometry (EI‒MS). 
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CHAPTER 3 
Pharmacological Evaluation of Organosilane Thiosemicarbazone Compounds as 
Antiparasitic Agents 
 
 
3.1  Introduction  
The development of a potential antiparasitic lead compound derived from whole‒cell 
phenotypic screening may involve the following:  
 
In Vitro Evaluation 
The first course of action involves testing drug efficacy in vitro. For example, in terms of 
Plasmodium falciparum, the asexual erythrocytic stage human P. falciparum parasites are 
cultured and dosed with a control drug (usually chloroquine and artesunate) and the tested 
compounds. The in vitro antiplasmodial assay protocols are generally based on either 
microscopic detection of 3H-hypoxanthine uptake inhibition, Giemsa‒stained slides, flow 
cytometry, fluorescence or the determination of parasite lactate dehydrogenase (pLDH) 
activity.1–3 These detection methods can be used to quantitatively assess the antiplasmodial 
activity of the compound. Of course the assay protocol and detection method may change 
depending on the microbe of interest.  
 
Cytotoxicity Studies 
After a compound is identified as being effective against parasitic cells, further testing is done 
to identify compounds which are cytotoxic overall. Cytotoxicity studies involve the in vitro 
evaluation of compounds against a mammalian cell‒line. A common method to assess cell 
growth is the colorimetric MTT‒assay.4,5 
 
The selectivity index of a compound is determined: 
 
Selectivity index (SI) =     
𝐶𝑦𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦
𝐴𝑛𝑡𝑖𝑝𝑙𝑎𝑠𝑚𝑜𝑑𝑖𝑎𝑙 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦
 
 
A compound with a large SI value displays selectivity towards parasitic cells.  
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In Vivo Evaluation 
Compounds selected for in vivo evaluations are subject to efficacy studies. These studies assess 
the ability of a compound to elicit a pharmacological response, thus eliminating ineffective 
compounds in the early stages of pre‒clinical studies. Promising lead compounds identified as 
having in vivo pharmacological effects are subsequently studied to determine the associated 
pharmacokinetic and pharmacodynamic factors. 
  
Pharmacokinetics studies the changes in drug concentration as it moves through the body 
(Figure 3.1) in terms of the rate at which the drug is absorbed, distributed, metabolised and 
excreted (ADME).6–8 
 
Absorption is the process of a drug before it enters systemic circulation. It considers factors 
such as blood flow, total surface area and contact time at the absorption site.  
 
Distribution considers the passage of a drug, after entering systemic circulation, from the 
plasma to tissues and active sites. The distribution of the drug is dependent on factors such as 
the size of the drug, lipid solubility (polarity), the degree of ionisation at physiological pH 
(non−ionised compounds are lipid soluble), the blood flow and the extent of binding to tissue 
proteins and plasma.  
 
 
Figure 3.1  Flow diagram illustrating the journey of the drug through the body. 
 
Metabolism (Biotransformation) is the irreversible process of transforming the administered 
compound into metabolites. Metabolism generally occurs in the liver before reaching the 
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systemic circulation thus reducing the amount of the administered compound in the system. 
Administered compounds may be metabolised to their active forms (prodrugs) or the 
drugs/active metabolites may be metabolised further to an inactive non‒toxic form. The 
process of metabolism may alter compounds, making them more soluble and easily 
excreted/secreted.  
 
Elimination is one of the most important stages in the drug’s journey, as accumulation without 
any means of elimination could lead to severe toxicity. The drug/metabolites can be removed 
from the body via excretion or secretion. Removal of metabolites may occur using renal 
(kidney) or biliary excretion, or removal may occur via sweat, saliva or exhalation of 
metabolites (secretion).    
 
Pharmacodynamics looks at how the drug affects the body, as well as the potency and 
efficacy of the drug in relation to the active site.  
 
Pharmacokinetics and pharmacodynamics are used to determine the time course, therapeutic 
window, the dose selection and adverse effects. This is done by evaluating the tested 
compound in terms of the rate of reaction (metabolism or elimination), and basic parameters 
such as the area under the curve (AUC), maximum plasma concentration (cmax), time of 
maximum concentration (tmax), volume of distribution (Vd), half-life (t1/2), bioavailability (F %) 
and clearance (CL) are taken into consideration when monitoring the progress of a drug within 
the body.6–8    
 
Animal models 
Compounds are considered for in vivo testing if they are found to be effective during in vitro 
screening, low toxicity and good metabolic stability. The purpose of pre‒clinical work is to 
develop sufficient data on the drug’s safety to support the decision to proceed to clinical trials. 
Therefore, animal testing is used to measure drug bioavailability, the toxicity of the drug, to 
monitor its metabolism and how quickly the drug and its metabolites are excreted from the 
body. In vivo screening progressively moves from smaller models, such as rodents, to larger 
models if favourable pharmacokinetic properties are established.1 
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Animal pharmacokinetic studies are usually performed in mice due to availability of inbred 
mice, and provide information on the behaviour of host immune cells in the presence of the 
tested compound. In vivo screenings may be conducted to test compounds on erythrocytic or 
liver stage malaria.9 Mouse models are generally infected with rodent malaria strains P. 
berghei, P. chabaudi, P. vinckei or P. yoelii. These strains of rodent parasites have different red 
blood cell growth that is used as experimental models for human disease.  
 
The differences in rodent and human parasite strains mean that the data collected does not 
model the human pharmacodynamics exactly. Nevertheless, this is still a good approximation 
for pre‒clinical trials. In recent years, humanised mouse models have become the model of 
choice for researchers. Immunocompromised mice are grafted with either human erythrocyte or 
hepatocytes, thus enabling the mouse to accommodate the human P. falciparum parasite in the 
asexual blood or hepatic stage.10–12 However, this model is still relatively new and thus 
expensive.     
 
3.2  Pharmacological Evaluation of Thiosemicarbazone−Containing 
Compounds 
The pharmacological activities of the synthesised thiosemicarbazone compounds (Figure 3.2) 
were evaluated through in vitro screening. The compounds were screened against NF54 
chloroquine‒sensitive and Dd2 chloroquine‒resistant strains of Plasmodium falciparum, and 
their cytotoxicity evaluated against the Chinese Hamster Ovarian (CHO) cell‒line. Selected 
compounds were also tested for their ability to inhibit β−haematin formation as a possible 
mechanism of action. The antiparasitic activity of these compounds was also tested against the 
metronidazole‒sensitive G3 strain of Trichomonas vaginalis. Furthermore, selected 
ferrocenyl‒derived TSC compounds were evaluated for their antitumour activity against the 
A2780 cisplatin‒sensitive and A2780cisR cisplatin‒resistant human ovarian carcinoma 
cell‒lines, as well as non‒tumourigenic KMST‒6 human fibroblast skin cell‒line. This was to 
determine the selectivity of these compounds towards parasitic and tumourigenic cell‒lines. 
Furthermore, a selected compound was also evaluated in a preliminary in vivo efficacy study in 
a P. berghei mouse model. 
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Figure 3.2  Illustration of the screened thiosemicarbazone compounds (2.1‒2.14). 
 
3.2.1  Predicting Lipophilicity  
The incorporation of silicon into the framework of these compounds was carried out on the 
basis that an enhancement of the compound’s lipophilicity may lead to an enhancement of 
pharmacological activity. The logP values of the ferrocenyl‒ and aryl‒derived 
dithiocarbamates and thiosemicarbazones were calculated to determine if a relationship existed 
between lipophilicity and the pharmacological activity observed.  
 
These calculations were carried out by first determining the clogP values of the aryl‒derived 
dithiocarbamates and thiosemicarbazones using ChemBioDraw Ultra v13.0. The 
ferrocenyl‒derived compounds could not be calculated directly using the aforementioned 
method. Instead the ferrocenyl‒derived compounds were calculated using a method combining 
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data from ChemBioDraw and the fragmental approach proposed by Rekker et al.13 and Lanez 
et al.14–16 
 
 
A1 
 
A2 
 
A3 
 
A4 
 
A5 
 
A6 
  
A7 
 
A8 
 
A9 
 
A10 
 
A11 
 
A12 
 
A13 
 
A14 
 
A15 
 
A16 
 
A17 
 
A18 
 
A19 
 
A20 
Figure 3.3  Reference compounds (A1–A20) used to validate the method. 
 
The fragmental approach, which involved the generation of fragmental constants associated 
with each atom (aliphatic or aromatic), was produced from experimental logP values.13 In 
addition to fragmental constants, this method also considers various characteristics of the 
compounds, such as resonances, hydrogen bonding, etc. The logP value calculated using the 
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fragmental approach is adjusted with a correction factor which depends on the relevant features 
present.13 However, this method cannot be applied to metal containing compounds. For 
ferrocenyl‒containing compounds, the logP value of ferrocene (Fc) was assumed to be the 
same as the experimental value which is 2.66.14,17 In this particular study, Fc-H (ferrocene less 
one hydrogen atom) was calculated by subtracting the fragmental constant for hydrogen, which 
results in a value of 2.456.14  
 
The data was used in the following equation:    
LogP(Fc derivative) = LogP(benzene derivative) – f(C6H5) + f(Fc-H)   
Where: LogP(benzene derivative) calculated using ChemBioDraw 
  f(C6H5) is obtained from fragmental approach13  
  f(Fc-H) is obtained from Lanez et al. reference15 
to predict the LogP values for the ferrocenyl compounds.  
 
However, before applying this method to the compounds evaluated herein, the method had to 
be validated. A set (n=20) of both ferrocenyl−containing and organic compounds (Figure 3.3) 
with reported experimental logP values were selected to validate this method.  
 
Representative calculation  
A representative calculation was carried out on compound A1, whereby the clogP value was 
determined for the benzene‒derivative (right) using ChemBioDraw. The logP value was then 
determined for the ferrocenyl‒derivative (left) using the equation below. 
 
 
 
 
LogP(Fc derivative) = LogP(benzene derivative) – f(C6H5) + f(Fc-H)   
                            = 1.999 – [6xC + 5xH] + 2.456 
                            = 1.999 – [6(0.110) + 5(0.204)] + 2.456 
                            = 2.775  
The above calculation was used to determine the theoretical values for compounds A1–A11, 
whereas the clogP values were taken directly from ChemBioDraw for compounds A12–A20 
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(Table 3.1). The regression analysis function in Microsoft Excel was used to determine how 
well the experimental logP values for the twenty reference compounds A1–A20 compared to 
the estimated values. The data was plotted to produce the graph in Figure 3.4.  
 
Table 3.1 Experimental and estimated logP values for compounds A1−A20. 
Compound Experimental LogP Estimated LogP 
A1 2.6418 2.78 
A2 4.4218 4.76 
A3 4.6819 4.74 
A4 4.9020 4.89 
A5 4.3821 4.18 
A6 5.1022 5.32 
A7 4.6318 4.31 
A8 4.7723 4.38 
A9 5.2723 4.93 
A10 4.5915 4.81 
A11 3.8221 3.86 
A12 2.9824 3.33 
A13 2.4425 2.21 
A14 2.6824 2.62 
A15 2.3926 2.63 
A16 
(Isoniazid) 
-0.7027 -0.67 
A17 
(Salicylamide) 
1.2827 1.28 
A18 
(Pentoxifylline) 
0.2927 0.12 
A19 
(Pseudoephedrine) 
0.8928 0.89 
A20 
(Phenobarbital) 
1.4727 1.36 
 
As seen in Figure 3.4, there is a good correlation between the experimental and estimated 
values, where the slope of the graph (=0.9907) is close to 1 and 98.48 % of the compounds fit 
the model. Furthermore, the p‒value (8.262 x 10−18) is considerably smaller than 0.05, which 
suggests that there is no significant difference between the two sets of data. Therefore, no 
correction is required. 
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Figure 3.4  Relationship between the experimental and theoretical logP values. 
 
Predicting the logP values for the thiosemicarbazones 
The logP values for the Schiff base dithiocarbamates and thiosemicarbazones were determined 
using the method described above. The clogP values obtained for the benzene‒ and 3,4-
dichlorobenzene‒derivatives are listed in Table 3.2 and Table 3.3, respectively.  
 
Table 3.2  The clogP values calculated using ChemBioDraw. 
Compound clogP 
Benzene-derivative of 2.1a 2.68 
Benzene-derivative of 2.1b 3.436 
Benzene-derivative of 2.3a 4.292 
Benzene-derivative of 2.3b 4.708 
 
Prediction: 
LogP(Fc derivative) = LogP(benzene derivative) – f(C6H5) + f(fc-H) 
                            = 2.68 – [1.68] + 2.456 = 3.456 
 
The logP values for compounds 2.1b, 2.3a, 2.3b and the ferrocenylTSC were calculated using 
the above method.  
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Table 3.3  Compilation of the estimated logP values for compounds 1‒5. 
Compound LogP Compound LogP 
 
2.1a 
3.456 
 
2.1b 
4.212 
 
2.2a 
3.986 
 
2.2b 
4.742 
 
2.3a 
5.068 
 
2.3b 
5.484 
 
2.4a 
5.598 
 
2.4b 
6.127 
 
2.5 
5.562 
 
FerrocenylTSC29 
3.177a 
 
3,4-DichloroacetophenoneTSC30 
3.820a   
         aCalculated following procedure described above. 
 
A comparison of the logP values for ferrocenyl‒ and 3,4-dichloroaryl‒dithiocarbamates and 
their corresponding TSC reveals that the TSC compounds are more lipophilic (Table 3.3). As 
seen in Table 3.3, a comparison of the organosilane TSC 2.4b (logP = 6.127) and its carbon 
analogue 2.5 (logP = 5.562) demonstrates that the silicon‒containing compound has a higher 
logP value, as expected. Furthermore, the logP values of two non‒silicon thiosemicarbazones 
(FerrocenylTSC; 3,4-DichloroacetophenoneTSC) which are analogous to compounds 2.3a and 
2.4b, and contain a terminal primary amine, were also calculated. The logP values for the 
previously prepared TSC compounds were significantly lower than the corresponding TSCs 
(2.3a, 2.4b) evaluated in this study. 
 
The logP values of the ruthenium(II)‒, rhodium(III)‒ and palladium(II) complexes could not 
be calculated using the same method as the non‒coordinated compounds. However, inclusion 
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of the arene and cyclopentadienyl fragments of the ruthenium and rhodium complexes, 
respectively, are expected to enhance the lipophilicity of the compounds to which they are 
coordinated. On the other hand, the palladium complexes are not expected to be as lipophilic as 
the ruthenium and rhodium complexes due to the presence of the hydrophilic PTA ligand. As 
previously mentioned, pharmacological evaluation of these compounds may reveal whether or 
not a relationship exists between lipophilicity and potency. 
 
3.2.2  In Vitro Antiplasmodial and Cytotoxicity Studies 
The in vitro antiplasmodial activity of the Schiff base dithiocarbamates (2.1; 2.2) and their 
corresponding organosilane (2.3; 2.4) and non‒silicon (2.5) thiosemicarbazones was evaluated 
against the NF54 (CQS) strain of P. falciparum. The corresponding ruthenium‒ (2.6b; 2.7; 
2.8), rhodium‒ (2.9a; 2.10; 2.11) and palladium‒ (2.12‒2.14) complexes were also screened 
against this strain. Chloroquine diphosphate (CQDP) and artesunate were used as the control 
drugs in this study. The IC50 values are listed in Table 3.4 and illustrated in Figure 3.5 and 3.6, 
while the resistance and selectivity indices are listed in Table 3.5. 
 
 
Figure 3.5  Antiplasmodial evaluation against the NF54 strain of P. falciparum. 
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Table 3.4  Antiplasmodial data for compounds 2.1‒2.14. 
Compound 
IC50 (µM) 
NF54 Dd2 CHO 
 
2.1a (R=H) 52.17±11.69 ND ND 
2.1b (R=CH3) 3.76±1.35 13.70±1.32 0.49±0.21 
 
2.2a (R=H) 27.33±7.85 ND ND 
2.2b (R=CH3) 2.59±0.89 10.95±1.06 1.20±0.41 
 
2.3a (R=H) 1.65±0.37 2.62±0.29 > 267.81 
2.3b (R=CH3) 7.92±1.99 ND ND 
 
2.4a  
(R=H; X=Si) 
1.26±0.69 6.91±0.48 25.10±1.23 
2.4b  
(R=CH3; X=Si) 
2.24±0.26 2.40±0.57 29.28±0.89 
2.5  
(R=CH3; X=C) 
175.74±43.03 ND ND 
 
2.6b 7.81±0.56 ND ND 
 
2.7a  
(R=H; X=Si) 
2.92±0.33 4.28±0.33 71.82±18.11 
2.7b  
(R=CH3; X=Si) 
4.19±0.12 6.66±2.58 21.54±3.80 
2.8  
(R=CH3; X=C) 
2.57±0.99 2.29±0.25 3.65±0.63 
 
2.9a 1.80±0.04 2.27±0.10 53.49±1.45 
 
2.10a  
(R=H; X=Si) 
3.73±0.96 3.11±0.58 14.89±0.37 
2.10b  
(R=CH3; X=Si) 
1.31±0.29 1.18±0.09 10.85±1.00 
2.11  
(R=CH3; X=C) 
3.41±0.41 1.01±0.16 4.10±0.19 
 
2.12 1.43±0.29 1.26±0.03 3.93±0.26 
 
2.13 (X=Si) 0.55±0.10 0.29±0.05 3.54±0.21 
2.14 (X=C) 0.83±0.12 0.34±0.08 2.73±0.34 
Chloroquine  0.0097±0.0039 0.19±0.06 ND 
Artesunate  0.0104±0.0026 0.05±0.02 ND 
Emetine  ND ND 0.13±0.0062 
ND = Not determined 
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When comparing the data for the Schiff base dithiocarbamates (2.1; 2.2), it is observed that 
2.1b and 2.2b are the most active with IC50 values of 3.76 and 2.59 μM, respectively. 
Incorporation of the organosilane moiety generally led to the enhancement of activity for the 
TSCs (Figure 3.5). Compound 2.5, a non‒silicon analogue of compound 2.4b, was tested in 
order to determine the impact of introducing silicon. Compound 2.5 (175.74 μM) was found to 
be significantly less potent compared to its silicon counter‒part 2.4b (2.24 μM), which 
suggests that the incorporation of the silicon atom plays a role in moderating antiplasmodial 
activity. 
 
Returning to the previously calculated logP values, thiosemicarbazones 2.3a, 2.4a and 2.4b 
had the highest logP values of 5.07, 5.60 and 6.13, respectively (Table 3.3), and generally 
displayed the lowest IC50 values. Furthermore, previously evaluated ferrocenylTSC [3.4 μM 
(NF54); 6.4 μM (Dd2)] and 3,4-dichloroacetophenone TSC [14.1 μM (NF54); 9.82 μM (Dd2)] 
are comparable in activity to the organosilane TSCs 2.3a and 2.4b, respectively.30,31 As seen in 
Table 3.3, the ferrocenyl‒ and 3,4-dichloroactophenone‒derived TSC compounds have low 
logP values of 3.18 and 3.82, respectively. This suggests that the activity of these compounds 
may be related to their lipophilicity. 
 
The ruthenium complexes were found to be slightly less active than the corresponding TSCs. 
However, the potency of the non‒silicon compound (2.5) is significantly enhanced upon 
complexation with ruthenium (2.8; 2.57 μM, NF54). This may be related to an enhancement in 
lipophilicity, or the interaction of the complex with the target. The rhodium complexes 2.9a 
and 2.10a were less potent when compared to the organosilane TSC (2.3a; 2.4a, Table 3.4). 
Compound 2.10b was found to be more active than the corresponding free TSC (2.4b) and a 
significant enhancement in activity was once again observed for the non‒silicon complex 
(2.11). However, the non‒silicon rhodium complex (2.11) was less potent than its silicon 
counter‒part 2.10b. At this stage, a larger series of compounds need to be evaluated before a 
conclusive statement can be made with regards to the use of ruthenium(II) versus rhodium(III).  
The cyclopalladated complexes 2.12‒2.14 were significantly more active than the TCSs 
(Figure 3.5) and more potent when compared to the ruthenium and rhodium complexes. A 
comparison of similarly structured complexes 2.13 (IC50 = 0.55 μM) and 2.14 (IC50 = 0.83 μM) 
shows a slight enhancement of activity for the silicon‒containing complex. 
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Further testing was done on the compounds which exhibited antiplasmodial activity below 5 
μM. The compounds were specifically tested for their antiplasmodial activity against the Dd2 
(CQR) strain of P. falciparum. The cytotoxicity of these compounds was also evaluated against 
a Chinese Hamster Ovarian cell‒line, using Emetine as the control drug (Figure 3.6). The 
Schiff base dithiocarbamates [2.1b; 2.2b] were significantly less active against the Dd2 strain 
when compared to the NF54 strain (Figure 3.5 and 3.6). The same loss of activity was observed 
for the organosilane TSCs (2.3a; 2.4a; 2.4b), the ruthenium complexes (2.7a; 2.7b) and the 
rhodium complexes (2.9a; 2.10b). The non‒silicon complex 2.11 was more potent against the 
Dd2 strain (1.01 μM) than the NF54 strain (3.41 μM). The potency of the cyclopalladated 
complexes 2.12‒2.14 against the Dd2 strain was higher than that against the NF54 strain, with 
IC50 values of 1.26, 0.29 and 0.34 μM, respectively. 
 
 
Figure 3.6  Antiplasmodial evaluation against the Dd2 strain of P. falciparum and the cytotoxicity studies tested 
on the Chinese Hamster Ovarian cell‒line. *not active at the tested concentration. 
 
Resistance indices [RI = 
IC50 (Dd2)
IC50 (NF54)
] were calculated for the TSC compounds which displayed 
activity against the Dd2 strain and plotted in the graph seen in Figure 3.7. The data points 
either positioned around or below the line correspond to RI values equal to 1 or less than, 
respectively.  Compounds displaying low RI values are of interest as this suggests that such 
compounds may be active against a broader range of sensitive and resistant strains. The tested 
compounds generally displayed low RI values in comparison to chloroquine (19.59) and 
artesunate (4.81). The non‒silicon ruthenium‒ (2.8), rhodium‒ (2.11) and palladium complexes 
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(2.14), as well as organosilane rhodium (2.10a‒b) and palladium (2.12; 2.13) complexes had 
RI values below 1 (Figure 3.7). This suggests that they are likely to be active against resistant 
strains and that the incorporation of a metal may be important in overcoming drug‒resistance.   
 
 
Figure 3.7  Resistance index (RI) correlation between CQR Dd2 and CQS NF54 strains of P. falciparum. 
 
In addition to the resistance index, the selectivity indices [SI1 or 2 = 
IC50 (CHO)
IC50 (NF54) or (Dd2)
] were also 
calculated to determine if the tested compounds were more selective towards the parasite 
strains or mammalian cells. Overall, the organosilane thiosemicarbazones (2.4a; 2.4b), the 
ruthenium‒ (2.7a) and rhodium‒ (2.9a) complexes were the least cytotoxic, and thus 
significantly more selective for the parasitic cells (Table 3.5). The SI1 values for the previously 
mentioned compounds ranged between 13 and 30 for the NF54 strain and 4 and 24 for the Dd2 
strain. As highlighted before, the cyclopalladated complexes were the most potent of the tested 
compounds and show good selectivity indices (Table 3.5), though not to the same extent as 
mentioned for the compounds above.   
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Table 3.5  The resistance and selectivity indices for selected compounds. 
Compound SI1a SI2b 
 
2.1b 0.13 0.036 
2.2b 0.46 0.11 
 
2.4a (X=Si) 19.92 3.63 
2.4b (X=C) 13.07 12.20 
 
2.7a (R=H; X=Si) 24.60 16.78 
2.7b (R=CH3; X=Si) 5.14 3.23 
2.8 (R=CH3; X=C) 1.42 1.59 
 
2.9a (R=H; X=Si) 29.72 23.56 
2.10a (R=H; X=Si) 3.99 4.79 
2.10b (R=CH3; X=Si) 8.28 9.19 
2.11 (R=CH3; X=C) 1.20 4.06 
 
2.12 (X=Si) 2.75 3.12 
2.13 (X=Si) 6.44 12.21 
2.14 (X=C) 3.29 8.03 
              aSI1 = IC50(CHO)/IC50(NF54); bSI2 = IC50(CHO)/IC50(Dd2) 
 
Previously reported ruthenium(II) p‒cymene complexes displayed low to moderate activity 
against P. falciparum, in the range observed for the ruthenium complexes (2.6‒2.8) reported 
herein.29 A comparison of the cyclopalladated complexes (2.12‒2.14) with previously reported 
cyclopalladated complexes reveal an enhancement of activity for the compounds reported 
herein.30,32 Unfortunately there are no rhodium TSC complexes to which the rhodium 
complexes (2.9‒2.11) reported herein can be compared. Furthermore, no comment can be made 
on the selectivity of the previously reported TSCs towards parasitic strains due to a lack of 
data.  
 
The thiosemicarbazone compounds evaluated in this study generally display improved activity 
compared to the previously evaluated thiosemicarbazone compounds.  
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3.2.3  β−Haematin Inhibition Studies     
The NP‒40 detergent mediated assay33,34 was used to establish if selected thiosemicarbazone 
compounds (2.4b, 2.9a and 2.10b), along with chloroquine as the control, inhibits β‒haematin 
(synthetic haemozoin) formation. Table 3.6 gives the IC50 values obtained for this study. 
 
The organosilane thiosemicarbazone ligand 2.4b did not exhibit activity at the tested 
concentration. On the other hand, the rhodium(III) complexes 2.9a (IC50 = 150.3 µM) and 
2.10b (IC50 = 38.1 µM) displayed inhibitory effects. The superior activity of the rhodium(III) 
complex 2.10b relative to chloroquine (IC50 ~ 74 µM) is noteworthy.  
 
Table 3.6  β‒haematin inhibition activity of 2.4b, 2.9a, 2.10b and CQ 
Compound IC50 (µM) [95% confidence interval] 
 
2.4b n.a.a 
 
2.9a 150.3 [144.9 to 155.8] 
 
2.10b 38.09 [35.94 to 40.38] 
CQ 73.76 [71.32 to 76.28] 
             an.a. = not active at the tested concentration 
 
No direct correlation could be drawn between the β‒haematin inhibition data and the in vitro 
antiplasmodial data reported in Section 3.2.2. The difference in antiplasmodial activity 
observed for compounds 2.4b, 2.9a and 2.10b was not as pronounced as seen for the 
corresponding β‒haematin inhibition data. However, a relationship does exist between the 
antiplasmodial activity and the ability of the rhodium compounds to inhibit β‒haematin 
formation. Furthermore, a larger number of diverse rhodium compounds would have to be 
tested before a conclusive statement can be made about the mode of action of these 
compounds.  
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3.2.4  In Vitro Antitrichomonal Studies   
The synthesised compounds (50 M solutions) were screened to determine general growth 
inhibition against the G3 strain of Trichomonas vaginalis. DMSO and metronidazole were 
employed as controls for the screening, and the antitrichomonal activity data is illustrated in 
Figure 3.8 and listed in Table 3.6. 
 
The Schiff base dithiocarbamates (2.1; 2.2) and thiosemicarbazones (2.3; 2.4; 5) generally 
displayed poor inhibitory effects (< 50 %, Figure 3.8). The ruthenium (2.6b; 2.7) and rhodium 
(2.9a; 2.10; 2.11) complexes, on the other hand, were significantly more potent. The 
complexes generally display inhibitory effects above 90 %, with the ferrocenyl−derived TSC 
rhodium complex (2.9a) displaying 100 % inhibition.  
 
 
Figure 3.8  Percentage growth inhibition of T. vaginalis (G3 strain) at a test concentration of 50 M.  
 
The non‒silicon containing TSC ligand (2.5) and rhodium complex (2.11) displayed the lowest 
inhibitory effects when compared to the silicon containing TSCs and the rhodium complexes, 
respectively (Figure 3.8). The cyclopalladated complexes (2.12‒2.14) were significantly less 
active than the ruthenium and rhodium complexes, exhibiting inhibitory effects (< 41 %, 
Figure 3.8) comparable to that of the dithiocarbamates and TSCs.  
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Table 3.7  Antitrichomonal inhibition data for the tested compounds against the G3 strain.   
Compound  IC50 (μM) 
 
2.6b 35.21 ± 0.22 
 
2.7a (R=H) 17.53 ± 0.88 
2.7b (R=CH3) 12.55 ± 0.61 
 
2.9a 7.51 ± 0.81 
 
2.10a 7.28 
Metronidazole  0.72 
  
Dose‒response curves were constructed for the thiosemicarbazone compounds displaying 
inhibition above 90 %, and used to determine the IC50 values, which are listed in Table 3.7. 
The ferrocenyl‒derived TSC ruthenium complex 2.6b (IC50 = 35.21 μM) was less active than 
its 3,4-dichloroaryl‒derived TSC ruthenium counterparts 2.7a (IC50 = 17.53μM) and 2.7b (IC50 
= 12.55 μM). Rhodium complexes 2.9a and 2.10a exhibited similar activity with IC50 values of 
7.51 μM and 7.28 μM, respectively. The rhodium complexes were generally more effective in 
inhibiting G3 parasite growth compared to the ruthenium complexes.  
 
As previously mentioned in Chapter 1 (Section 1.5) and Chapter 2 (Section 2.1), research on 
the use of metal‒containing compounds for antitrichomonal treatment is scarce. Within our 
group we have evaluated TSC‒containing palladium‒, platinum‒ and ruthenium‒complexes 
for their antitrichomonal activity against either the T1 or G3 strains of T. vaginalis.29,35,36 The 
complexes were weak growth inhibitors of the T. vaginalis parasite.  
  
Overall, the silicon‒containing TSC ruthenium(II)‒ and rhodium(III)‒complexes reported 
herein were the most effective parasite growth inhibitors., albeit not as effective as the FDA 
approved drug Metronidazole. 
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3.2.5  In Vitro Antitumour Studies 
Ferrocenyl compounds such as ferrocifen and its analogues have displayed significant 
antiproliferative effects on human cancer cell‒lines.37,38 Preliminary cytotoxicity studies were 
carried out on selected ferrocenyl compounds, which were screened against the 
cisplatin‒sensitive (A2780) and cisplatin‒resistant (A2780cisR) human ovarian carcinoma 
cell‒lines, as well as non‒tumourigenic human fibroblast cells (KMST‒6). The IC50 values are 
listed in Table 3.8.  
 
Table 3.8  Antitumour data for ferrocenyl‒derived compounds 2.1, 2.3, 2.6b and 2.12. 
Compound 
IC50 (µM) 
SI1a SI1b 
A2780 A2780CisR KMST-6 
 
2.1a 42.67 ± 5.0 76.52 ± 4.1 73.86 ± 5.2 1.73 0.96 
2.1b 120.7 ± 2.9 150.2 ± 3.8 85.83 ± 5.0 0.71 0.57 
 
2.3a 111.1 ± 5.9 110.2 ± 10.5 104.6 ± 8.7 0.94 0.95 
2.3b 82.14 ± 12.1 113.4 ± 4.0 132.3 ± 5.9 1.61 1.17 
 
2.6b 12.45 ± 2.5 18.91 ± 3.6 17.23 ± 2.6 1.38 0.91 
 
2.12 111.6 ± 5.0 134.1 ± 5.7 85.17 ± 4.9 0.76 0.63 
Cisplatin  1.97 ± 3.4 18.90 ± 0.8 44.04 ± 0.8 22.35 2.33 
aSI1 =IC50(KMST-6)/IC50(A2780); bSI2 = IC50(KMST-6)/IC50(A2780cisR) 
 
The Schiff base dithiocarbamates 2.1a appears to be slightly more active than compound 2.1b 
against both the A2780 and A2780cisR cell‒lines (Table 3.8). A loss of activity is observed for 
the organosilane TSC 2.3a, whilst 2.3b [82.13 μM (A2780); 113.4 μM (A2780cisR)] displays a 
slight improvement in activity. On the other hand, a significant improvement in activity is 
observed for the ruthenium complex [2.6b; 12.45 μM (A2780); 18.91 μM (A2780cisR)] when 
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compared to the corresponding TSC 2.3b. The activity against the resistant strain is 
comparable to the activity of cisplatin (18.90 μM).  
 
A loss in activity was observed for the palladium complex [111.6 μM (A2780); 134.1 μM 
(A2780cisR)] when compared to the corresponding TSC 2.3b [82.14 μM (A2780); 113.4 μM 
(A2780cisR)]. Additionally, the TSC 2.3b was also less toxic towards the non‒tumourigenic 
cell‒line KMST‒6 than the cyclopalladated complex 2.12 (Table 3.8). Rhodium complex 2.9a 
did not display any activity at the highest tested concentration. 
 
In general, the tested compounds exhibited similar cytotoxicities against the tumourigenic and 
the non‒tumourigenic cell‒lines, and thus displayed no selectivity.    
 
3.2.6  Evaluation using a Plasmodium Berghei infected Mouse Model 
As mentioned in Section 3.1, pre‒clinical mouse studies are practical models for the 
experimental study of human malaria. Rodent Plasmodium species are analogues to human 
malaria parasites in terms of structure, physiology and life cycle, and thus relatively good 
models for initial studies.39 Compound 2.13, which displayed good antiplasmodial activity 
[IC50 = 0.55 (NF54) and 0.29 (Dd2) μM] along with good selectivity [SI1 = 6.44 (NF54) and 
SI2 = 12.21 (Dd2)] was chosen for in vivo evaluation (project no. 013/028). 
 
Stability of Compound 2.13   
When evaluating the biological activity of a particular compound, it is important to ensure that 
the metal‒based compounds proposed as being biologically active are in fact responsible for 
the observed activity. Therefore, it is important to monitor metal‒based compounds in solution 
in order to either ensure stability of the compound or identify the active species. Therefore, as a 
model system the stability of complex 2.13 was investigated and monitored by 1H NMR 
spectroscopy over a 72 hr period at 37 °C. The 1H NMR spectra (Figure 3.9) of complex 2.13 
were recorded in (a) DMSO‒d6 and (b) DMSO‒d6:D2O (9:1, v/v). The spectra remain 
unchanged over the study period. 
 
 
Chapter 3: Pharmacological evaluation of TSCs 
 
80 
 
 
 
 
Figure 3.9  1H NMR spectra of a solution of compound 2.13 in (a) DMSO−d6 and (b) DMSO−d6:D2O heated at 
37 ˚C over 72 hr.  
 
The dosing formulation for compound 2.13 was prepared as a suspension in a hydroxypropyl 
methylcellulose (HPMC) and dimethyl sulfoxide (9:1, v/v) vehicle. Hydroxypropyl 
methylcellulose is an inert polymer, which has been used in the pharmaceutical industry to 
control the release of an orally administered compound in the digestive tract, and is not toxic to 
animals such as mice.40 In this study, doses were delivered via intragastric administration (oral 
gavage) to healthy male C57BL/6 mice. 
 
Toxicity study 
In a preliminary study, compound 2.13 was administered orally at three different 
concentrations [50, 30 and 10 mg/kg dose; to one mouse each (M1-3); Table 3.9] once a day for 
four days. The weight of the mice and general behaviour was used as an indication of health 
and monitored continuously throughout the experimentation period. As per protocol, the 
experiment would be stopped if a 15 % loss in initial body weight was observed.  
 
 
a 
b 
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Table 3.9  Dosage information for mice M1‒M3. 
 
M1 M2 M3 
Dose (mg/kg) 50 30 10 
Final Concentrationa  
(mg/mL) 
6.25 3.75 1.25 
Volume Administereda  
(μL) 
270 280 250 
                       a Calculated for an average mouse weight of 35 grams.  
 
Over the course of four days no visible discomfort or the maximum weight loss (15 %) was 
observed. Therefore, no significant toxicity was observed at the tested concentrations.  
 
Efficacy study 
An efficacy study similar to a Peter’s four‒day suppressive test was carried out in mice 
infected with the CQS P. berghei ANKA strain to evaluate the blood schizontocidal activity of 
the formulations. Three groups (negative control; positive control; test compound) consisting 
of three mice each were studied (Table 3.9). Groups A and C were the negative and positive 
control groups, respectively. They were administered either as a blank formulation vehicle 
(Group A) or 20 mg/kg chloroquine (Group C) via oral gavage (Table 3.10; Figure 3.10). 
Group B was administered as a suspension of compound 2.13 (50 mg/kg in DMSO:HPMC) via 
oral gavage.  
 
Table 3.10  Formulations for Groups A‒C. 
 
Group A 
Group B 
Compound 2.13 
Group C 
Chloroquine 
Dose (mg/ kg) -a 50 20 
Final concentration (mg/ml) - 6.25 2.5 
Delivery Vehicle DMSO : HPMC (1:9) DMSO : HPMC (1:9) H2O 
Volume Administered (μL) 200 200b 240c 
a not applicable; b Calculated for an average mouse weight of 25 grams; c Calculated for an average mouse weight 
of 30 grams. 
 
The mice received the first dose two hours after infection on day 0, followed by the second, 
third and fourth dose at intervals of 24 hours (Figure 3.10). The weight of the mice was 
monitored (Figure 3.11) and a change of less than 15 % suggested no significant negative 
effects during the testing period. Blood samples were collected on day 4 and analysed using 
flow cytometry. 
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Figure 3.10  Diagram showing the experimental design of the efficacy study.   
 
Transgenic parasitic strains, such as P. berghei ANKA strain, express green fluorescent 
proteins (GFP), which enables fluorescence‒activated cell sorting (FACS) using flow 
cytometry. FACS is a specialised flow cytometry method for the sorting of mixtures of 
biological cells based on differences in light scattering and fluorescent characteristics. 
Therefore, red blood cells infected with the parasite expressing GFP can be distinguished from 
uninfected red blood cells, and thus detected by flow cytometry. The percentage parasitaemia 
determined using flow cytometry is listed in Table 3.11.  
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Figure 3.11  Graph showing the average body weight versus time for the mice infected with P. berghei and 
treated with compound 2.13 in a Peter’s four‒day suppressive test, along with positive (chloroquine) and negative 
controls.    
 
As seen in Table 3.11, a comparison of the overall average percentage parasitaemia revealed 
that Group B (Compound 2.13) had a similar value to that of Group A (negative control). 
Group C, which received the control drug chloroquine, displayed a significant clearance of 
parasitaemia (Table 3.11). Therefore, the test compound had no effect on the percentage 
parasitaemia.  
 
Table 3.11  Percentage parasitaemia detected for Groups A‒C. 
 Group A Group B Group C 
 A1 A2 A3 B1 B2 B3 C1 C2 C3 
Regional stats 10.37 9.70 11.03 14.11 10.56 10.58 0.25 0.20 0.17 
Histogram stats 10.43 9.78 11.10 14.28 10.64 10.67 0.28 0.22 0.19 
Individual Average 10.40 9.74 11.06 14.19 10.60 10.62 0.26 0.21 0.18 
Overall average  10.40   10.61*  0.22  
*Calculated using B2 and B3. 
 
Attempts were made to develop an HPLC‒UV method to analyse compound 2.13. Blood 
samples spiked with compound 2.13 were subjected to either protein precipitation or 
liquid‒liquid extraction methods.   
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Protein precipitation involves the additional of an organic solvent (such as acetonitrile) to the 
spiked blood sample to extract the compound. This is followed by centrifugation and collection 
of the supernatant.41 The supernatant was then analysed by HPLC‒UV after a suitable 
reverse‒phase C18 column, wavelength (from UV‒vis studies) and solvent system gradients 
[acetonitrile: H2O (0.1% formic acid)] were selected.  
 
When analysing a specified concentration of the tested compound, at a particular wavelength, 
the chromatogram would ideally display a peak with a specific intensity (and area) at a specific 
retention time. Therefore, analysis of the supernatant collected after protein precipitation was 
based on the intensity of the peak at the identified retention time for compound 2.13. However, 
analysis of the supernatant from protein precipitation gave chromatograms with varying peak 
intensities for spiked samples of the same concentration. Therefore, the recovery of compound 
2.13 was not consistent. 
 
Following on from these results, the liquid‒liquid extraction method was used. The 
liquid‒liquid extraction method uses a buffer in combination with the spiked blood sample and 
immiscible organic solvent.41 The buffer is used to ensure the presence of the largest amount of 
unionised complex, which can then be extracted with the organic solvent. Therefore, Britton 
Robinson Universal buffer solutions with a pH range between 3 and 11 were used to determine 
at which pH the largest amount of unionised complex was extracted. However, despite initial 
results identifying pH 9 as the ideal pH, reproducibility studies failed and the recovery of 
compound 2.13 was not consistent.  
 
One problem with these extraction methods is the possibility of protein binding, which may be 
the case in this work. Therefore, future studies involving either inductively coupled plasma 
mass spectrometry (ICP‒MS) analysis of the precipitated proteins or protein binding studies 
may prove or disprove that idea.  
 
Unfortunately no useful information was obtained from this study. However, determining if 
compound 2.13 was indeed interacting with proteins may assist with future ADME studies for 
other metal complexes, and may shed light on the fate of compound 2.13 in the mouse model. 
As mentioned above, compound 2.13 was administered orally as a suspension. Therefore, 
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determining the bioavailability, as well as potential metabolism products, may also contribute 
to why the tested compound did not display any effect on the percentage parasitaemia.  
 
3.3  Summary 
The Schiff base dithiocarbamates (2.1; 2.2) and thiosemicarbazone compounds (2.3‒2.14) were 
screened as potential antiparasitic agents against parasitic strains Plasmodium falciparum and 
Trichomonas vaginalis.  
 
The compounds (2.1−2.14) were evaluated for their antiplasmodial activity against the 
CQ‒sensitive NF54 and CQ‒resistant Dd2 strains of P. falciparum. The compounds generally 
displayed antiplasmodial activity in the low micromolar range. The cyclopalladated complexes 
(2.12−2.14) were found to be the most potent, with the 3,4-dichloroaryl derivatives (2.13; 2.14) 
displaying activity below 1 μM against both strains. Selected compounds were also evaluated 
for their cytotoxicity against the Chinese Hamster Ovarian (CHO) cell‒line. As proposed, 
compounds containing the incorporated organosilane moiety have reduced cytotoxicity 
compared to the dithiocarbamates and non‒silicon compounds. 
  
Selected compounds (2.4b, 2.9b, 2.10b) were evaluated for their ability to inhibit the formation 
of β‒haematin. The rhodium complexes 2.9b and 2.10b had a moderate inhibition effect on the 
formation of β‒haematin, whereas the metal−free thiosemicarbazone 2.4b had no effect. 
 
The antitrichomonal activity of the TSC compounds was also evaluated against the 
metronidazole‒sensitive G3 strain of T. vaginalis. The ruthenium and rhodium complexes 
displayed growth inhibitions above 90 %, whereas the dithiocarbamates, thiosemicarbazones 
and the cyclopalladated complexes had no significant effects. The IC50 values were determined 
for complexes displaying inhibitions above 90 %. The ruthenium (2.6b; 2.7a; 2.7b) and 
rhodium (2.9a; 2.10a) complexes displayed moderate IC50 values (7‒35 μM), with the rhodium 
complexes appearing to be more effective inhibitors of G3 parasite growth compared to the 
ruthenium complexes. 
 
Preliminary antitumour activities of selected ferrocenyl compounds were determined against 
cisplatin‒sensitive (A2780) and cisplatin‒resistant (A2780cisR) human ovarian carcinoma 
cell‒lines, as well as non‒tumourigenic human fibroblast skin cells (KMST‒6). The 
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compounds displayed moderate activities (18‒150 μM), but did not show any selectivity 
between the tumourigenic and non‒tumourigenic cell‒lines. 
 
Cyclopalladated complex 2.13, which displayed good in vitro antiplasmodial activity, was 
chosen for in vivo evaluation in a mouse model. This compound did not display any signs of 
toxicity at the highest tested concentration (50 mg/kg). Compound 2.13 was evaluated for in 
vivo efficacy in a P. berghei mouse model and was found to be inactive.    
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CHAPTER 4 
Synthesis and Characterisation of Organosilane Derivatives of Heterocyclic 
Compounds Containing Quinoline and Benzothiazole   
 
 
4.1  Introduction 
Heterocycles, such as quinolines, benzothiazoles, benzimidazoles, benzoxazoles, imidazoles to 
name a few, form part of another class of pharmacologically significant compounds in 
medicinal chemistry.1 Thus, the identification of heterocyclic compounds among naturally 
occurring biologically active compounds led to a boom in the synthesis of derivatives thereof. 
In this project quinoline‒ and benzothiazole‒based compounds were explored. 
 
As mentioned in Chapter 1 (Section 1.2.3) chloroquine was one of the most widely‒used 
antimalarial drugs, and thus its mechanism of action has been thoroughly studied. Neutral 
chloroquine (CQ) is transported into the digestive vacuole via simple diffusion, and protonated 
under the acidic conditions of the digestive vacuole. However, due to marked difference in the 
biology of parasite strains, compounds with various physico-chemical properties are tolerated 
differently. Mutations of various Plasmodium falciparum genes and proteins have been 
associated with drug resistance, for example the development of P. falciparum CQ resistance 
transporter (PfCRT), which is present only in CQ‒resistant strains.2,3 Due to the presence of 
these transporters, the protonated form of CQ is transported out of the vacuole, resulting in a 
marked decrease in accumulated CQ and thus a decrease in activity.  
 
Therefore, identifying compounds which are able to circumvent the above mentioned 
resistance mechanism is of great importance. Ferroquine (I, Figure 4.1), which was briefly 
mentioned in Chapter 1 (Section 1.6.1), is an analogue of chloroquine containing a ferrocenyl 
moiety in the side‒chain and has received a lot of attention due to enhanced potency against 
chloroquine‒resistant strains of P. falciparum.4,5 Studies have also shown that the activity of 
ferroquine is unrelated to mutations in P. falciparum genes.6,7 Additionally, the differences in 
basicity and lipophilicity of ferroquine and chloroquine at cytosolic and digestive vacuole pH 
results in more efficient accumulation of ferroquine than chloroquine.8 Furthermore, the folded 
conformation brought about as a result of a noncovalent intramolecular interaction, is also 
believed to contribute to the accumulation of the ferroquine.5,9  
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The role of the ferrocenyl moiety present in ferroquine includes influencing the lipophilicity 
and redox properties of the compound.5,8 This has led to the investigation of a range of 
quinoline‒based analogues containing a metal fragment.10–17 The position of the ferrocenyl 
moiety was varied in these analogues14,15,18 (II, Figure 4.1), aminoquinoline nitrogen alkylated5 
(III, Figure 4.1), changed the substituent on the terminal nitrogen16,17,19–21 (IV & V, Figure 
4.1), and incorporation of metal‒containing structures based on ruthenocene5, rhenium22 and 
chromium compounds23 (VI, Figure 4.1).  
 
 
Figure 4.1  Metallo‒compounds (I−VI) displaying antiplasmodial activity.4,5,14,16,17,22,23 
 
The majority of the literature published on metal‒containing compounds has related to their 
activity against P. falciparum, with a limited number of complexes screened against parasitic 
strains of Trichomonas vaginalis. However, a report on the evaluation of ferroquine against the 
metronidazole‒sensitive CMP (Chatenay‒Malabry Parasitology) strain of T. vaginalis, has 
been published, but no activity was noted.24 In another study, the inhibitory effects of binuclear 
rhodium(I) complexes of quinoline-based compounds were evaluated with the complexes 
found to display promising results against the G3 strain of T. vaginalis.25        
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As mentioned in Chapter 1 (Section 1.3.3), 5-nitroimidazole compounds such as metronidazole 
or tinidazole produce cytotoxic nitro radical‒ion intermediates from the reduction of the nitro 
groups.26 These reactive nitrogen species act similar to ROS, and thus the presence of an 
oxidisable ferrocenyl moiety may be important for potential antitrichomonal agents. On the 
other hand, the mechanism of action and antiparasitic (antiplasmodial and antitrichomonial) 
activity of benzothiazole‒based compounds have not been as thoroughly explored.27–30 There 
have been a few publications relating to the activity of the benzothiazole‒based compounds to 
their interactions with DNA and enzymes, or the effect they have on mitochondria.29,31,32 
However, no conclusive targets have been identified. Perhaps further evaluation of 
benzothiazole‒based compounds will reveal potent antiparasitic and antitrichomonal agents 
which are able to circumvent the parasite resistance mechanism. 
 
Unlike ferrocenyl‒containing quinoline compounds, research focussed on 
ferrocenyl‒containing benzothiazole‒based compounds does not feature as prominently in 
literature. The only examples of ferrocenylbenzothiazoles are thiosemicarbazone‒based 
compounds (Figure 4.2) evaluated as antitumour agents.33,34 
 
 
Figure 4.2  Ferrocenylbenzothiazole connected via a thiosemicarbazone.34 
 
As mentioned in Chapter 1 (Section 1.4.1) and Chapter 2 (Section 2.1), there was an interest in 
exploring whether or not incorporation of silicon would favourably alter the pharmacological 
activity and selectivity of the compounds studied in this project. A previous study conducted 
within our research group investigated the preparation and evaluation of an organosilane 
ferroquine derivative (V, Figure 4.1). This compound displayed promising in vitro activity with 
IC50 values of 7.32 and 53.87 nM against the P. falciparum strains NF54 and Dd2, 
respectively.17 Chloroquine displayed IC50 values of 5.43 nM (NF54) & 108.36 nM (Dd2). 
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The promising pharmacological results observed with compound V (Figure 4.1) prompted 
further investigation into ferrocenyl‒containing quinoline‒ and benzothiazole−based 
compounds, with respect to activity against P. falciparum and T. vaginalis. 
   
4.2  Results and Discussion 
4.2.1  Synthesis and Characterisation of Ferrocenyl‒Containing Aminoquinolines  
Synthesis 
Ferroquine and its quaternised form were prepared using published methods set forth by Biot et 
al. as illustrated in Scheme 4.1.4,35 2-[(N,N-dimethylamino)methyl]-ferrocenylmethylamine 
was prepared from the starting material 2-[(N,N-dimethylamino)methyl]ferrocene. This was 
achieved via aldehyde and oxime intermediates. The 2-[(N,N-dimethylamino)methyl]-
ferrocenylmethylamine was reacted with 4,7-dichloroquinoline in a nucleophilic aromatic 
substitution reaction to prepare ferroquine, which in turn was quaternised using 
iodomethane.4,35  
 
 
Scheme 4.1  Preparation of ferroquine and its quaternised form.4,35 
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Scheme 4.2  The synthesis of ferrocenyl‒containing aminoquinolines (4.1‒4.5).  
Reagents and conditions: 8 eq. of (aminomethyl)trimethylsilane (4.1), 2,2’-dimethylpropan-1-amine (4.2),  
(3-aminopropyl)trimethylsilane (4.3), 4,4’-dimethylpentan-1-amine (4.4) or (aminomethyl)dimethylphenylsilane 
(4.5); CH3CN, K2CO3, reflux, 3 days.  
 
The ferrocenyl‒containing aminoquinolines (4.1‒4.5) were prepared by the procedure outlined 
in Scheme 4.2. Nucleophilic substitution of the trimethylammonium group by 
amine‒terminated organosilanes (aminomethyl)trimethylsilane, (3-aminopropyl)trimethyl-
silane or (aminomethyl)dimethylphenylsilane, as well as the corresponding carbon analogues 
2,2’-dimethylpropan-1-amine and 4,4’-dimethylpentan-1-amine, yielded the desired 
compounds. Previously published compound 4.117 was prepared following the method 
described herein. 
 
Compounds 4.1‒4.5 were isolated in moderate yields (48 ‒ 85 %) as orange or yellow solids. 
The compounds were thermally stable, melting at around 150 ˚C. Compounds 4.1‒4.5 were 
soluble in most organic solvents, such as chlorinated and alcoholic solvents. 
 
Characterisation 
Compounds 4.1‒4.5 were fully characterised using NMR (1H, 13C{1H}, COSY, HSQC) 
spectroscopy, infrared (IR) spectroscopy and electron impact (EI) mass spectrometry. 
 
NMR Spectroscopy 
The 1H NMR spectra of compounds 4.1‒4.5 were recorded in CDCl3. The protons of the 
aromatic quinoline ring were observed in the expected region 6.46‒8.56 ppm. The ferrocenyl 
protons of the substituted and unsubstituted cyclopentadienyl rings resonate between 4.10 and 
4.30 ppm (Figure 4.4).  
 
The methylene protons H−11 and H−12 of compounds 4.1‒4.5 are diastereotopic protons due 
to the planar chirality of the ferrocenyl moiety, brought about as a result of 1,2-disubstitution 
of the cyclopentadienyl ring. The same applies to the methylene protons H−13 of compounds 
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4.1, 4.2 and 4.5. The signal for one H−11 proton appears as a doublet at ~4.3 ppm (J = 13.2 
Hz) and the signal for the other H−11 proton overlaps with the signal of the unsubstituted 
ferrocenyl ring (confirmed using COSY). The H−12 protons resonate as two doublets at around 
3.5 and 3.7 ppm (J ~ 12.3 Hz). The observed doublets were due to geminal coupling of the 
methylene protons.  
 
The formation of the proposed compounds was also confirmed by the presence of signals for 
the incorporated amine side‒chain. Two doublets were observed for the methylene protons 
H−13 of compounds 4.1, 4.2 and 4.5, whereas three upfield signals corresponding to the propyl 
spacer of compounds 4.3 and 4.4 were observed (Figure 4.4). Furthermore, the methyl protons 
[Si(CH3)3 or C(CH3)3] of compounds 4.1−4.5 resonate as singlets at 0.046, 0.91, −0.036, 0.85 
and 0.34 ppm, respectively. The protons of the methyl groups for Si(CH3)3 are more shielded 
than C(CH3)3 due to the electropositive silicon. 
 
 
Figure 4.4  The 1H NMR spectrum of compound 4.3. 
 
The 13C{1H} NMR spectra for compounds 4.1‒4.5 were recorded in CDCl3. The quinoline 
carbon atoms resonate between 98.6 and 152.1 ppm. The peaks for the ferrocenyl carbon atoms 
were observed in the range 66.1 to 86.1 ppm, with the quaternary carbon atoms being the most 
deshielded (identified using HSQC). 
   
In addition to the above mentioned carbon atoms, the three methylene carbon atoms of 
compounds 4.1, 4.2 and 4.5 resonate as three peaks in the range 38.8–62.5 ppm, whilst the 
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spectra for compounds 4.3 and 4.4 displayed the expected five signals (14.2‒53.4 ppm). The 
most shielded methylene carbon atoms were those situated closest to the electropositive silicon. 
The methyl carbon atoms of the (Si(CH3)3) group of compounds 4.1, 4.3 and 4.5 were heavily 
shielded, and the signal was observed at −2.29, −1.74 and ‒3.99 ppm, respectively. As 
expected, the methyl carbon atoms [C(CH3)3] were more deshielded than the signals observed 
for the silicon‒containing compounds. The methyl carbon atoms resonate at 27.9 and 29.3 
ppm, whilst the quaternary carbon atom [C(CH3)3] was observed at 31.5 and 30.1 ppm for 
compounds 4.2 and 4.4, respectively.    
 
Infrared Spectroscopy and Mass Spectrometry 
Infrared analysis of compounds 4.1‒4.5 was carried out using attenuated total reflection 
(ATR). The absorption band corresponding to the stretching frequency of the C=N (quinoline 
ring) bond was observed at 1611 cm-1 (4.1‒4.4) and 1609 cm-1 (4.5) for the compounds 
analysed. 
   
The identity of compounds 4.2−4.5, which have molecular masses of 475.1470, 519.1552, 
503.1782 and 553.1396 g.mol-1, was further confirmed using electron impact mass 
spectrometry. The molecular ion peaks were observed at m/z 475.09, 519.14, 503.12 and 
553.14 for compounds 4.2‒4.5, respectively. 
 
Molecular Structure        
Crystals suitable for single‒crystal X−ray diffraction were grown by the slow evaporation of 
solutions of 4.2 and 4.3 in dichloromethane and acetone, respectively. Both compounds 
crystallised as red blocks in a triclinic crystal system with the centrosymmetric space group Pī. 
Selected bond lengths and angles are listed in Table 4.1, with selected crystallographic data 
tabulated in Table 4.2.   
 
As expected, due to the electropositive nature of the silicon atom, less electron density is 
contributed to Si−C bond formation. Therefore, the terminal C−C bonds [C(22)−C(23) and 
C(23)−C(24)] of compound 4.2 are shorter than the corresponding C−Si bonds [C(24)−Si(1) 
and Si(1)−C(25)] of compound 4.3, with lengths of ~1.53 and ~1.87 Å, respectively (Table 
4.1). Furthermore, differences in C−N bond lengths have been noted for the bonds N(2)−C(9) 
and N(3)−C(22). Due to the proximity of the aromatic quinoline ring, resonance extends to the 
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N(2)−C(9) bond resulting in a bond length of 1.36 Å. This bond length is significantly shorter 
than 1.47 Å, which has been noted for the N(3)−C(22) bond of the side−chain (Table 4.1) 
 
                                                     Table 4.1  Selected bond lengths (Å) and angles (˚) 
 4.2 4.3 
Bond Lengths (Å) 
C(22)−C(23) 1.531(3) − 
C(24)−Si(1) − 1.8722(19) 
N(3)−C(22) 1.465 1.467(2) 
N(2)-C(9) 1.366(3) 1.364(2) 
C(23)−C(24) 1.538(3) 1.522 
Si(1)−C(25) − 1.872(3) 
Hydrogen Bond Lengths (Å) 
N(2)−H(2)∙∙∙∙N(3) 3.160(2) 2.993(2) 
N(3)−H(3)∙∙∙∙N(1) 3.404(3) − 
Bond Angles (˚) 
C(9)−N(2)−C(10) 119.54(17) 120.85(14) 
C(21)−N(3)−C(22) 111.53(17) 113.05(14) 
N(3)−C(22)−C(23) 115.1(2) 111.44(16) 
C(23)−C(24)−Si(1) − 114.89(13) 
Hydrogen Bond Angles (˚) 
N(3)−C(22)−C(23) 145.9 155.7(19) 
N(3)−H(3)∙∙∙∙N(1) 159 − 
Dihedral Bond Angles (˚) 
C(10)−C(11)−C(12)−C(21) −7.7(3) 1.5(2) 
N(2)−C(10)−C(11)−C(12) 70.5(2) 67.39(19) 
C(11)−C(12)−C(21)−N(3) −77.4(2) −74.4(2) 
 
It is evident from the molecular structures, that both compounds 4.2 and 4.3 have a folded 
conformation due to intramolecular hydrogen bonding between the aromatic amine nitrogen 
N(2) and the aliphatic amine nitrogen N(3) (Figure 4.5). In both cases, the nitrogen atom N(2) 
acts as the H‒donor and the nitrogen atom N(3) as the acceptor. This folded conformation has 
previously been observed for ferroquine derivatives, including compound 4.1.5,9–11,17 For 
compound 4.2, the crystal data listed in Table 4.1 suggests that the compound could also fold 
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in a different manner due to hydrogen bonding between the quinoline nitrogen atom N(1) and 
the aliphatic amine nitrogen atom N(3). 
 
 
a) 
 
b) 
Figure 4.5  ORTEP representations of compound 4.2 (a) and 4.3 (b) with ellipsoids drawn at the 50 % 
probability level. 
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                           Table 4.2  Crystal data of compounds 4.2 and 4.3. 
 4.2 4.3 
Chemical formula C26H30ClFeN3   C27H34ClFeN3Si 
Formula weight 475.83 519.96 
Crystal system Triclinic Triclinic 
Space group Pī Pī 
Crystal size (mm) 0.05 x 0.09 x  0.15 0.21 x 0.32 x 0.34 
a, b, c (Å) 
8.6284(12), 10.9159(15), 
26.353(4) 
6.6872(6), 7.7098(7), 25.388(2) 
α, β, γ (°) 83.680(3), 84.639(3), 73.336(3) 
92.4700(10), 94.337(2), 
95.214(2) 
V/Å3 2358.4(6) 1298.13(19) 
Z 4 2 
T/K 173 173 
Dc/g.cm−3 1.340   1.330 
μ/mm−1 0.771 0.750 
Scan range/° 1.96 < θ < 28.4   1.66 < θ < 27.2 
Unique reflections 11751 5756 
Reflections used [I > 2σ(I)] 8046 4992 
Rint 0.057   0.035 
R indices (all data) 0.0413, wR2 0.0903, S 1.03   0.0339, wR2 0.0809, S 1.03   
Goodness-of-fit 1.026 1.027 
Max, Min Δρ/e Å −0.34; 0.40 −0.31; 0.33 
 
Compound 4.3 was further reacted with [RuCl2(η6-p-iPrC6H4Me)]2, [RuCl2(η6-p-
C6H5O(CH2)2OH)]2 and [RhCl2(Cp*)]2 to prepare heterobimetallic complexes with compound 
4.3 binding in a monodentate mode via the quinoline nitrogen atom. Analyses of the solids 
(TLC and IR) confirmed the formation of the proposed complexes. As seen in Figure 4.6, when 
[RuCl2(η6-p-iPrC6H4Me)(4.3)] was analysed by 1H NMR spectroscopy in DMSO‒d6, no 
differences in chemical shifts were observed between that of the starting material and the new 
complex. The same trend was observed for [RuCl2(η6-p-C6H5O(CH2)2OH)(4.3)] and 
[RhCl2(Cp*)(4.3)]. This suggests cleavage of the ruthenium‒nitrogen bond. If the complex was 
stable in DMSO-d6, even a slight shift should have been observed for the signal of the proton 
(H‒2) adjacent to the quinoline C=N bond.  
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Figure 4.6 1H NMR spectra for [RuCl2(η6-p-iPrC6H4Me)]2, 4.3 and [RuCl2(η6-p-iPrC6H4Me)(4.3)] in DMSO-d6. 
 
Patra et al. investigated a range of N-heterocyclic-[Ru(η6-arene)Cl2] complexes and noted 
similar observations when analysed in DMSO‒d6.36 They observed that upon cleavage of the 
metal-nitrogen bond, the signal observed corresponds to the N-heterocyclic compound and the 
[Ru(η6-arene)(DMSO)Cl2] complex.36 Therefore, preparations of these complexes were 
abandoned as stock solutions for biological assays are made using dimethyl sulfoxide.   
 
4.2.2 Synthesis and Characterisation of Ferrocenyl−Containing Aminobenzothiazoles 
Benzothiazole‒based compounds which are analogous to those in Section 4.2.1 were prepared. 
All components, except the quinoline ring, were kept the same as in Section 4.2.1 which allows 
one to determine the contribution of the benzothiazole ring to any observed pharmacological 
activity.  
 
Synthesis 
6-Chloro-2-iodobenzothiazole (4.6) was prepared as described in Scheme 4.4, via a 
Sandmeyer‒type reaction. As seen in Figure 4.7, the benzothiazole diazonium salt was 
prepared by the nucleophilic addition of the primary amine to the nitrosonium ion (prepared in 
situ from H2SO4 and NaNO2). 
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Figure 4.7  Mechanism for the formation of 6-chloro-2-iodobenzothiazole. 
 
Further reaction of the stable diazonium salt was possible in the presence of a suitable 
nucleophile. Therefore, the desired compound 4.6 was prepared via a nucleophilic substitution 
reaction with iodide (from potassium iodide), which results in the liberation of N2 gas (Figure 
4.7).  
 
Compound 4.7 was prepared via a nucleophilic substitution reaction, whereby 2-[(N,N-
dimethylamino)methyl]ferrocenylmethylamine substitutes the iodide in the 2nd position as 
illustrated in Scheme 4.3. 2-[(N,N-Dimethylamino)methyl]ferrocenylmethylamine was 
prepared via published methods as seen in Scheme 4.1.4 
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Scheme 4.3  The synthesis of a ferrocenyl−containing aminobenzothiazoles (4.7−4.11).  
Reagents and conditions: (i) H2SO4, NaNO2, 0˚C, 0.25 hr; (ii) KI, rt, 24 hr; (iii) THF, K2CO3, 30 ˚C, 3 days; 
(iv) Acetone, MeI, rt, 6 hr; (v) 8 eq. of (aminomethyl)trimethylsilane (4.9), 2,2’-dimethylpropan-1-amine (4.10) 
or (3-aminopropyl)trimethylsilane (4.11); CH3CN, K2CO3, reflux, 2 days. 
 
Attempts were made to prepare the ferrocenyl−containing aminobenzothiazole 4.7 via a Schiff 
base condensation reaction between 2-[(N,N-dimethylamino)methyl]ferrocenyl-
carboxaldehyde and 2-amino-6-chlorobenzothiazole. The resulting imine compound was not 
stable and decomposition was accelerated when exposed to light. However, the stable 
compound 4.7 could be prepared in low yields, in a one‒pot reductive amination reaction. This 
two part reaction [imine formation; imine reduction (NaBH4)] was achieved when the reaction 
was carried out in dichloromethane (in the presence of a drying agent), with the exclusion of 
light and refluxing at 45 ˚C for 24 hr to prepare the imine (not isolated). The reduction of the 
imine was then carried out at room temperature (light excluded) with a reducing agent in 
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DCM:MeOH (2:1). No increase in overall yield was observed even after allowing 48 hr for 
imine formation. Lower yields were obtained when the reaction was carried out in purely 
alcoholic solvents or heated at higher temperatures, even in the presence of drying agents or the 
use of a Dean‒Stark apparatus. 
 
The quaternised compound 4.8 was prepared by reacting compound 4.7 with iodomethane. The 
ferrocenyl‒containing aminobenzothiazoles (4.9‒4.11) were prepared by the procedure 
outlined in Scheme 4.4. Nucleophilic substitution of the trimethylammonium group by 
amine‒terminated organosilanes, (aminomethyl)trimethylsilane and (3-
aminopropyl)trimethylsilane, as well as a corresponding carbon analogue 2,2’-dimethylpropan-
1-amine, yielded the desired compounds. 
 
Compounds 4.6−4.11 were isolated as orange or yellow solids in low to moderate yields 
(18−72 %). The compounds were thermally stable, melting between 130 and 180 ˚C, and were 
soluble in most organic solvents, such as chlorinated and alcoholic solvents. 
 
Characterisation 
Compounds 4.6−4.11 were fully characterised using NMR (1H; 13C{1H}; COSY) spectroscopy, 
infrared (IR) spectroscopy and mass spectrometry (EI‒MS; ESI−MS). 
 
NMR Spectroscopy  
The 1H NMR spectra of compounds 4.6, 4.7 and 4.9−4.11 were recorded in CDCl3 and 4.8 in 
DMSO−d6. It is evident from the 1H NMR spectra for compounds 4.6 and 4.7 that the 
compounds were successfully synthesised due to the shifts observed for the signals of the 
aromatic protons (Figure 4.8). The conjugated system of the starting material 2-amino-6-
chlorobenzothiazole results in the H−8 proton resonating upfield relative to H−5, due to the 
presence of the NH2 group. However, formation of compound 4.6, which contains the 
electron‒withdrawing iodo substituent, results in a less conjugated system. This in turn results 
in H−8 resonating more downfield relative to H−5. 
  
Furthermore, reacting compound 4.6 with 2-[(N,N-dimethylamino)methyl]ferrocenyl-
methylamine reintroduces an electron−donating amine, which once again results in H−8 
resonating upfield relative to H−5 (Figure 4.8). In addition to the shifts observed for the 
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aromatic signals, a broad signal observed at 8.31 ppm corresponds to the newly incorporated 
NH of compound 4.7, which confirms formation of the desired compound. 
 
 
 
 
Figure 4.8  The 1H NMR spectra of 2-amino-6-chlorobenzothiazole, compound 4.6 and compound 4.7. 
 
As seen with the aminoquinoline derivatives in Section 4.2.1, chiral compounds are produced 
due to the 1,2-disubstitution of the cyclopentadienyl ring of the ferrocenyl moiety. Therefore, 
the H−10 and H−11 protons are diastereotopic and experience geminal coupling. For the 
methylene protons H−11, two doublets are observed, each accounting for one proton (Figure 
4.8). 
 
Quaternisation of compound 4.7 was confirmed by the presence of a singlet at 2.96 ppm, which 
corresponds to the nine methyl protons of the trimethylammonium [‒N(CH3)3+] group. Upon 
substitution of the trimethylammonium group of compound 4.8 with the various amines, the 
4.6 
4.7 
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signal is now absent, and the signals for the protons of the incorporated amine side‒chain are 
observed. This confirms preparation of compounds 4.9−4.11.  
 
The protons of the incorporated amine side‒chain resonate in a similar manner to that observed 
for the aminoquinoline derivatives in Section 4.2.1. The H−12 protons of compounds 4.9 and 
4.10 resonate as two doublets, while three signals were observed for the protons of the propyl 
chain of compound 4.11. Additionally, singlets were observed for the methyl protons of the 
Si(CH3)3 and C(CH3)3 groups. The ferrocenyl and aromatic protons were observed in the 
expected regions 7.22−7.50 ppm and 4.05−4.28 ppm respectively, for compounds 4.9−4.11. 
 
The 13C{1H} NMR spectra for compounds 4.6, 4.7 and 4.9−4.11 were recorded in CDCl3 and 
compound 4.8 in DMSO−d6. The aromatic carbon atoms were observed in the expected region 
between 119 and 151 ppm, with the remaining benzothiazole carbon C−2 resonating 
significantly downfield at ~166 ppm (4.6: 152.8 ppm) for the ferrocenyl‒containing 
compounds (4.7−4.11). The ferrocenyl carbon atoms were also observed in the expected region 
(65–85 ppm). The CH2 carbon atoms resonate upfield (14–53 ppm) with the carbons closer to 
the electropositive silicon being more shielded. As seen with the aminoquinoline derivatives 
(4.1−4.4), the Si(CH3)3 carbon atoms resonate significantly upfield at approximately ‒2 ppm, 
while the C(CH3)3 carbon atoms resonate at 28.1 and 31.3 ppm. 
 
Infrared Spectroscopy and Mass Spectrometry 
Infrared analysis of compounds 4.6‒4.11 was carried out using ATR. The absorption band 
corresponding to the stretching frequency of the C=N (benzothiazole ring) of compound 4.6 
was observed at 1588 cm-1. Upon formation of the aminobenzothiazole compounds (4.7−4.11), 
the absorption band shifts slightly to a higher wavenumber around 1596 cm-1. 
 
Compounds 4.6‒4.11 were calculated to have molecular masses of 294.8719, 439.0566, 
580.9845, 497.0804, 481.1034 and 525.1116 g.mol-1. The identity of compounds 4.6, 4.7, 
4.9−4.11 was further confirmed using electron impact mass spectrometry. Compound 4.8 was 
identified using electrospray ionisation mass spectrometry. The molecular ion peaks were 
observed at m/z 294.82, 439.04, 497.01, 481.08 and 525.00 for compounds 4.6, 4.7 and 
4.9−4.11, respectively. The mass spectrum for compound 4.8 revealed a peak at m/z 454.0808 
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corresponding to [M]+, which is the positively charged fragment (excludes the iodide 
counter‒ion). 
  
4.2.3  Synthesis and Characterisation of Ferrocenylamines  
In order to determine the contribution of the ferrocenyl moiety to the pharmacological activity, 
ferrocenyl compounds containing the amines used in Sections 4.2.1 and 4.2.2 were prepared. 
 
Synthesis 
Ferrocenylamines (4.12; 4.13) were prepared via a reductive amination reaction. 
Ferrocenecarboxaldehyde was reacted with either (aminomethyl)trimethylsilane or 2,2’-
dimethylpropan-1-amine via a Schiff‒base condensation reaction, followed by the reduction of 
the imine with sodium borohydride (Scheme 4.4).  
 
 
Scheme 4.4 The synthesis of ferrocenylamines.  
Reagents and conditions: (i) (aminomethyl)trimethylsilane (4.12) or 2,2’-dimethylpropan-1-amine (4.13), 
DCM, 35 °C, 5 hr, in dark; (ii) NaBH4, DCM−MeOH (v/v, 5:2), rt, overnight. 
 
Compound 4.12 was isolated as a sticky orange solid, whereas compound 4.13 was isolated as 
an orange powder. The compounds were isolated in good yields (~95 %), with a melting point 
range of 55.2−57.2 ˚C for compound 4.13.   
 
Characterisation 
The compounds were fully characterised using NMR (1H; 13C{1H}) spectroscopy, infrared 
spectroscopy and mass spectrometry (EI‒MS). 
 
NMR Spectroscopy 
The 1H NMR spectra for compounds 4.12 and 4.13 were recorded in CDCl3. The expected 
ferrocenyl signals were observed. Two triplets (J ~1.6 Hz) each accounting for two protons 
were observed at 4.11 and 4.21 ppm, with a singlet corresponding to the unsubstituted 
cyclopentadienyl ring observed at 4.13 ppm. In addition to the ferrocenyl signals, two singlets 
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corresponding to the methylene protons were observed. The methylene protons (H−1) adjacent 
to the ferrocenyl moiety were observed at 3.52 ppm. As expected, the methylene protons (H−2) 
of compound 4.12 were more shielded (2.11 ppm) than those of the carbon analogue 4.13 (2.40 
ppm).    
 
The ferrocenyl, methylene and methyl carbons were all accounted for in the 13C{1H} NMR 
spectra. 
 
Infrared Spectroscopy and Mass Spectrometry 
Infrared spectral analysis of compounds 4.12 and 4.13 confirmed the absence of absorption 
bands for C=O (aldehyde) or C=N (imine) moieties. The presence of an absorption band for the 
newly incorporated NH was observed at 3093 and 3088 cm-1 for 4.12 and 4.13, respectively. 
 
The structure of the compounds 4.12 and 4.13 were further confirmed by electron impact mass 
spectrometry. Molecular ion peaks observed at m/z 301.09 and 285.02 correspond to compound 
4.12 and 4.13, respectively. 
 
4.3  Summary 
Ferroquine and its quaternised form were prepared via published methods. A series of 
ferrocenyl‒containing aminoquinolines (4.1−4.5) were prepared via a nucleophilic substitution 
reaction. The quaternised form of ferroquine was reacted with various amines, such as 
(aminomethyl)trimethylsilane, 2,2’-dimethylpropan-1-amine, (3-aminopropyl)trimethylsilane, 
4,4’-dimethylpentan-1-amine and (aminomethyl)dimethylphenylsilane. Compounds 4.1−4.5 
were fully characterised using NMR (1H; 13C{1H}; COSY; HSQC) spectroscopy, infrared (IR) 
spectroscopy and electron impact mass spectrometry (EI‒MS). The molecular structures of 
compounds 4.2 and 4.3 were determined using single‒crystal X‒ray diffraction. Both 
compounds crystallise in a folded conformation due to intramolecular hydrogen bonding 
between the nitrogen atoms on opposite sides of the ferrocenyl moiety. In the case of 
compound 4.2, hydrogen bonding could also occur between the quinoline nitrogen and the NH 
of the side‒arm.  
 
Following on from the series of ferrocenyl‒containing aminoquinolines, a series of 
benzothiazole‒based compounds was prepared.  
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6-Chloro-2-iodobenzothiazole (prepared via a Sandmeyer‒type reaction) was reacted with 2-
[(N,N-dimethylamino)methyl]ferrocenylmethylamine in a nucleophilic substitution reaction to 
prepare the ferrocenyl‒containing aminobenzothiazole 4.7. This was followed by the 
quaternisation of compound 4.7 by reacting with iodomethane. The quaternised compound 4.8 
was subsequently reacted with various amines, such as (aminomethyl)trimethylsilane, 2,2’-
dimethylpropan-1-amine and (3-aminopropyl)trimethylsilane to afford compounds 4.9−4.11, 
respectively. Compounds 4.7−4.11 were fully characterised using NMR (1H; 13C{1H}; COSY) 
spectroscopy, infrared (IR) spectroscopy and mass spectrometry (Electron Impact; Electrospray 
Ionisation).  
 
Ferrocenylamines 4.12 and 4.13 were prepared by a reductive amination reaction. The imine 
was prepared by reacting ferrocenecarboxaldehyde with either (aminomethyl)trimethylsilane or 
2,2’-dimethylpropan-1-amine, which was then reduced to the amine. Compounds 4.12 and 4.13 
were fully characterised using NMR (1H; 13C{1H}) spectroscopy, infrared (IR) spectroscopy 
and electron impact mass spectrometry (EI−MS).   
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CHAPTER 5 
Pharmacological Evaluation of Organosilane Heterocycle−Based Compounds 
as Antiparasitic Agents 
 
 
5.1  Introduction 
As mentioned in Chapter 3 (Section 3.1), one approach to identifying potential antiparasitic 
lead compounds is based on whole‒cell phenotypic screening, which initially involves in vitro 
evaluation against the parasite of interest and cytotoxicity studies against mammalian 
cell‒lines. Furthermore, identification of potential effective lead compounds by means of in 
vitro evaluation is generally followed by determining how the compound exerts its 
pharmacological effects.    
 
Mechanism of Action 
The route by which an active compound exerts its pharmacological effects is of significance. 
Drugs may interact with receptors, enzymes, ion channels or the survival process used by the 
foreign microbe. Therefore, mechanisms involving the inhibition of haemozoin formation 
especially in case of antimalarial agents, the generation of reaction species [reactive oxygen 
species (ROS) or reactive nitrogen species (RNS)] or interactions with DNA to name a few, are 
studied.1,2 In terms of haemozoin inhibition, the NP‒40 β‒haematin inhibition assay is used.3 
The neutral detergent NP‒40 is used to mimic lipids and mediates β‒haematin formation in the 
assay. Therefore, the amount of β‒haematin can be quantified using the colorimetric pyridine 
ferrochrome method developed by Egan et al.4 
 
Furthermore, when looking at ferroquine as an example, various components have been 
identified as being essential for the overall biological activity (Figure 5.1). As part of this 
project, the ferroquine derivatives prepared retained the ferrocene and 4-aminoquinoline cores, 
as well as a 7-chloro substituent. As seen in Figure 5.1, the importance of each component has 
been summarised.5 
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Figure 5.1  Proposed structure‒activity relationship for ferroquine.5 
 
However, in addition to identifying potential mechanisms of action, it is also important to 
determine the drug metabolism and pharmacokinetics profile of a potential drug lead. 
 
In Vitro Models of Drug Metabolism 
Metabolism, or biotransformation, generally refers to the process of converting a hydrophobic 
compound to a more hydrophilic form. This conversion, which is facilitated by enzymes (e.g. 
cytochrome P450 family6), allows either for the generation of the active compound, 
inactivation of the active compound or generation of potentially toxic compounds to be 
excreted (Figure 5.2). Metabolism of a compound can be divided into two phases.7 The first 
phase of metabolism occurs in the hepatic system; however, compounds may be further 
metabolised (phase II) in tissues such as gastrointestinal epithelial, renal, skin, and lung tissues. 
Metabolic processes such as oxidation, reduction or hydrolysis may occur in phase I 
metabolism, whereas phase II metabolism involves conjugation of naturally occurring 
compounds to the metabolism product of phase I.7     
 
Metabolic stability is defined as the percentage of parent compound lost over time in the 
presence of a metabolically active test system, i.e. enzyme. Therefore, metabolic stability 
assays are used to estimate the susceptibility of the test compound to metabolism. In general, if 
> 70 % of a compound remains after the incubation period then the compound is relatively 
stable, whereas < 30 % suggests that the compound is unstable. These assays employ the use of 
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liver models, such as liver microsomes, hepatocytes or liver slices, depending on the purpose 
of the assay.8,9 In more high‒throughput screenings, the use of microsomes is more applicable. 
 
 
Figure 5.2  Diagram illustrating the metabolism of a compound. 
 
If a compound displays good stability, another important concept to determine is the half‒life 
of the compound. Half‒life refers to the amount of time taken for the drug plasma 
concentration to reduce to half the initial concentration.10 Knowing the half‒life of the 
compound may assist in dosing plans, where a compound with a longer half‒life may be 
administered at lower dosages and less frequently. In the case of drug toxicity or side effects, 
the half‒life can be used to determine how long it will take for the drug to clear.  
 
Furthermore, an important analysis tool for metabolic stability studies is liquid 
chromatography‒tandem mass spectrometry technique (LC‒MS/MS). Liquid chromatography 
is used to separate possible metabolites, whereas mass spectrometry is used to determine the 
masses of the metabolites and thus utilised to identify the metabolite.11  
 
5.2  Pharmacological Evaluation of Ferrocenyl‒Containing Aminoquinolines 
and Aminobenzothiazoles 
The pharmacological activities of the synthesised ferrocenyl‒containing aminoquinoline and 
aminobenzothiazole compounds (Figure 5.3) were evaluated through in vitro screening. The 
compounds were screened against the NF54 chloroquine‒sensitive and Dd2 
chloroquine‒resistant Plasmodium falciparum strains, and their cytotoxicity evaluated against 
the Chinese Hamster Ovarian (CHO) cell‒line. Selected compounds were also tested for their 
ability to inhibit β‒haematin formation as a potential mechanism of action. Based on the data 
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for compounds screened against P. falciparum strains, compounds were selected for further in 
vitro testing in metabolic stability studies. Additionally, the antiparasitic activity of these 
ferrocenyl‒containing aminoquinoline and aminobenzothiazole compounds was also 
determined against the metronidazole‒sensitive G3 strain of T. vaginalis. Furthermore, the 
cytotoxicity of selected compounds were evaluated against the WHCO1 oesophageal cancer 
cell‒line 
 
 
Figure 5.3  Ferrocenyl‒containing aminoquinolines (4.1−4.4) and aminobenzothiazoles (4.7; 4.9‒4.11). 
 
5.2.1  Predicting Lipophilicity    
An important physicochemical characteristic to consider when searching for a compound 
suitable for in vivo models is the lipophilicity of the compound of interest. As mentioned in 
Chapter 4 (Section 4.1), there is a marked difference in the lipophilicity of ferroquine and 
chloroquine, which influences accumulation of the compound.5 Therefore, the logP values of 
the ferrocenyl‒containing aminoquinolines and aminobenzothiazoles were determined using 
the method described in Chapter 3.  
 
The clogP values of the benzene‒derivatives were determined using ChemBioDraw and listed 
in Table 5.1. These clogP values were used in combination with the fragmental constant 
approach to determine the logP value for the ferrocenyl−containing compounds.  
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Table 5.1  clogP values calculated for the benzene‒derivatives using ChemBioDraw v13.0. 
Compound cLogP Compound cLogP 
Derivative of 4.1 6.498 Derivative of 4.7 4.583 
Derivative of 4.2 5.933 Derivative of 4.9 6.538 
Derivative of 4.3 6.954 Derivative of 4.10 5.973 
Derivative of 4.4 6.991 Derivative of 4.11 6.994 
Derivative of 4.5 7.977   
 
Prediction: 
logP(Fc derivative) = clogP(benzene derivative) – f(C6H4) + f(Fc-2H) 
                          = 6.498 – 1.476 + 2.252 = 7.274 
                
 
Table 5.2  Compilation of the estimated logP values for compounds 4.1‒4.5, 4.7 and 4.9‒4.11. 
Compound LogP Compound LogP 
 
4.1 
7.274 
 
4.2 
6.709 
 
4.3 
7.730 
 
4.4 
7.767 
 
4.5 
8.753 
 
 
4.7 
5.359 
 
4.9 
7.314 
 
4.10 
6.749 
4.11 
7.770   
 
The logP values of the remaining aminoquinolines and aminobenzothiazoles were calculated as 
illustrated above and the data listed in Table 5.2. The logP value for ferroquine (= 5.112) and 
 
4.1 
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the estimated value of the benzothiazole derivative (= 5.373) are relatively similar. 
Furthermore, with the incorporation of the amine side‒chains, a significant increase of between 
1.3 and 2.5 logP units was calculated. As expected, the estimated logP values also confirm that 
extending the side‒chain from 1‒carbon to 3‒carbons increases the logP value (Table 5.2). A 
further increase in the logP value is generally observed for the silicon‒containing compounds. 
 
As further confirmation for this method, the logP values were calculated using only the 
fragmental approach. However, the fragmental approach could only be utilised for the carbon 
analogues due to a lack of fragmental data for silicon.  
 
For compound 4.2:  
 
Fragments13 to consider:  
Cl + Quinolinyl-H + Fc-2H + NHar +NHaliph + 3CH2 
+ 3CH3 + C  
LogP = 0.933 + 1.617 + 2.252 + (−0.938) + (−1.814) + 3(0.519) + 3(0.724) + 0.110 = 5.889 
 
However, as mentioned in Chapter 3, the fragmental method employs correction factors (CM = 
0.219) when features such as hydrogen bonding are present.13 It is also known from the crystal 
structures of compounds 4.1‒4.3 (Chapter 4; Section 4.2.1) that the compounds experience 
intramolecular hydrogen bonding. As determined by Rekker et al.13, one hydrogen bond is 
equivalent to three CM.  
 
Therefore, logP of compound 4.2 = 5.889 + 3CM   
                                                       = 6.546 
 
Table 5.3  Comparison of estimated logP data. 
Compound Estimated LogP1 
(ChemBioDraw‒fragment method) 
Estimated LogP2 
(Fragmental method) 
∆LogPa 
4.2 6.709 6.546 0.163 
4.4 7.767 7.584 0.183 
4.7 5.359 5.356 0.003 
4.10 6.749 6.532 0.217 
  a∆LogP = estimated LogP1 – estimated LogP2 
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The logP values of compounds 4.4, 4.7 and 4.10 were calculated using the above method and 
the values listed in Table 5.3. When comparing the estimated logP value calculated using the 
ChemBioDraw‒fragmental method to that calculated using only the fragmental approach, the 
values are within a small error range. This confirms that the ChemBioDraw‒fragmental 
method is suitable for estimating the logP values of these types of compounds. 
 
5.2.2  Stability of compounds 4.3 and 4.11  
As mentioned in Chapter 3, the stability of compounds in solution is important when 
evaluating the pharmacological activity. Therefore, as a model system for the stability of the 
aminoquinoline compounds, compound 4.3 was investigated and monitored by 1H NMR 
spectroscopy over a 72 hr period at 37 °C. The 1H NMR spectra for compound 4.3 were 
recorded in DMSO−d6:D2O (9:1, v/v; Figure 5.4a). 
 
 
 
Figure 5.4  1H NMR spectra of compounds 4.3 (a) and compound 4.11 (b) in DMSO−d6:D2O (9:1, 
v/v) heated at 37 ˚C over 72 hr. 
a 
b 
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Similarly, the aminobenzothiazole compound 4.11 was also monitored in DMSO−d6:D2O (9:1, 
v/v; Figure 5.4b) under the conditions described above. As seen in Figure 5.4, the spectra 
remain unchanged over the study period, attesting to the stability of these compounds.  
 
5.2.3  In Vitro Antiplasmodial and Cytotoxicity Studies 
The ferrocenyl‒containing aminoquinolines (4.1−4.4) and aminobenzothiazoles (4.7; 4.9−4.11) 
were initially screened against the NF54 chloroquine‒sensitive strain of P. falciparum. In 
addition to the ferrocenyl‒containing heterocycles, 2-amino-6-chlorobenzothiazole (2-NH2-6-
ClBenz) and ferrocenylamines (4.12; 4.13) were also evaluated to determine their contribution 
to any observed pharmacological activity. Chloroquine diphosphate (CQDP) and artesunate 
were used as the control drugs in this study. The IC50 values are illustrated in Figure 5.5 and 
Table 5.4.  
 
 
Figure 5.5  Antiplasmodial evaluation against the P. falciparum strain NF54. 
 
As seen in Figure 5.5, the ferrocenyl‒containing aminoquinolines (4.1−4.4) displayed 
pharmacological activities in the low nanomolar range (6.90–31.37 nM). The non‒silicon 
derivatives (4.2 & 4.4) are slightly more potent than the silicon‒containing analogues; 
however, when comparing compounds in the nanomolar range this difference is not significant. 
Therefore, against the chloroquine‒sensitive strain the ferrocenyl‒containing aminoquinolines 
display similar activities.  
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When comparing the IC50 data for ferroquine (IC50 = 24.90 nM) with its benzothiazole 
analogue 4.7 (IC50 = 1865.48 nM), the benzothiazole analogue is significantly less active than 
the quinoline analogue. Amongst the ferrocenyl‒containing aminobenzothiazoles, an 
enhancement of activity is observed for the amine‒terminated compounds (4.9−4.11) in 
comparison to compound 4.7. Furthermore, the ferrocenyl−containing aminobenzothiazoles 
4.9−4.11 displayed activity with IC50 values between 565.39 and 950.21 nM, where a slight 
enhancement of activity is observed for the silicon‒containing analogues (Figure 5.5).   
 
Table 5.4  Antiplasmodial and cytotoxicity data of selected compounds (4.1‒4.4, 4.7 & 4.9‒4.13) 
Compound  
IC50 (nM) 
NF54 
IC50 (nM) 
Dd2 
IC50 (µM) 
CHO 
 
4.1 
(X=Si) 
13.32 ± 2.46 13.40 ± 0.69 3.87 ± 1.43 
4.2 
(X=C) 
6.90 ± 0.86 13.87 ± 2.82 15.36 ± 0.90 
 
4.3 
(X=Si) 
31.37 ± 10.45 27.13 ± 3.58 9.64 ± 1.25 
4.4 
(X=C) 
11.45 ± 0.79 35.57 ± 6.16 3.62 ± 0.32 
 
4.7 
1865.48 ± 
11.84 
ND 16.90 ± 1.28 
 
4.9 
(X=Si) 
637.76 ± 
195.15 
718.24 ± 
91.14 
7.14 ± 0.44 
4.10 
(X=C) 
950.31 ± 
72.37 
163.80 ± 
33.26 
6.63 ± 1.91 
 
4.11 565.39 ± 9.98 
415.17 ± 
48.56 
3.90 ± 0.78 
 
4.12 
(X=Si) 
3168.59 ± 
76.39 
59.45 ± 10.30 
276.01 ± 
53.14 
4.13 
(X=C) 
> 3507 ND 
212.90 ± 
30.51 
2-Amino-6-chlorobenzothiazole  
4960.74 ± 
790.69 
ND > 541.56 
Ferroquine  24.90 ± 2.84 17.34 ± 5.90 24.44 ± 0.65 
Chloroquine  13.66 ± 3.25 301.37 ± 9.07 ND 
Artesunate  < 5.2 16.91 ± 2.86 ND 
Emetine  ND ND 0.23 ± 0.01 
 ND = not determined 
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Furthermore, when examining the data for 2-amino-6-chlorobenzothiazole and the 
ferrocenylamines (4.12; 4.13), it is evident that on their own these components are not as 
effective against the sensitive parasitic strain. 2-Amino-6-chlorobenzothiazole (IC50 = 4960.74 
nM) and the silicon‒containing ferrocenylamine 4.12 (IC50 = 3168.59 nM) were significantly 
less potent than the ferrocenyl−containing aminoquinolines and aminobenzothiazoles, whereas 
the ferrocenylamine 4.13 was not effective at the highest tested concentration (> 1000 ng/mL).  
 
Overall, when comparing the activity of the aminoquinolines (4.1−4.4) with their 
corresponding aminobenzothiazoles (4.9−4.11), the quinoline−based compounds displayed 
superior activity against the P. falciparum strain NF54. The aminoquinolines display similar 
activity to that of chloroquine and ferroquine.  
    
 
Figure 5.6  Antiplasmodial evaluation against Dd2 strain of P. falciparum. 
 
Ideally, a lead compound would be more promising if it was also effective against the strain 
resistant to the known treatments. Therefore, the compounds were also evaluated against the 
chloroquine‒resistant Dd2 strain of P. falciparum (Table 5.4 and Figure 5.7). The 
ferrocenyl‒containing aminoquinolines (4.1‒4.4) displayed similar IC50 values (13‒36 nM) 
against the Dd2 strain, which was also comparable to that observed against the NF54 strain. 
The activity was also comparable to ferroquine. Furthermore, when compared to chloroquine 
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(IC50 = 179.10 nM), the ferrocenyl−containing aminoquinolines were more potent against the 
Dd2 strain. 
 
The activity of the aminobenzothiazoles (4.9‒4.11) varied with IC50 values of 718.24, 163.80 
and 415.17 nM, respectively. When compared to the activity observed against the NF54 strain, 
the silicon‒analogues displayed similar activity against both strains, whereas the 
carbon‒analogue (4.10) was significantly more effective against the resistant strain. The 
carbon‒analogue was also more effective against the resistant strain than chloroquine. Once 
again, the aminobenzothiazoles were not as effective as the aminoquinolines. 
 
The ferrocenylamines (4.12, 4.13) which displayed poor effects against the CQ‒sensitive 
strain, exhibited significantly improved activity for compound 4.12 (IC50 value = 59.45 nM) 
against the CQ‒resistant strain.    
 
 
Figure 5.7  Resistance indices for tested compounds (4.1‒4.4, 4.9‒4.11, 4.12). 
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Furthermore, resistance indices [RI = 
IC50 (Dd2)
IC50 (NF54)
] were calculated for the compounds (4.1−4.4, 
4.9‒4.12) evaluated against the resistant strain (Figure 5.7). The black line in Figure 5.7 
corresponds to a RI value of 1. The silicon‒containing aminoquinolines (4.1, 4.3), the 
ferrocenyl‒containing aminobenzothiazoles (4.9‒4.11), the silicon-containing ferrocenylamine 
(4.12) and ferroquine have RI values around or below 1. Furthermore, the aminobenzothiazoles 
had RI values significantly smaller than the aminoquinolines.  
 
The synthesised compounds (4.1−4.4, 4.7, 4.9‒4.13, FQ) were also screened for their 
cytotoxicity against the Chinese Hamster Ovarian (CHO) cell‒line (Table 5.4). This data was 
used to calculate selectivity indices [SI = 
IC50 (CHO)
IC50 (NF54) or (Dd2)
] which are represented in Figure 
5.8. 
 
 
Figure 5.8  Selectivity indices calculated for the tested compounds (4.1−4.4, 4.7, 4.9‒4.12, FQ).  
SI1 = IC50(CHO)/ IC50 (NF54). SI2 = IC50(CHO)/ IC50 (Dd2) 
    
As seen in Figure 5.8, the aminoquinolines (SI = 288‒2227) displayed greater selectivity 
towards parasitic strains than the corresponding aminobenzothiazole analogues (SI = 6.9‒41). 
Amongst the two series of compounds, the carbon‒analogues with the methylene spacer had 
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the largest SI values. On the other hand, the ferrocenylamine 4.12 displayed the greatest 
selectivity towards the CQ‒resistant parasites.  
 
As determined in Section 5.2.1, the logP values estimated for the quinoline‒ and 
benzothiazole‒based compounds were fairly similar. Therefore, for the benzothiazole‒based 
compounds the pharmacological activity is unlikely to be related to lipophilicity and possible 
accumulation at the target site.  
 
Overall, the evaluated compounds displayed promising results and are good candidates for 
further testing. 
     
5.2.4  β‒Haematin Inhibition Studies     
The NP−40 detergent mediated assay was used to establish if selected ferrocenyl‒containing 
aminoquinolines and aminobenzothiazoles prepared in this study inhibit β‒haematin (synthetic 
haemozoin) formation. It has been widely established that quinoline−based compounds inhibit 
the formation of β−haematin (and haemozoin). Ferrocenyl‒containing aminoquinolines 4.3 and 
4.4 were selected to determine if incorporation of silicon improves the effect on the observed 
β‒haematin inhibitory activity. A preliminary study was done on the ferrocenyl‒containing 
aminobenzothiazole 4.7 to determine if an analogous benzothiazole‒based compound would 
inhibit β‒haematin formation. Chloroquine was the control compound. The IC50 values for 4.3 
and 4.4 are listed in Table 5.5 and Figure 5.9 illustrates the concentration dose‒response curve 
for 4.7. 
 
Table 5.5  Tabulation of β‒haematin inhibition activity of 4.3, 4.4 and CQ 
Compound 
 IC50 (µM)  
[95% confidence interval] 
 
4.3 9.03 [8.125−10.03] 
 
4.4 10.02 [9.143−10.98] 
CQ  73.76 [71.32−76.28] 
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Compounds 4.3 and 4.4 are analogous ferrocenyl‒containing aminoquinolines, and the effect 
of silicon on the inhibition of β‒haematin formation was investigated. Both aminoquinolines 
4.3 and 4.4 inhibited the formation of β‒haematin with IC50 values of 9.03 and 10.02 μM, 
respectively. These IC50 values are significantly lower than that observed for chloroquine 
(73.76 μM), suggesting that these ferrocenyl−containing compounds are more effective 
inhibitors of β‒haematin formation. Incorporation of silicon only has a moderate effect on the 
inhibition of β‒haematin.  
 
Compound 4.1 has previously been evaluated for its β‒haematin inhibition activity, displaying 
inhibitory effects with an IC50 value of 16.2 μM.14. As seen for other ferrocenyl‒containing 
aminoquinolines, the compounds probably binds to haematin via π‒π stacking.15 However, 
from the crystal structure of compound 4.3 (Figure 4.5), it can be seen that the propyl 
side‒chain dangles either above or below the quinoline ring. Therefore, perhaps incorporation 
of the longer propyl side-chain further prevents the formation of β‒haematin. 
 
On the other hand, the aminobenzothiazole 4.7, which is analogous to ferroquine had no effect 
on the inhibition of β‒haematin formation (Figure 5.9). Therefore, the 
aminobenzothiazole‒based compounds may exert their pharmacological effects via a different 
mechanism.  
 
 
Figure 5.9  Concentration dose−response curves for NP−40 detergent mediated β‒haematin assays of 
ferrocenyl‒containing aminobenzothiazole 4.7 and chloroquine. 
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5.2.5  In Vitro Microsomal Metabolic Stability Studies 
Due to the in vitro antiplasmodial activity observed, the microsomal stability of compounds 
4.1‒4.3 and ferroquine were assessed in human and mouse liver microsomes using the single 
point assay.16 As seen in Figure 5.10, after 30 min incubation time at 0.40 mg protein/mL 
microsomes, compounds 4.1‒4.3 were rapidly metabolised.  
 
 
Figure 5.10  Percentage of compound (4.1‒4.3, FQ) remaining after incubation with liver microsomes. 
 
The compounds were unstable when incubated with both human and mouse liver microsomes. 
For the organosilane‒containing compounds (4.1; 4.3), less than 10 % of the parent compound 
remained after incubation in human liver microsomes. The same result was observed for 
compound 4.1 in mouse liver microsomes, with compound 4.3 metabolising more slowly. In 
general, the carbon‒analogue metabolised more slowly than the silicon‒containing analogues. 
Furthermore, compounds 4.2 and 4.3 are as unstable as ferroquine when incubated with mouse 
liver microsomes (Figure 5.10). When comparing ferroquine with compound 4.2, ferroquine is 
significantly more stable when incubated with human liver microsomes and the incorporation 
of the amine side‒chain (4.2) did not improve stability. 
 
5.2.6  In Vitro Antitrichomonal Studies   
In vitro antitrichomonal screening was carried out for the synthesised ferrocenyl‒containing 
aminoquinoline and aminobenzothiazole compounds to determine general growth inhibition 
against the metronidazole‒sensitive G3 strain of Trichomonas vaginalis. DMSO was employed 
as a control for the screening, and the antitrichomonal activity data is listed in Table 5.6. 
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Compounds 4.1−4.3 were tested at 50 μM concentration, while the remaining compounds were 
tested at 100 μM concentration. As seen in Table 5.6, the ferrocenyl‒containing 
aminoquinolines and aminobenzothiazoles generally display good activity with parasite growth 
inhibition above 90 %. When analysing the data for aminoquinolines 4.1−4.3 (tested at 50 μM), 
the carbon analogue 4.2 was a more effective inhibitor (91.42 %) when compared to its silicon 
analogue 4.1 (24.33 %). However, when evaluating the corresponding aminobenzothiazoles 4.9 
and 4.10, similar inhibitory effects (99 %) were observed.    
 
The ferrocenylamines 4.12 and 4.13, along with 2-amino-6-chlorobenzothiazole, were screened 
to determine if the ferrocenyl, amine‒side chain or benzothiazole moiety would be effective as 
is. The tested compounds were poor inhibitors of parasite growth, displaying effects below 40 
%. Therefore, once again the different physicochemical properties of the ferrocenyl‒containing 
aminoquinolines and aminobenzothiazoles, over their individual components, led to improved 
activities. 
 
Table 5.6  Percentage growth inhibition of the G3 strain of T. vaginalis. 
    aTested at 50 μM; bTested at 100 μM. 
 
The IC50 values were determined for compounds displaying percentage inhibitions above 90 % 
(Table 5.7). As seen in Table 5.7, the compounds displayed moderate activity in the 
Compound % Growth Inhibition ± SE 
 
4.1 (X=Si; n=1) 24.55 ± 2.14a 
4.2 (X=C; n=1) 91.42 ± 1.35a 
4.3 (X=Si; n=3) 77.08 ± 6.85a 
4.4 (X=C; n=3) 100b 
 
4.7 94.5 ± 7.91b 
 
4.9 (X=Si; n=1) 99.4 ± 1.09b 
4.10 (X=C; n=1) 99.3 ± 1.28b 
4.11 (X=Si; n=3) 90.5 ± 8.53b 
 
4.12 (X=Si) 29.8 ± 20.4b 
4.13 (X=C) 27.9 ± 11.2b 
2-Amino-6-chlorobenzothiazole  34.4 ± 13.7b 
FQ  54.20 ± 1.45a 
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micromolar range, with the carbon analogue 4.4 being the most effect parasite growth inhibitor 
with an IC50 value of 8.30 μM. No definite trend could be observed when comparing 
compounds with methylene and propyl spacers. These compounds were not as effective as the 
FDA approved drug metronidazole (IC50 = 0.72 μM). 
 
Table 5.7  Antitrichomonal data for the compounds (4.2; 4.4; 4.7; 4.9; 4.11)  
Compound IC50 (μM) G3 Strain  
4.2 (X=C; n=1) 20.27 
4.4 (X=C; n=3) 8.30 
4.7 25.16 
4.9 (X=Si; n=1) 38.07 
4.11 (X=Si; n=3) 38.09 
Metronidazole 0.72 
 
5.2.7  In Vitro Antitumour Studies   
Ferrocenyl‒containing aminoquinoline and aminobenzothiazoles, along with 2-amino-6-
chlorobenzothiazole and ferrocenylamines, were screened for their cytotoxicity against the 
WHCO1 oesophageal cancer cell‒line. Ferrocenyl‒containing aminoquinolines (4.1, 4.3, 4.4), 
ferrocenyl‒containing aminobenzothiazoles (4.9, 4.10) and the ferrocenylamine 4.12 were 
excluded from the assay due to poor solubility at the highest stock concentration. The results 
for the tested compounds are illustrated in Figure 5.11. 
 
 
FQ: IC50 = 17.3 μM [13.1 to 22.8]* 
 
 
4.2: IC50 = 8.90 μM [7.01 to 11.31]* 
 
4.6: IC50 = ~10.08 μM 
 
 
4.11: IC50 = 1.74 μM [0.56 to 5.35]* 
Figure 5.11  Cytotoxicity of ferrocenyl‒containing aminoquinolines (FQ; 4.2) and aminobenzothiazole (4.7; 
4.11). *95 % Confidence Interval. 
 
2-Amino-6-chlorobenzothiazole and the silicon‒containing ferrocenylamine 4.12, which were 
tested in order to identify active components, were not cytotoxic at the highest tested 
concentration. However, when evaluating the combination of the heterocyclic ring and 
IC50 
IC50 
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ferrocenyl moiety in the form of ferroquine and the analogous benzothiazole‒based 4.7, the 
compounds displayed significant cytotoxicity with IC50 values of 17.3 and 10.2 µM, 
respectively. A slight improvement was observed for the benzothiazole‒based compound (4.7) 
when compared to the quinoline‒based compound (FQ). Additionally, with the incorporation 
of an amine side‒chain a further enhancement in activity was observed. Of the tested 
compounds, the silicon‒containing benzothiazole‒based compound 4.11 was the most potent 
with an IC50 value of 1.74 µM.  
 
The screening of a larger group of ferrocenyl−containing aminoquinoline and 
aminobenzothiazoles would have to be conducted to definitively conclude if silicon‒containing 
benzothiazole‒based compounds are the most effective against the WHCO1 oesophageal 
cancer cell‒line. 
 
5.3  Summary 
Ferrocenyl‒containing aminoquinolines and aminobenzothiazoles were screened for the 
antiparasitic effects against Plasmodium falciparum and Trichomonas vaginalis. When tested 
against the NF54 CQS strain of P. falciparum, the aminoquinolines (4.1‒4.4) were the most 
effective with activities in the low nanomolar range, whereas the corresponding 
aminobenzothiazoles (4.7; 4.9‒4.11) displayed activities in the low micromolar range. 
Furthermore, when evaluated against the Dd2 CQR strain, the aminoquinolines were once 
again more effective than the aminobenzothiazoles. However, the aminobenzothiazoles were 
generally more effective against the CQ‒resistant strain than the CQ‒sensitive strain, as is 
evidenced by the calculated RI values. Additionally, the aminoquinolines and 
aminobenzothiazole displayed selective antiparasitic activity.  
 
The ferrocenyl‒containing aminoquinolines (4.3; 4.4) were effective inhibitors of β‒haematin, 
displaying improved inhibitory effects when compared to chloroquine. On the other hand, the 
benzothiazole‒based compound (4.7) was not at all effective at inhibiting the formation of 
β‒haematin. Microsomal metabolic stability studies revealed that the ferrocenyl‒containing 
aminoquinolines are metabolised more quickly than ferroquine. For this reason they are not 
expected to perform well in vivo. Future optimisation studies would benefit from metabolite 
identification studies as some of the metabolites may be pharmacologically active, and thus 
may contribute to in vivo activity. 
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When tested for antitrichomonal activity, the compounds were generally effective at inhibiting 
parasite growth with percentage inhibitions above 90 % and moderate IC50 values. Compounds 
with propyl spacers generally displayed better inhibitory effects than the corresponding 
compounds with a methylene spacer. 
 
The cytotoxicity of the compounds was evaluated against the WHCO1 oesophageal cancer 
cell‒line. Incorporation of the amine side‒chain led to an improvement in cytotoxicity. 
Furthermore, the aminobenzothiazole compounds was found to be more cytotoxic than the 
aminoquinoline compounds. 
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CHAPTER 6 
Conclusions and Future Outlook 
 
 
6.1  Summary and Conclusions 
6.1.1  Synthesis 
The first series of compounds prepared were ferrocenyl‒ and aryl‒derived organosilane‒based 
thiosemicarbazones, along with their ruthenium, rhodium and palladium complexes. Five new 
thiosemicarbazones (2.3‒2.5) were prepared via a nucleophilic substitution reaction of a 
methanethiol group (dithiocarbamate) with the selected amine. These thiosemicarbazones were 
further reacted with [Ru(η6-p-iPrC6H4Me)Cl2]2 to synthesise two heterobimetallic complexes 
(2.6a‒b) and three mononuclear complexes (2.7a‒b; 2.8). The thiosemicarbazones were also 
reacted with [Rh(Cp*)Cl2]2 to prepare two heterobimetallic complexes (2.9a‒b) and three 
mononuclear complexes (2.10a‒b; 2.11). The cationic complexes prepared above involved 
bidentate N,S‒chelation of the thiosemicarbazone to the ruthenium or rhodium metal centre via 
dative bonds. Additionally, thiosemicarbazones (with a methyl group on the imine carbon) 
were selected as suitable for the preparation of neutral ortho‒cyclopalladated complexes 
(2.12‒2.14). The thiosemicarbazone was reacted with the palladium precursor 
cis‒[Pd(PTA)2Cl2], in the presence of trimethylamine as the base facilitating the abstraction of 
the proton on the ferrocenyl or aryl ring, to bring about C‒H activation. These compounds 
were fully characterised using NMR (1H, 13C{1H}, 31P{1H}, COSY, HSQC) spectroscopy, 
infrared spectroscopy and mass spectrometry [electron impact, electrospray ionisation]. 
 
The second series of compounds prepared were ferrocenyl‒containing aminoquinolines 
(4.1‒4.5). These compounds were ferroquine derivatives, whereby the terminal dimethylamine 
group was replaced with amine side‒chains consisting of both organosilane and carbon 
analogues. This displacement was carried out via the quaternisation of the terminal 
dimethylamine group, followed by the substitution of the trimethylammonium [‒N(CH3)3+] 
group with the amine. The third series of compounds prepared were ferrocenyl‒containing 
aminobenzothiazoles (4.9‒4.11), which were benzothiazole‒based analogues of the second 
series. The benzothiazole‒based analogue of ferroquine (4.7) was prepared by reacting 6-
chloro-2-iodobenzothiazole with 2-[(N,N-dimethylamino)methyl]-ferrocenylmethylamine in a 
substitution reaction. The terminal dimethylamine group of compound 4.7 was quaternised 
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(compound 4.8) using iodomethane, and the resulting trimethylammonium [‒N(CH3)3+] group 
substituted with the appropriate amine side‒chains to prepare the desired compounds. The 
compounds were fully characterised using NMR (1H; 13C{1H}; COSY; HSQC) spectroscopy, 
infrared spectroscopy and mass spectrometry (Electron Impact; Electrospray Ionisation). The 
preparation of the ferrocenyl‒containing aminoquinolines (4.2; 4.3) was further confirmed by 
the molecular structures of the two compounds which were determined using single‒crystal 
X‒ray diffraction. As seen with ferroquine1 and the previously reported compound 4.12, both 
compounds 4.2 and 4.3 also crystallised in a folded conformation due to intramolecular 
hydrogen bonding between the nitrogen atoms on opposite sides of the ferrocenyl moiety. 
Therefore, these ferrocenyl‒containing heterocyclic compounds can be synthesised 
successfully, and in good yields, via a halide substitution reaction, as opposed to the lower 
yielding reductive amination method.  
 
6.1.2  Pharmacological Evaluation 
The thiosemicarbazones, along with the ruthenium, rhodium and palladium complexes, were 
screened for their in vitro antiplasmodial activity against the chloroquine‒sensitive NF54 and 
chloroquine‒resistant Dd2 strains. The thiosemicarbazone compounds generally displayed 
activities in the low micromolar range. Overall, the cyclopalladated thiosemicarbazone 
complexes were the most effective against both strains. In general, the organosilane derivatives 
also showed selectivity towards the parasites. The cyclopalladated complexes (2.12‒2.14) were 
not tested for their ability to inhibit the formation of β‒haematin as previous studies of 
similarly structured square‒planar cyclopalladated3 and cycloplatinated4 complexes did not 
inhibit β‒haematin formation. Therefore, the rhodium complexes which also displayed 
promising activities were evaluated for their ability to inhibit the formation of β‒haematin. The 
rhodium complexes displayed inhibitory effects, whereas the metal‒free compound was 
ineffective. Therefore, due to the in vitro activities noted, the incorporation of 
thiosemicarbazone in compounds to be evaluated as antiplasmodial agents still has merit for 
future studies.    
 
Cyclopalladated complex 2.13, which displayed good in vitro antiplasmodial activity, was 
chosen for in vivo evaluation in a Plasmodium berghei mouse model. The compound was 
administered orally using a HPMC:DMSO vehicle at concentrations of 10, 30 and 50 mg/kg. 
As the compound did not display any signs of toxicity at the highest tested concentration (50 
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mg/kg), compound 2.13 was evaluated at a 50 mg/kg concentration in a P. berghei infected 
mouse model. The compound was found to be inactive, where no reduction in parasitaemia was 
observed. Attempts were also made to develop as HPLC‒UV method to analyse blood samples 
collected during the study. However, this proved unsuccessful due to inconsistent observations. 
There was also an interest in determining how effective these compounds are against another 
parasite. Therefore, the thiosemicarbazone compounds were also screened for their 
antitrichomonal activity against the metronidazole‒sensitive G3 strain of Trichomonas 
vaginalis. The ruthenium (2.6‒2.8) and rhodium (2.9‒2.11) complexes displayed growth 
inhibitions above 90 %, whereas the dithiocarbamates (2.1; 2.2), thiosemicarbazones (2.3‒2.5) 
and the cyclopalladated complexes (2.12‒2.14) had no significant effect. Furthermore, within 
the thiosemicarbazone and rhodium thiosemicarbazone series, the carbon analogues were less 
effective inhibitors of parasite growth than the organosilanes. The IC50 values were determined 
for complexes displaying inhibitions above 90 %. The ruthenium (2.6b; 2.7a; 2.7b) and 
rhodium (2.9a; 2.10a) complexes displayed moderate IC50 values (7‒35 μM), with the rhodium 
complexes appearing to be more effective inhibitors of G3 parasite growth compared to the 
ruthenium complexes. Therefore, perhaps the geometry of the ruthenium and rhodium 
complexes influences how the complexes exert their effects when compared to that observed 
for the square‒planar palladium complex.  
 
Preliminary antitumour activities of selected ferrocenyl‒containing thiosemicarbazone 
compounds were determined against cisplatin‒sensitive (A2780) and cisplatin‒resistant 
(A2780cisR) human ovarian carcinoma cell‒lines, as well as non‒tumourigenic human 
fibroblast skin cells (KMST‒6). The compounds displayed moderate activities (18‒150 μM) 
and did not show any selectivity between the tumourigenic and non‒tumourigenic cell‒lines. 
Therefore, these types of ferrocenyl-derived thiosemicarbazone compounds may not be 
suitable for these cell‒lines. 
 
The ferrocenyl‒containing aminoquinolines (4.1‒4.4) and aminobenzothiazoles (4.7; 4.9‒4.11) 
were also screened against the NF54 and Dd2 strains of Plasmodium falciparum. The 
aminoquinolines and aminobenzothiazoles displayed activities in nanomolar and micromolar 
ranges, respectively. For the aminoquinolines, similar activities were observed against both 
strains. On the other hand, the aminobenzothiazoles were more effective against the 
CQ‒resistant strain. Therefore, with resistance index values close to or below 1, these 
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ferrocenyl‒containing aminoquinolines and aminobenzothiazoles may exert their effects via a 
different mechanism to that of chloroquine. 
  
In terms of potential mechanisms of action, chloroquine is a known inhibitor of haemozoin 
formation. The same applies for ferroquine. The inhibition of β‒haematin, synthetic form of 
haemozoin, is also seen for the ferrocenyl‒containing aminoquinolines (4.3; 4.4), but not for 
the aminobenzothiazole 4.7. Therefore, it is possible that the mechanisms of action for the 
aminoquinolines are similar to that of chloroquine and ferroquine. Similar to ferroquine, the 
aminoquinolines may also be able to overcome the resistance mechanism, and thus are able to 
accumulate in the digestive vacuole where they exert their effects.  
 
Metabolic stability studies conducted on the ferrocenyl‒containing aminoquinolines (4.1‒4.3) 
revealed that the compounds metabolise more rapidly than ferroquine. It has also been 
observed that the organosilane derivatives metabolised more rapidly than the carbon analogue. 
When comparing the C‒C and C‒Si σ‒bonds, it is known that due to the larger atom size of 
silicon in comparison to carbon that the bond C‒Si is longer and thus weaker. This was also 
confirmed by the crystal data for compounds 4.12 and 4.3. Additionally, due to the more 
electropositive nature of silicon, it is more susceptible to nucleophilic attack. This may result in 
a more degradable compound. Daher et al. analysed ferroquine and its metabolites.5 They 
identified metabolism products with a free terminal amine (loss of methyl groups), a 
hydroxylation product, a N‒oxidation product and 4-amino-7-chloroquinoline. These 
metabolites were found to be less effective than ferroquine when screened against two strains 
(3D7 and W2) of P. falciparum. However, it would be interesting to determine the activity of 
these metabolites against the NF54 and Dd2 strains. Therefore, identification of the 
metabolism products for compounds 4.1‒4.3 may shed light on whether or not the C‒Si bond is 
the first site of metabolism.  
 
The ferrocenyl‒containing aminoquinolines and aminobenzothiazoles were effective inhibitors 
of T. vaginalis parasite growth with percentage inhibitions above 90 % and moderate IC50 
values. On the other hand, the ferrocenylamines and 2-amino-6-chlorobenzothiazole, which are 
essentially the components the aminoquinolines and aminobenzothiazoles consist of, were poor 
inhibitors of T. vaginalis growth. FDA approved treatments for trichomoniasis are primarily 5-
nitroimidazole-based compounds which exert their pharmacological effects through the 
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reduction of the nitro groups and formation of nitro radical−ion intermediates which are able to 
interact with DNA.6 Therefore, it would be interesting to determine by which mechanism these 
ferrocenyl‒containing aminoquinolines and aminobenzothiazoles exert their pharmacological 
effects against trichomonads.  
 
When screened for cytotoxicity against the WHCO1 oesophageal cancer cell‒line, the 
compounds containing the amine side‒chain were more cytotoxic than ferroquine and its 
benzothiazole analogue. Furthermore, the aminobenzothiazoles were found to be more 
cytotoxic than the aminoquinolines.  
 
6.2  Future Outlook 
Although the pharmacological activities observed for the thiosemicarbazone compounds, 
ferrocenyl‒containing aminoquinolines and ferrocenyl‒containing aminobenzothiazoles proved 
to be promising, they could be improved upon. However, understanding how these compounds 
exert their pharmacological activities may assist in designing new compounds with improved 
activities.   
 
Mechanisms of action such as β‒haematin inhibition, cysteine protease inhibition, DNA 
interactions, mitochondrial interactions or generation of reactive species, to name a few, may 
give preliminary information on how a compound may exert its pharmacological effects. 
However, despite many of these studies being conducted in closed systems, they may point 
researchers in a direction to investigate within cells and mammalian systems as there are 
various other factors that may either contribute to observed activity or prevent the compound 
from displaying any pharmacological effects. Based on the results stated in Chapter 3 (Section 
3.2.3), the rhodium thiosemicarbazone complexes inhibited the formation of β‒haematin. 
Hence, it would be interesting to computationally model the interaction between the rhodium 
complexes and β-haematin to determine how the rhodium complexes inhibits β-haematin 
formation. Based on the β‒haematin inhibition assay, the aminoquinolines inhibit the formation 
of β‒haematin, whereas the aminobenzothiazoles does not inhibit β‒haematin formation. 
Modelling studies of quinoline compounds have shown that the quinoline ring π-stacks with 
the β‒haematin to prevent dimerization.1 Therefore, it would be interesting to model the 
benzothiazole compound to determine why a similar inhibition mechanism does not occur.  
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Furthermore, as mentioned in Chapter 3 (Section 3.2.6) preliminary method development work 
was carried out for compound 2.13 using HPLC‒UV. One of the drawbacks to using protein 
precipitation or liquid‒liquid extraction methods, is the possibility of protein binding, which 
may have been the case for this work. Therefore, future studies involving either inductively 
coupled plasma mass spectrometry (ICP−MS) analysis of the precipitated proteins or protein 
binding studies may prove or disprove that idea. Furthermore, developing a procedure to 
extract complexes by disrupting protein‒complex binding without affecting the complex, as 
well as developing a HPLC‒UV or HPLC‒MS method which can be applied to coordination 
and organometallic complexes would be useful.    
 
As mentioned before, developing new compounds with improved physico‒chemical properties 
may lead to compounds with improved pharmacological activities. It would be interesting to 
evaluate cycloruthenated and cyclorhodated thiosemicarbazone complexes to determining if 
the ortho‒cyclometalated versions display improved activity over the N,S‒chelated complexes 
reported herein. It would also be interesting to determine if the cyclorhodated complexes 
display β‒haematin formation inhibition. Preparing metabolically stable quinoline‒ and 
benzothiazole‒based hybrid compounds containing other organometallic moieties with 
improved aqueous solubility may be an avenue to investigate.  
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CHAPTER 7 
Experimental Section 
 
  
7.1  General remarks 
All reagents and solvents were purchased from commercial suppliers. All reagents were 
purchased from Aldrich and used without further purification. Palladium(II) chloride, 
ruthenium(III) trichloride trihydrate and rhodium(III) trichloride trihydrate were kindly 
donated by Anglo American Platinum Limited. Methyl hydrazinecarbodithioate1, Schiff base 
dithiocarbamates [ferrocenyl2 (2.1a), acetylferrocenyl3 (2.1b), 3,4-dichloroacetophenone4 
(2.2b)], [Ru(η6-p-iPrC6H4Me)Cl2]25, [Rh(Cp*)Cl2]26 and cis−[Pd(PTA)2Cl2]7 were synthesised 
by means of published methods. 2-[(N,N-dimethylamino)methyl]ferrocene carboxaldehyde, 2-
[(N,N-dimethylamino)methyl]ferrocene oxime, 2-[(N,N-dimethylamino)methyl]ferrocene-
methylamine, ferroquine and quaternised ferroquine were also prepared via published 
methods.4,8 Nuclear magnetic resonance (NMR) spectra were recorded on either a Varian 
Mercury 300 spectrometer (1H at 300.08 MHz), a Bruker 400 Biospin GmbH spectrometer (1H 
at 400.20 MHz, 13C{1H} at 100.60 MHz, 31P{1H} at 161.80 MHz) or a Bruker 600 FT 
spectrometer (1H at 600.100 MHz, 13C{1H} at 150.60 MHz) at ambient temperature using the 
residual solvent peak as internal standard for 1H NMR and 13C NMR. Infrared (IR) spectra 
were determined using a either a Perkin–Elmer Spectrum 100 FT‒IR or a Bruker FT‒IR 
spectrometer, and were recorded either using KBr pellets or ATR. Elemental analyses (C, H 
and N) were recorded on a Thermo Flash 1112 Series CHNS‒O Analyser. Mass spectrometry 
was either carried out on a JEOL GCmateII and data were recorded using Electron Impact (EI) 
mode or on a Waters API Quattro Micro triple quadrupole mass spectrometer (samples injected 
into a stream of 50% acetonitrile and 0.1% formic acid) and data recorded using Electrospray 
Ionisation (ESI) mass spectrometry in the positive mode. Melting points were determined on 
the Büchi Melting Point apparatus B‒540. Purity of selected compounds was checked using an 
analytical Agilent HPLC 1260 equipped with an Agilent DAD 1260 UV/vis detector and a X 
Bridge C18 column (2.5 μM, 50 mm x 3 mm). The compounds were eluted using a mixture of 
solvent A (10 mM NH4OAc/H2O) and solvent B (10 mM NH4OAc/MeOH) at a flow rate of 
0.9 mL/min. The gradient elution conditions were as follows: 10% solvent B between 0 and 1 
min, 10−95% solvent B between 1 and 3 min, 95% solvent B between 3 and 5 min. 
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Single‒crystal X‒ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite‒monochromated Mo‒K radiation ( = 0.71073 Å). The  
 
7.2  Organosilane thiosemicarbazones 
7.2.1  Schiff base dithiocarbamates  
3,4-Dichlorobenzaldamine Schiff base dithiocarbamates  (2.2a) 
Methyl hydrazinecarbodithioate (1.01 g, 8.28 mmol) 
was suspended in dry isopropanol (5.00 mL), after 
which the 3,4-dichlorobenzaldehyde (1.45 g, 8.29 
mmol) was dissolved in iso-propanol (10.0 mL) was 
added. The pale yellow mixture was heated at 70 ˚C for 24 hr, during which the starting 
material dissolved followed by the precipitation of a solid. The solid was collected by suction 
filtration and washed with cold isopropanol. Compound 2.2a was isolated as an off‒white 
powder (1.58 g, 68 %). m.p.: 200.9‒201.4 ˚C. 1H NMR (399.95 MHz, DMSO‒d6): δ (ppm) = 
13.4 (s, 1H, NH); 8.21 (s, 1H, HC=N); 7.94 (s, 1H, H‒2); 7.71 (m, 2H, H‒5 & H‒6); 2.53 (s, 
3H, SCH3). 13C{1H} NMR (100.64 MHz, DMSO‒d6): δ (ppm) = 199.0 (C=S); 143.4 (C=N); 
134.2; 132.8; 131.8; 131.1; 128.7; 127.0; 16.7 (SCH3). FT‒IR (KBr, cm-1): ν = 1586 (m, 
C=N); 812 (s, C=S). EI+−MS (277.9504 g.mol-1): m/z 277.94 ([M]+, 100%). Elemental 
analysis for C9H8Cl2N2S2 (277.95 g.mol-1): Found C 38.77, H 2.82, N 9.46 %; Calculated C 
38.72, H 2.89, N 10.03 %. 
 
7.2.2  Functionalised thiosemicarbazones 
Ferrocenyl‒((trimethylsilyl)methyl) thiosemicarbazone  (2.3a) 
An excess of (aminomethyl)trimethylsilane (0.220 mL, 
1.64 mmol) was added to the flask under N2. 
Compound 2.1a (0.500 g, 1.57 mmol) and dry ethanol 
(10.0 mL) was added to the silane. The reaction 
mixture was heated at 70 ˚C under argon for 22 hr, cooled to room temperature and added 
water (10.0 mL). The compound was extracted using DCM (20.0 mL) and washed with H2O (6 
x 30.0 mL). The organic layer was collected, dried over MgSO4 and the solvent removed. The 
resulting solid was suspended in minimum diethyl ether, stirred in pentane and collected by 
suction filtration. Compound 2.3a was obtained as a light brown solid (0.199 g, 34 %). m.p.: 
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117.5 ˚C (Decomposition w/o melting). 1H NMR (300.08 MHz, CDCl3): δ (ppm) = 9.22 (s, 
1H, NNH); 7.68 (s, 1H, HC=N); 7.32 (br s, 1H, NH); 4.57 (t, 3JHH = 2.00 Hz, 2H, C5H4); 4.42 
(t, 3JHH = 2.00 Hz, 2H, C5H4); 4.21 (s, 5H, C5H5); 3.26 (d, 3JHH = 5.60 Hz, 2H, CH2); 0.18 (s, 
9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 166.4 (C=S); 143.1 (C=N); 
78.0, 70.5, 69.3, 67.6 (Fc); 34.9 (CH2); ‒2.48 (Si(CH3)3). IR (KBr, cm-1): ν = 1606 (s, C=N); 
1245 (m, Si-CH3); 856 (m, C=S). EI+−MS (373.0724 g.mol-1): m/z 373.07 ([M]+, 100 %). 
Elemental analysis for C16H23FeN3SiS (373.07 g.mol-1): Found C 51.10, H 6.38, N 11.30 %; 
Calculated C 51.47, H 6.21, N 11.25 %. 
 
Ferrocenylethylidene-((trimethylsilyl)methyl) thiosemicarbazone  (2.3b) 
An excess of (aminomethyl)trimethylsilane (0.0900 
mL, 0.672 mmol) was added to the flask under N2. 
Compound 2.1b (0.202 g, 0.609 mmol) and dry 
ethanol (15.0 mL) was added to the silane. The 
reaction mixture was heated at 70 ˚C under argon for 7 hr and stirred overnight at room 
temperature. Water (10.0 mL) was added to the flask, precipitating a solid. The solid was 
collected by suction filtration and washed with water, followed by minimal ethanol. Compound 
2.3b was isolated as an orange-brown solid (0.165 g, 70 %). m.p.: 125.0‒126.2 ˚C. 1H NMR 
(300.07 MHz, DMSO‒d6): δ (ppm) = 9.88 (s, 1H, NNH); 7.95 (t, 3JHH = 5.70 Hz, 1H, NH); 
4.74 (t, 3JHH = 1.80 Hz, 2H, C5H4); 4.38 (t, 3JHH = 1.80 Hz, 2H, C5H4); 4.17 (s, 5H, C5H5); 3.18 
(d, 3JHH = 6.00 Hz, 2H, CH2); 2.19 (s, 3H, CH3); 0.10 (s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 
MHz, CDCl3): δ (ppm) = 178.1 (C=S); 148.0 (C=N); 82.5; 70.3; 69.3; 66.8 (Fc); 34.7 (CH2); 
14.2 (CH3); ‒2.50 (Si(CH3)3). FT‒IR (KBr, cm-1): ν = 1600 (m, C=N); 1243 (m, Si-CH3); 851 
(s, C=S). EI+−MS: m/z 387.04 ([M]+, 100 %). Elemental analysis for C17H25FeN3SiS (387.07 
g/mol): Found C 52.42, H 6.87, N 11.07 %; Calculated C 52.71, H 6.50, N 10.85 %. 
 
General procedure for the synthesis of compounds 2.4a−b 
An excess of (aminomethyl)trimethylsilane was added to the flask under N2. The 
thiosemicarbazone thioester and dry ethanol (15.0 mL) was added to the silane. The reaction 
mixture was refluxed under argon for 24 hr, after which water (10.0 mL) was added to the 
flask, precipitating a solid. The ethanol was removed, and the white solid was collected by 
suction filtration and washed with water, followed by a minimal volume of ethanol. 
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3,4-Dichlorobenzylidene-(trimethylsilyl)methyl thiosemicarbazone  (2.4a) 
(Aminomethyl)trimethylsilane (0.270 mL, 2.02 
mmol), compound 2.2a (0.500 g, 1.82 mmol). 
Compound 2.4a was obtained as an off-white 
solid (0.375 g, 62 %). m.p.: 141.2‒143.1 ˚C. 1H 
NMR (300.07 MHz, CDCl3): δ (ppm) = 9.84 (s, 1H, NNH); 7.78 (s, 1H, HC=N); 7.69 (d, 3JHH 
= 1.80 Hz, 1H, H‒2); 7.48 (d, 3JHH = 8.40 Hz, 1H, H‒5); 7.41 (dd, 3JHH = 1.80, 8.40 Hz, 1H, 
H‒6); 7.38 (br s, 1H, NH); 3.28 (d, 3JHH = 6.00 Hz, 2H, CH2); 0.18 (s, 9H, Si(CH3)3). 13C{1H} 
NMR (100.64 MHz, CDCl3): δ (ppm) = 177.7 (C=S); 139.3 (C=N); 134.1; 133.6; 133.3; 
130.9; 128.5; 126.0; 35.0 (CH2); ‒2.44 (Si(CH3)3). FT‒IR (KBr, cm-1): ν = 1602 (s, C=N); 
1250 (m, Si-CH3); 854 (s, C=S). EI+−MS (333.0286 g.mol-1): m/z 333.00 ([M]+, 76 %); 
317.9801 ([M‒CH3]+, 100 %). Elemental analysis for C12H17Cl2N3SiS (333.03 g.mol-1): 
Found (%) C 43.04, H 5.18, N 12.47; Calculated (%) C 43.24, H 5.14, N 12.62. 
 
3,4-Dichlorophenylethylidene-((trimethylsilyl)methyl) thiosemicarbazone  (2.4b) 
(Aminomethyl)trimethylsilane (0.250 mL, 1.87 
mmol), compound 2.2b (0.501 g, 1.71 mmol). 
Compound 2.4b was obtained as a white solid 
(0.492 g, 83 %). m.p.: 153.8‒156.7 ˚C. 1H 
NMR (300.07 MHz, DMSO‒d6): δ (ppm) = 10.2 (s, 1H, NNH); 8.41 (t, 3JHH = 5.70 Hz, 1H, 
NH); 8.13 (d, 3JHH = 2.40 Hz, 1H, H‒2); 7.85 (dd, 3JHH = 2.40, 8.40 Hz, 1H, H‒6); 7.65 (d, 
3JHH = 8.40 Hz, 1H, H‒5); 3.24 (d, 3JHH = 6.30 Hz, 2H, CH2); 2.28 (s, 3H, CH3); 0.10 (s, 9H, 
Si(CH3)3). 13C{1H} NMR (100.64 MHz, DMSO‒d6): δ (ppm) = 177.3 (C=S); 144.3 (C=N); 
138.4; 131.4; 131.2; 130.2; 127.9; 126.4; 34.5 (CH2); 13.7 (CH3); ‒1.84 (Si(CH3)3). FT‒IR 
(KBr, cm-1): ν = 1616 (s, C=N); 1252 (m, Si-CH3); 846 (s, C=S). EI+−MS (347.0442 g.mol-1): 
m/z 347.02 ([M]+, 31 %); 331.9837 ([M‒CH3]+, 89 %). Elemental analysis for 
C13H19Cl2N3SiS (347.04 g.mol-1): Found C 44.78, H 5.77, N 11.71 %; Calculated C 44.82, H 
5.50, N 12.06 %. 
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3,4-Dichloroacetophenone(neopentyl) thiosemicarbazone  (2.5) 
2,2’‒Dimethylpropan-1-amine (0.210 mL, 1.79 
mmol) was added to the flask under N2. 
Compound 2.2b (0.501 g, 1.71 mmol) and dry 
ethanol (20.0 mL) was added to the amine. The 
yellow reaction mixture was heated at 70 ˚C for 48 hr. Water (10.0 mL) was added and the 
precipitate was collected by suction filtration. The solid was washed with water followed by 
minimal ethanol ad dried. Compound 2.5 was isolated as a white solid (0.471 g, 83 %). m.p.: 
192.2‒193.0 ˚C. 1H NMR (399.95 MHz, CDCl3): δ (ppm) = 8.63 (s, 1H, NNH); 7.77 (d, 3JHH 
= 1.60 Hz, 1H, H‒2); 7.74 (br s, 1H, NH); 7.50 (m, 2H, H‒5 & H‒6); 3.60 (d, 3JHH = 5.60 Hz, 
2H, CH2); 2.26 (s, 3H, CH3); 1.04 (s, 9H, C(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ 
(ppm) = 178.4 (C=S); 143.7 (C=N); 137.4; 133.7; 133.0; 130.6; 128.0; 125.1; 55.8 (CH2); 32.2 
(C(CH3)3); 27.4 (C(CH3)3); 13.3 (CH3). FT‒IR (KBr, cm-1): ν = 1615 (s, C=N); 858 (m, C=S). 
EI+−MS (331.0672 g.mol-1): m/z 330.98 ([M]+, 64 %). Elemental analysis for C14H19Cl2N3S 
(331.07 g.mol-1): Found C 50.42, H 5.86, N 12.63 %; Calculated C 50.60, H 5.76, N 12.64 %. 
 
7.2.3  Thiosemicarbazone Ruthenium(II) Complexes 
General method: 
The ruthenium dimer [Ru(η6-p-iPrC6H4Me)Cl2]2 was dissolved in DCM (5.00 mL) followed by 
the addition of two equivalents of the organosilane thiosemicarbazone. The reaction mixture 
was stirred at room temperature for 4 hr. The solvent was reduced (~1 mL) and added to 
stirring diethyl ether to precipitate a solid. The solid was collected by suction filtration and 
washed with diethyl ether.  
 
 [Ru(II)Cl(η6‒MeC6H4iPr)(2.3a)]Cl  (2.6a) 
Ruthenium dimer (0.0500 g, 0.0816 mmol), 
Compound 2.3a (0.0650 g, 0.174 mmol). 
Compound 2.6a was isolated as an orange-red 
powder (0.0678 g, 61 %). m.p.: 102.9 ˚C 
(Decomp. without melting). 1H NMR (300.07 
MHz, CDCl3): δ (ppm) = 8.68 (br s, 1H, NH); 8.60 (s, 1H, HC=N); 6.06 (s, 1H, C5H4); 5.52 
(d, 3JHH = 6.00 Hz, 1H, p‒cym); 5.20 (br s, 2H, p‒cym); 5.13 (d, 3JHH = 6.00 Hz, 1H, p‒cym); 
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4.65 (br s, 3H, C5H4); 4.34 (s, 5H, C5H5); 2.99 (t, 3JHH = 6.30 Hz, 2H, CH2); 2.66 (m, 1H, 
CH(CH3)2); 2.13 (s, 3H, CH3(p-cym)); 1.19 (d, 3JHH = 6.90 Hz, 3H, CH(CH3)2); 1.14 (d, 3JHH = 
6.90 Hz, 3H, CH(CH3)2); 0.21 (s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ 
(ppm) = 158.6 (C=N); 101.6 (p‒cymquatern.); 88.5, 87.3, 83.8, 81.6 (p‒cym); 70.0‒72.6 (Fc); 
36.1 (CH2); 30.5 (CH(CH3)2); 22.7 (CH(CH3)2); 21.7 (CH(CH3)2); 18.5 (CH3(p-cym)); ‒2.56 
(Si(CH3)3). FT‒IR (KBr, cm-1): ν = 1633 (w, C=N); 860 (s, C=S). ESI+−HRMS (678.9866 
g.mol-1): m/z 608.0793 ([M‒H‒Cl]+, 40 %); 304.5437 ([M‒Cl]2+, 100 %). Elemental analysis 
for C26H37Cl2FeN3RuSiS.¼C5H12 (697.01 g.mol-1): Found (%) C 46.88, H 5.72, N 5.92; 
Calculated (%) C 46.91, H 5.78, N 6.03. 
 
 [Ru(II)Cl(η6‒MeC6H4iPr)(2.3b)]Cl  (2.6b) 
Ruthenium dimer (0.0383 g, 0.0625 mmol); 
Compound 2.3b (0.0506 g, 0.131 mmol). 
Compound 2.6b was isolated as a red powder 
(0.0598 g, 69 %). m.p.: 183.8 ˚C (Decomp. 
with melting). 1H NMR (399.95 MHz, 
CDCl3): δ (ppm) = 12.4 (s, 1H, NNH); 10.3 (t, 3JHH = 6.00 Hz, 1H, NH); 6.28 (s, 1H, C5H4); 
5.37 (d, 3JHH = 6.00 Hz, 1H, p‒cym); 4.89 (d, 3JHH = 6.00 Hz, 1H, p‒cym); 4.81 (d, 3JHH = 5.60 
Hz, 1H, p‒cym); 4.74 (d, 3JHH = 6.00 Hz, 1H, p‒cym); 4.65 (d, 3JHH = 6.00 Hz, 2H, C5H4); 
4.56 (s, 1H, C5H4); 4.29 (s, 5H, C5H5); 3.05 (m, 5H, CH3 & CH2); 2.57 (m, 1H, CH(CH3)2); 
2.07 (s, 3H, CH3(p-cym)); 1.13 (d, 3JHH = 6.80 Hz, 3H, CH(CH3)2); 1.08 (d, 3JHH = 6.80 Hz, 3H, 
CH(CH3)2); 0.23 (s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 178.5 
(C=S); 168.2 (C=N); 102.2, 102.1 (p-cymquatern.); 89.5, 87.3 (p-cym); 86.5 (Fcquatern.); 84.1, 81.3 
(p-cym); 72.9, 71.9, 71.4, 70.5, 69.8 (Fc); 36.6 (CH2); 30.5 (CH(CH3)2); 27.7 (CH3); 22.8 
(CH(CH3)2); 21.4 (CH(CH3)2); 18.4 (CH3(p-cym)); ‒2.26 (Si(CH3)3). FT‒IR (ATR, cm-1): ν = 
1624 (w, C=N); 858 (s, C=S). ESI+−HRMS (693.0392 g.mol-1): m/z 622.0960 ([M‒H‒Cl]+, 
100 %); 311.5522 ([M‒Cl]2+, 98 %). Elemental analysis for C27H39Cl2FeN3RuSiS (693.04 
g.mol-1): Found C 46.48, H 5.97, N 5.62 %; Calculated C 46.75, H 5.66, N 6.05 %. 
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 [Ru(II)Cl(η6‒MeC6H4iPr)(2.4a)]Cl  (2.7a) 
Ruthenium dimer (0.0765 g, 0.125 mmol); 
Compound 2.4a (0.0860 g, 0.257 mmol). 
Compound 2.7a was isolated as a light 
orange powder (0.115 g, 72 %). m.p.: 
156.1 ˚C (Decomp. with melting). 1H 
NMR (399.95 MHz, CDCl3): δ (ppm) = 8.91 (br s, 1H, NH); 8.77 (s, 1H, HC=N); 8.67 (s, 1H, 
H‒2); 7.88 (d, 3JHH = 8.40 Hz, 1H, H‒5); 7.64 (d, 3JHH = 8.40 Hz, 1H, H‒6); 5.49 (d, 3JHH = 
5.70 Hz, 1H, p‒cym); 4.98 (d, 3JHH = 6.00 Hz, 1H, p‒cym); 4.90 (d, 3JHH = 6.00 Hz, 1H, 
p‒cym); 4.86 (d, 3JHH = 5.70 Hz, 1H, p‒cym); 3.03 (d, 3JHH = 6.00 Hz, 2H, CH2); 2.64 (m, 1H, 
CH(CH3)2); 2.12 (s, 3H, CH3(p-cym)); 1.18 (d, 3JHH = 6.90 Hz, 3H, CH(CH3)2); 1.12 (d, 3JHH = 
6.90 Hz, 3H, CH(CH3)2); 0.18 (s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ 
(ppm) = 177.7 (C=S); 156.4 (C=N); 136.2; 133.4; 132.7; 132.6; 130.9; 129.8; 104.2, 103.7 (p-
cymquatern.); 88.5, 88.2, 82.7, 81.2 (p-cym); 36.5 (CH2); 30.8 (CH(CH3)2); 22.9 (CH(CH3)2); 
21.5 (CH(CH3)2); 18.7 (CH3(p-cym)); ‒2.49 (Si(CH3)3). FT‒IR (KBr, cm-1): ν = 1630 (s, C=N); 
856 (s, C=S). ESI+−HRMS (638.9808 g.mol-1): m/z 568.0345 ([M‒H‒Cl]+, 100 %); 284.5207 
([M‒Cl]2+, 57 %). Elemental analysis for C22H31Cl4N3RuSiS.H2O (658.56 g.mol-1): Found 
40.06, 4.77, 5.94 %; Calculated C 40.13, H 5.05, N 6.38 %. 
 
 [Ru(II)Cl(η6‒MeC6H4iPr)(2.4b)]Cl  (2.7b) 
Ruthenium dimer (0.0495 g, 0.0808 mmol); 
Compound 2.4b (0.0561 g, 0.161 mmol). 
Compound 2.7b was isolated as an orange 
powder (0.0883 g, 84 %). m.p.: 190.8 ˚C 
(Decomp. with melting). 1H NMR (300.07 
MHz, CDCl3): δ (ppm) = 12.7 (s, 1H, NNH); 10.4 (br s, 1H, NH); 8.23 (s, 1H, H‒2); 7.68 (m, 
2H, H‒5 & H‒6); 5.32 (d, 3JHH = 6.30 Hz, 1H, p‒cym); 4.90 (d, 3JHH = 6.00 Hz, 1H, p‒cym); 
4.71 (d, 3JHH = 6.30 Hz, 1H, p‒cym); 4.10 (d, 3JHH = 5.40 Hz, 1H, p‒cym); 3.07 (d, 3JHH = 5.40 
Hz, 2H, CH2); 2.93 (s, 3H, CH3); 2.65 (m, 1H, CH(CH3)2); 2.06 (s, 3H, CH3(p-cym)); 1.16 (d, 
3JHH = 6.90 Hz, 3H, CH(CH3)2); 1.10 (d, 3JHH = 6.60 Hz, 3H, CH(CH3)2); 0.22 (s, 9H, 
Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 178.5 (C=S); 165.9 (C=N); 141.2; 
134.7; 133.2; 131.5; 130.6; 128.1; 105.9, 102.5 (p-cymquatern.); 88.9, 88.1, 84.0, 82.5 (p-cym); 
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36.8 (CH2); 30.6 (CH(CH3)2); 26.8 (CH3); 23.5 (CH(CH3)2); 21.1 (CH(CH3)2); 18.7 (CH3(p-
cym)); ‒2.30 (Si(CH3)3). FT‒IR (KBr, cm-1): ν = 1633 (s, C=N); 866 (s, C=S). ESI+−HRMS 
(654.0042 g.mol-1): m/z 582.0500 ([M‒H‒Cl]+, 100 %); 291.5291 ([M‒Cl]2+, 42 %). 
Elemental analysis for C23H33Cl4N3RuSiS (654.00 g.mol-1): Found C 42.37, H 5.27, N 6.14 
%; Calculated C 42.20, H 5.08, N 6.42 %. 
 
[Ru(II)Cl(η6‒MeC6H4iPr)(2.5)]Cl  (2.8) 
Ruthenium dimer (0.0515 g, 0.0841 mmol); 
Compound 2.5 (0.0575 g, 0.173 mmol). 
Compound 2.8 was obtained as an orange 
powder (0.0896 g, 83 %). m.p.: 197.7 ˚C 
(Decomp. without melting). 1H NMR 
(399.95 MHz, CDCl3): δ (ppm) = 12.99 (s, 1H, NNH); 10.4 (s, 1H, NH); 8.22 (s, 1H, H‒2); 
7.68 (m, 2H, H‒5 & H‒6); 5.32 (d, 3JHH = 5.60 Hz, 1H, p‒cym); 4.92 (d, 3JHH = 5.60 Hz, 1H, 
p‒cym); 4.73 (d, 3JHH = 6.40 Hz, 1H, p‒cym); 4.10 (d, 3JHH = 5.60 Hz, 1H, p‒cym); 3.41 (m, 
2H, CH2); 2.96 (s, 3H, CH3); 2.65 (m, 1H, CH(CH3)2); 2.06 (s, 3H, CH3(p-cym)); 1.17 (d, 3JHH = 
7.20 Hz, 3H, CH(CH3)2); 1.11 (d, 3JHH = 6.80 Hz, 3H, CH(CH3)2); 1.08 (s, 9H, C(CH3)3). 
13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 178.46 (C=S); 166.85 (C=N); 141.24; 
134.83; 133.29; 131.50; 130.64; 128.18; 106.14, 102.73 (p-cymquaternary); 89.00, 88.02, 84.07, 
82.47 (p-cym); 57.81 (CH2); 32.50 (C(CH3)3); 30.63 (CH(CH3)2); 27.13 (CH3); 23.54 
(CH(CH3)2); 22.26 (C(CH3)3); 21.15 (CH(CH3)2); 18.73 (CH3(p-cym)). FT‒IR (ATR, cm-1): ν = 
1633 (s, C=N); 857 (s, C=S). ESI+−HRMS (638.0242 g.mol-1): m/z 568.0828 ([M+H‒Cl]+, 
100 %); 284.5441 ([M‒Cl]2+, 68 %). Elemental analysis for C24H33Cl4N3RuS.½C5H12 (673.05 
g.mol-1): Found (%) C 47.53 H 5.46 N 6.80; Calculated (%) C 47.25, H 5.84, N 6.24.    
 
7.2.4  Thiosemicarbazone Rhodium(III) Complexes 
General method: 
The rhodium dimer [Rh(Cp*)Cl2]2 was dissolved in DCM (5.00 mL), followed by the addition 
of two equivalents of the ligand. The solution was stirred at room temperature for 4 hr. The 
solvent was reduced (~1 mL) and the contents added to stirring pentane to precipitate a solid. 
The solid was collected by suction filtration and washed with pentane.  
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[Rh(III)Cl(Cp*)(2.3a)]Cl  (2.9a) 
Rhodium dimer (0.0404 g, 0.0654 mmol); 
Compound 2.3a (0.0486 g, 0.130 mmol). 
Compound 2.9a was isolated as a red solid 
(0.0730 g, 82 %). m.p.: 132.8 ˚C (Decomp. 
w/o melting). 1H NMR (399.95 MHz, 
CDCl3): δ (ppm) = 8.75 (s, 1H, NH); 8.62 (s, 1H, HC=N); 6.25 (s, 1H, C5H4); 4.64 (s, 1H, 
C5H4); 4.60 (s, 2H, C5H4); 4.34 (s, 5H, C5H5); 2.99 (m, 2H, CH2); 1.51 (s, 15H, Cp*); 0.24 (s, 
9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 176.2 (C=S); 158.5 (C=N); 
97.3 (d, 1JRhC = 7.45 Hz, Cp*quatern.); 75.6, 74.1, 73.2, 72.3, 70.4, 69.1 (Fc); 36.3 (CH2); 9.48 
(CH3(Cp*)); ‒2.42 (Si(CH3)3). FT‒IR (KBr, cm-1): ν = 1636 (w, C=N; 856 (s, C=S). 
ESI+−HRMS (681.0254 g.mol-1): m/z 610.0873 ([M‒H‒Cl]+, 88 %); 305.5477 ([M‒Cl]2+, 100 
%). Elemental analysis for C26H38Cl2N3FeRhSiS.½H2O (690.04 g.mol-1): Found C 45.11, H 
5.55, N 5.41 %; Calculated C 45.21, H 5.70, N 6.09 %. 
 
[Rh(III)Cl(Cp*)(2.3b)]Cl  (2.9b) 
Rhodium dimer (0.0556 g, 0.0900 mmol); 
Compound 2.3b (0.0683 g, 0.176 mmol). 
Compound 2.9b was obtained as an orange 
powder (0.0962 g, 78 %). 1H NMR (399.95 
MHz, Acetone‒d6): δ (ppm) = 10.90 (s, 1H, 
NNH); 7.86 (s, 1H, NH); 4.69 (t, 3JHH = 1.80 Hz, 2H, C5H4); 4.38 (t, 3JHH = 1.80 Hz, 2H, 
C5H4); 4.18 (s, 5H, C5H5); 3.31 (d, 3JHH = 6.30 Hz 2H, CH2); 2.40 (s, 3H, CH3); 1.62 (s, 15H, 
Cp*); 0.21 (s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, Acetone‒d6): δ (ppm) = 172.88 
(C=S); 153.18 (C=N); 94.58 (d, 1JRhC = 7.75 Hz, Cp*quatern.); 82.59, 70.18, 69.41, 67.35 (Fc); 
34.51 (CH2); 17.06 (CH3); 8.16 (CH3(Cp*)); ‒2.81 (Si(CH3)3). FT‒IR (KBr, cm-1): ν = 1638 (w, 
C=N); 856 (s, C=S). ESI+−HRMS (695.0480 g.mol-1): m/z 624.1039 ([M‒H‒Cl]+, 25 %); 
312.5549 ([M‒Cl]2+, 100 %). Elemental analysis for C27H40Cl2N3FeRhSiS.½H2O (704.05 
g.mol-1): Found (%) C 46.00, H 6.13, N 5.27; Calculated (%) C 46.02, H 5.87, N 5.97. 
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[Rh(III)Cl(Cp*)(2.4a)]Cl  (2.10a) 
Rhodium dimer (0.0410 g, 0.0663 mmol); 
Compound 2.4a (0.0445 g, 0.133 mmol). 
Compound 2.10a was isolated as a red 
powder (0.0796 g, 93 %). m.p.: 205.4 ˚C 
(Decomp. w/o melting). 1H NMR (399.95 
MHz, CDCl3): δ (ppm) = 11.55 (s, 1H, NNH); 7.94 (s, 1H, HC=N); 7.67 (d, 3JHH = 2.00 Hz, 
1H, H‒2); 7.44 (d, 3JHH = 8.80 Hz, 1H, H‒5); 7.36 (dd, 4JHH = 1.60 Hz, 3JHH = 8.00 Hz, 1H, 
H‒6); 7.10 (br s, 1H, NH); 3.20 (d, 4JHH = JHH = 5.60 Hz, 2H, CH2); 1.70 (s, 15H, Cp*); 0.20 
(s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 173.95 (C=S); 143.57 
(C=N); 134.30; 133.61; 133.20; 130.81; 128.53; 126.66; 95.43 (d, 1JRhC = 8.05 Hz, Cp*quatern.); 
34.80 (CH2); 8.89 (CH3(Cp*)); ‒2.41 (Si(CH3)3). FT‒IR (KBr, cm-1): ν = 1638 (w, C=N); 856 
(s, C=S). ESI+−HRMS (640.9886 g.mol-1): m/z 570.0446 ([M‒H‒Cl]+, 100 %); 285.5261 
([M‒Cl]2+, 30 %). Elemental analysis for C22H32Cl4N3RhSiS.½H2O (649.99 g.mol-1): Found 
(%) C 40.24, H 5.26, N 6.11; Calculated (%) C 40.62, H 5.12, N 6.46. 
 
[Rh(III)Cl(Cp*)(2.4b)]Cl  (2.10b) 
Rhodium dimer (0.0490 g, 0.0793 mmol); 
Compound 2.4b (0.0552 g, 0.158 mmol). 
Compound 2.10b was obtained as an orange 
solid (0.0839 g, 80 %). m.p. 112.7 ˚C 
(Decomp. w/o melting). 1H NMR (399.95 
MHz, CDCl3): δ (ppm) = 10.9 (s, 1H, NNH); 7.73 (m, 1H, H‒2); 7.43 (m, 2H, H‒5 & H‒6); 
7.39 (t, 3JHH = 5.20 Hz, 1H, NH); 3.16 (d, 3JHH = 5.60 Hz, 2H, CH2); 2.52 (s, 3H, CH3); 1.69 (s, 
15H, Cp*); 0.19 (s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 174.3 
(C=S); 149.4 (C=N); 137.9; 133.5; 132.7; 130.3; 128.2; 125.5; 95.2 (d, 1JRhC = 8.09 Hz, 
Cp*quatern.); 34.5 (CH2); 16.7 (CH3); 8.78 (CH3(Cp*)); ‒2.48 (Si(CH3)3). FT‒IR (KBr, cm-1): ν = 
1629 (w, C=N); 858 (s, C=S). ESI+−HRMS (655.0042 g.mol-1): m/z 584.0607 ([M‒H‒Cl]+, 
100 %); 292.5339 ([M‒Cl]2+, 98 %). Elemental analysis for C23H34Cl4N3RhSiS.½H2O (664.01 
g.mol-1): Found (%) C 41.42, H 5.08, N 6.26; Calculated (%) C 41.57, H 5.31, N 6.33. 
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[Rh(III)Cl(Cp*)(2.5)]Cl  (2.11) 
Rhodium dimer (0.0500 g, 0.0809 mmol); 
Compound 2.5 (0.0546 g, 0.164 mmol). 
Compound 2.11 was obtained as an orange 
solid (0.0741 g, 80 %). m.p.: 118.5 ˚C 
(Decomp. with melting). 1H NMR (399.95 
MHz, CDCl3): δ (ppm) = 10.9 (s, 1H, NNH); 7.71 (m, 1H, H‒2); 7.54 (t, 3JHH = 6.40 Hz, 1H, 
NH); 7.44 (m, 2H, H‒5 & H‒6); 3.49 (d, 3JHH = 5.60 Hz, 2H, CH2); 2.53 (s, 3H, CH3); 1.68 (s, 
15H, Cp*); 1.03 (s, 9H, C(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 173.7 
(C=S); 149.8 (C=N); 137.9; 133.6; 132.8; 130.4; 128.3; 125.5; 95.4 (d, 1JRhC = 8.05 Hz, 
Cp*quatern.); 55.5 (CH2); 31.9 (C(CH3)3); 27.5 (C(CH3)3); 16.9 (CH3).8.79 (CH3(Cp*)). FT‒IR 
(ATR, cm-1): ν = 1624 (w, C=N); 853 (s, C=S). ESI+−HRMS (639.0272 g.mol-1): m/z 
568.0739 ([M‒H‒Cl]+, 100 %); 283.5399 ([M‒Cl]2+, 62 %). Elemental analysis for 
C24H34Cl4N3RhS.H2O (648.03 g.mol-1): Found (%) C 44.10, H 5.44, N 6.18; Calculated (%) C 
44.44, H 5.44, N 6.48. 
 
7.2.5  Thiosemicarbazone Palladium(II) Complexes 
General procedure 
The thiosemicarbazone was dissolved in ethanol, followed by the addition of triethylamine 
(0.20 mL), and stirred for approximately 10 minutes. The palladium precursor 
cis‒[Pd(PTA)2Cl2] was added and the reaction mixture refluxed for 24 hr. The resulting solid 
was collected by suction filtration. If another phosphorus species was present, the solid was 
purified by washing the solid with a minimal volume of hot methanol to remove phosphorus 
impurity.  
  
[Pd(PTA)(2.3b)]  (2.12) 
cis‒[Pd(PTA)2Cl2] (0.0525 g, 0.107 mmol); 
Compound 2.3b (0.0738 g, 0.106 mmol). 
Compound 2.12 was isolated as a red powder 
(0.0434 g, 63 %). m.p.: 266.8 ˚C (Decomp. w/o 
melting). 1H NMR (399.95 MHz, DMSO‒d6): δ 
(ppm) = 6.56 (t, JHH = 6.00 Hz, 1H, NH); 4.65 (d, 
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4JPH = 12.40 Hz, 3H, NCH2(eq)N); 4.44 (m, 4H, NCH2(ax)N & C5H3); 4.38 (d, JHH = 2.40 Hz, 
1H, C5H3); 4.32 (t, JHH = 2.00 Hz, 1H, C5H3); 4.24 (s, 6H, PCH2N); 4.11 (s, 5H, C5H5); 2.79 
(d, JHH = 6.00 Hz, 2H, CH2); 2.14 (s, 3H, CH3); 0.038 (s, 9H, Si(CH3)3). 13C{1H} NMR 
(100.64 MHz, DMSO‒d6): δ (ppm) = 163.0 (C=N); 99.5 (d, 2JCP = 12.9 Hz, C‒Pd); 95.2 
(C‒CN); 75.4 (Fc); 72.5 (d, 3JCP = 6.74 Hz, NCH2N); 69.8, 68.5, 66.7 (Fc); 52.7 (d, 1JCP = 16.1 
Hz, PCH2N); 37.3 (CH2); 13.4 (CH3); ‒1.35 (Si(CH3)3). 31P{1H} NMR (162.01 MHz, 
DMSO‒d6): δ (ppm) = ‒41.6. FT‒IR (KBr, cm-1): ν = 1570 (s, C=N), 1530 (s, C=N); 807 (s, 
C‒S). EI+−MS (648.0520 g.mol-1): m/z 647.97 ([M]+, 75 %). Elemental analysis for 
C23H35FeN6PdPSiS (648.05 g.mol-1): Found C 42.13, H 5.53, N 13.03 %; Calculated C 42.57, 
H 5.44, N 12.95 %. 
 
[Pd(PTA)(2.4b)]  (2.13) 
cis‒[Pd(PTA)2Cl2] (0.107 g, 0.218 mmol); 
Compound 2.4b (0.0761 g, 0.218 mmol). 
Compound 2.13 was obtained as a yellow 
powder (0.0634 g, 48 %). m.p.: 240.2 ˚C 
(Decomp. with melting). 1H NMR (300.07 
MHz, DMSO‒d6): δ (ppm) = 7.25 (m, 2H, H‒2 
& NH); 7.11 (d, JHH = 3.60 Hz, 1H, H‒5); 4.58 (d, 4JPH = 12.6 Hz, 3H, NCH2(eq)N); 4.44 (d, 
4JPH = 12.9 Hz, 3H, NCH2(ax)N); 4.27 (s, 6H, PCH2N); 2.86 (d, JHH = 6.00 Hz, 2H, CH2); 2.23 
(s, 3H, CH3); 0.039 (s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, DMSO‒d6): δ (ppm) = 
163.3 (d, JCP = 7.04 Hz, C=N); 153.2 (Ar‒C); 136.3 (d, JCP = 8.05 Hz, C‒Pd); 130.3, 127.0, 
126.9, 126.6 (Ar‒C); 72.4 (d, 3JCP = 7.18 Hz, NCH2N); 51.5 (d, 1JCP = 15.4 Hz, PCH2N); 37.9 
(CH2); 13.5 (CH3); ‒1.39 (Si(CH3)3). 31P{1H} NMR (121.47 MHz, DMSO‒d6): δ (ppm) = 
‒49.6. FT‒IR (KBr, cm-1): ν = 1578 (s, C=N), 1560 (s, C=N); 807 (s, C‒S). EI+−MS 
(608.0082 g.mol-1): m/z 607.99 ([M+H]+, 1.8 %). Elemental analysis for C19H29Cl2N6PdPSiS 
(608.01 g.mol-1): Found C 37.10, H 4.86, N 13.16 %; Calculated C 37.50, H 4.81, N 13.82 %. 
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[Pd(PTA)(2.5)]  (2.14) 
cis‒[Pd(PTA)2Cl2] (0.147 g, 0.299 mmol); 
Compound 2.5 (0.0997 g, 0.300 mmol). 
Compound 2.14 was isolated as a yellow powder 
(0.0926 g, 52 %). m.p.: 242.1 ˚C (Decomp. with 
melting). 1H NMR (399.95 MHz, DMSO‒d6): δ 
(ppm) = 7.26 (s, 1H, H‒2); 7.17 (br s, 1H, NH); 
7.11 (d, JHH = 3.60 Hz, 1H, H‒5); 4.58 (d, 4JPH = 12.8 Hz, 3H, NCH2(eq)N); 4.45 (d, 4JPH = 12.8 
Hz, 3H, NCH2(ax)N); 4.28 (s, 6H, PCH2N); 3.14 (d, JHH = 6.40 Hz, 2H, CH2); 2.24 (s, 3H, 
CH3); 0.88 (s, 9H, C(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 165.5 (Ar‒C); 
161.6 (d, JCP = 7.4 Hz, C=N); 152.3 (Ar‒C); 135.7 (d, 2JCP = 8.76 Hz, C‒Pd); 131.7, 128.1, 
127.2 (Ar‒C); 72.4 (d, 3JCP = 7.18 Hz, NCH2N); 58.0 (CH2); 51.5 (d, 1JCP = 15.4 Hz, PCH2N); 
32.3 (C(CH3)3); 27.3 (C(CH3)3); 13.4 (CH3). 31P{1H} NMR (121.47 MHz, DMSO‒d6): δ 
(ppm) = ‒49.6. FT‒IR (KBr, cm-1): ν = 1582 (s, C=N), 1558 (s, C=N); 801 (s, C‒S). EI+−MS 
(592.0312 g.mol-1): m/z 592.09 ([M]+, 1.5 %). Elemental analysis for C20H29Cl2N6PdPS 
(592.03 g.mol-1): Found C 40.31, H 5.06, N 14.27 %; Calculated C 40.45, H 4.92, N 14.15 %. 
 
7.3  Ferrocenyl−Containing Aminoquinolines 
General method  
Quaternised ferroquine was refluxed in acetonitrile (20.0 mL), with 8 equivalents of various 
amines in the presence of K2CO3 (2 eq.), for 3 days. The cooled solution was diluted using 
chloroform:H2O (1:1; 60.0 mL) and extracted using chloroform (2 x 40.0 mL). The organic 
layer was dried over Na2SO4 and the solvent removed. The compound was purified using silica 
gel chromatography, eluting with ethyl acetate: petroleum ether: triethylamine (7:2:1). 
Previously published compound 4.1 was prepared following the method described above.  
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7-Chloro-4-[2-(N'-substituted aminomethyl)-N-ferrocenylmethyl(aminomethyl)trimethyl- 
silane]quinoline  (4.1) 
Quaternised ferroquine (0.307 g, 0.534 mmol); 
(aminomethyl)trimethylsilane (0.560 mL, 4.18 
mmol). Compound 4.1 was isolated as an 
orange solid (0.218 g, 83 %). Rf value = 0.63. 
m.p.: 154.6‒156.5 ˚C. 1H NMR (300.08 MHz, 
CDCl3): δ (ppm) = 8.55 (d, 3JHH = 5.40 Hz, 1H, H‒2); 7.94 (d, 4JHH = 2.40 Hz, 1H, H‒8); 7.71 
(d, 3JHH = 9.00 Hz, 1H, H‒5); 7.26 (dd, 4JHH = 2.40 Hz, 3JHH = 9.00 Hz, 1H, H‒6); 6.55 (br s, 
1H, NH); 6.50 (d, 3JHH = 5.40 Hz, 1H, H‒3); 4.37 (d, 3JHH = 13.20 Hz, 1H, H‒11); 4.28 (m, 
1H, C5H3); 4.24 (m, 1H, C5H3); 4.15 (m, 6H, C5H5 & H‒11); 4.12 (t, 3JHH = 2.40 Hz, 1H, 
C5H3); 3.76 (d, 3JHH = 12.30 Hz, 1H, H‒12); 3.49 (d, 3JHH = 12.30 Hz, 1H, H‒12); 2.21 (d, 3JHH 
= 13.80 Hz, 1H, H‒13); 2.11 (d, 3JHH = 13.80 Hz, 1H, H‒13); 0.046 (s, 9H, Si(CH3)3). 
Elemental analysis for C25H30ClFeN3Si (491.11 g/mol): Found C 61.13, H 6.25, N 8.71 %; 
Calculated C 61.08, H 6.15, N 8.55 %. 
 
7-Chloro-4-[2-(N'-substituted aminomethyl)-N-ferrocenylmethyl(amino-2,2’-dimethylpropyl)] 
quinoline  (4.2)                     
Quaternised ferroquine (0.201 g, 0.350 
mmol); 2,2’‒dimethylpropan-1-amine (0.340 
mL, 2.90 mmol). Compound 4.2 was obtained 
as an orange solid (0.111 g, 67 %). Rf value = 
0.52. m.p.: 143.1‒144.9 ˚C. 1H NMR (300.08 
MHz, CDCl3): δ (ppm) = 8.56 (d, 3JHH = 5.70 Hz, 1H, H‒2); 7.94 (d, 4JHH = 2.01 Hz, 1H, 
H‒8); 7.72 (d, 3JHH = 9.00 Hz, 1H, H‒5); 7.26 (dd, 4JHH = 2.10 Hz, 3JHH = 8.70 Hz, 1H, H‒6); 
6.46 (d, 3JHH = 5.10 Hz, 1H, H‒3); 6.20 (br s, 1H, NH); 4.35‒4.40 (m, 1H, H‒11); 4.27‒4.28 
(m, 1H, C5H3); 4.23‒4.24 (m, 1H, C5H3); 4.14‒4.21 (m, 2H, C5H5 & H‒11); 4.12 (t, 3JHH = 
2.40 Hz, 1H, C5H3); 3.72 (d, 3JHH = 12.40 Hz, 1H, H‒12); 3.51 (d, 3JHH = 12.40 Hz, 1H, 
H‒12); 2.46 (d, 3JHH = 11.70 Hz, 1H, H‒13); 2.39 (d, 3JHH = 11.40 Hz, 1H, H‒13); 0.91 (s, 9H, 
C(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 152.1, 149.7, 149.3, 134.7, 128.6, 
124.9, 121.9, 117.4, 99.2 (CAr); 86.1, 83.2 (Fcquat.); 70.3, 69.8, 69.1, 66.4 (Fc); 62.5, 49.2, 42.0 
(CH2); 31.5 (C(CH3)3); 27.9 (C(CH3)3). FT‒IR (ATR, cm-1): ν = 3270 (br, N‒H); 2948 (w, 
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N‒H); 1611 (w, C=N); 1577 (s, C=C). EI+−MS (475.1470 g.mol-1): m/z 475.09 ([M]+, 81 %). 
Elemental analysis for C26H30ClFeN3 (475.15 g.mol-1): Found C 65.30, H 6.59, N 8.32 %; 
Calculated C 65.66, H 6.36, N 8.84 %. 
 
7-Chloro-4-[2-(N'-substituted aminomethyl)-N-ferrocenylmethyl(aminopropyl)trimethyl- 
silane]quinoline  (4.3) 
Quaternised ferroquine (0.199 g, 0.347 
mmol); (3-aminopropyl)trimethylsilane 
(0.450 mL, 2.74 mmol). Compound 4.3 
was isolated as a yellow solid (0.129 g, 
72 %). Rf value = 0.36. m.p.: 
149.4‒150.9 ˚C. 1H NMR (300.08 MHz, CDCl3): δ (ppm) = 8.54 (d, 3JHH = 5.40 Hz, 1H, 
H‒2); 7.92 (d, 4JHH = 2.10 Hz, 1H, H‒8); 7.81 (d, 3JHH = 9.00 Hz, 1H, H‒5); 7.24 (dd, 4JHH = 
2.40 Hz, 3JHH = 9.00 Hz, 1H, H‒6); 6.48 (d, 3JHH = 5.40 Hz, 1H, H‒3); 4.38 (d, 3JHH = 13.20 
Hz, 1H, H‒11); 4.29‒4.30 (m, 1H, C5H3); 4.22‒4.24 (m, 1H, C5H3); 4.17‒4.20 (m, 6H, C5H5 & 
H‒11); 4.10 (t, 3JHH = 2.40 Hz, 1H, C5H3); 3.71 (d, 3JHH = 12.30 Hz, 1H, H‒12); 3.53 (d, 3JHH 
= 12.30 Hz, 1H, H‒12); 2.60‒2.70 (m, 2H, H‒13); 1.46‒1.59 (m, 2H, H‒14); 0.42 (t, 3JHH = 
8.40 Hz, 2H, H‒15); −0.036 (s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) 
= 152.1, 150.1, 149.4, 134.7, 128.4, 124.7, 122.6, 117.8, 98.9 (CAr); 85.6, 83.5 (Fcquat.); 70.7, 
70.2, 69.2, 66.1 (Fc); 53.4, 47.8, 42.4, 24.2, 14.2 (CH2); ‒1.74 (Si(CH3)3). FT‒IR (ATR, cm-
1): ν = 3198 (br, N‒H); 2954 (w, N‒H); 1611 (w, C=N); 1570 (s, C=C). EI+−MS (519.1552 
g.mol-1): m/z 519.14 ([M]+, 49 %). Elemental analysis for C27H34ClFeN3Si (519.15 g.mol-1): 
Found C 62.13, H 6.82, N 7.99 %; Calculated C 62.41, H 6.60, N 8.09 %. 
 
7-Chloro-4-[2-(N'-substituted aminomethyl)-N-ferrocenylmethyl(amino-4,4’- 
dimethylpentyl)]quinoline  (4.4) 
Quaternised ferroquine (0.194 g, 
0.337 mmol); 4,4’-dimethylpentan-1-
amine (0.380 mL, 2.64 mmol). 
Compound 4.4 was isolated as a 
yellow solid (0.144 g, 85 %). Rf 
value = 0.28. m.p.: 143.1‒144.5 ˚C. 1H NMR (300.08 MHz, CDCl3): δ (ppm) = 8.55 (d, 3JHH 
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= 5.40 Hz, 1H, H‒2); 7.92 (d, 4JHH = 2.40 Hz, 1H, H‒8); 7.80 (d, 3JHH = 9.00 Hz, 1H, H‒5); 
7.25 (dd, 4JHH = 2.40 Hz, 3JHH = 9.00 Hz, 1H, H‒6); 7.20 (br s, 1H, NH); 6.48 (d, 3JHH = 5.40 
Hz, 1H, H‒3); 4.37 (d, 3JHH = 12.90 Hz, 1H, H‒11); 4.27‒4.28 (m, 1H, C5H3); 4.20‒4.21 (m, 
1H, C5H3); 4.13‒4.18 (m, 6H, C5H5 & H‒11); 4.10 (t, 3JHH = 2.40 Hz, 1H, C5H3); 3.70 (d, 3JHH 
= 12.00 Hz, 1H, H‒12); 3.53 (d, 3JHH = 12.00 Hz, 1H, H‒12); 2.55‒2.66 (m, 2H, H‒13); 
1.40‒1.53 (m, 2H, H‒14); 1.11 (t, 3JHH = 8.70 Hz, 2H, H‒15); 0.85 (s, 9H, C(CH3)3). 13C{1H} 
NMR (100.64 MHz, CDCl3): δ (ppm) = 152.1, 150.1, 149.4, 134.6, 128.5, 124.7, 122.6, 
117.8, 98.9 (CAr); 85.6, 83.5 (Fcquat.); 70.4, 70.2, 69.2, 66.1 (Fc); 50.9, 47.9, 42.4, 41.6 (CH2); 
30.1 (C(CH3)3); 29.3 (C(CH3)3); 25.0 (CH2). FT‒IR (ATR, cm-1): ν = 3258 (br, N‒H); 2956 
(w, N‒H); 1611 (w, C=N); 1578 (s, C=C). EI+−MS (503.1782 g.mol-1): m/z 503.12 ([M]+, 78 
%). Elemental analysis for C28H34ClFeN3 (503.18 g.mol-1): Found C 66.73, H 6.77, N 8.08 %; 
Calculated C 66.78, H 6.81, N 8.35 %. 
 
7-Chloro-4-[2-(N'-substituted aminomethyl)-N-ferrocenylmethyl(aminomethyl)dimethylphenyl-
silane]quinoline  (4.5) 
Quaternised ferroquine (0.101 g, 0.176 
mmol); (aminomethyl)dimethylphenylsilane 
(0.25 mL, 1.39 mmol). Compound 4.5 was 
isolated as a yellow solid (0.0470 g, 48 %). 
Rf value = 0.66. m.p.: 157.0‒159.4 ˚C. 1H 
NMR (400.22 MHz, CDCl3): δ (ppm) = 8.52 (d, 3JHH = 5.40 Hz, 1H, H‒2); 7.92 (d, 4JHH = 
2.10 Hz, 1H, H‒8); 7.56 (d, 3JHH = 9.00 Hz, 1H, H‒5); 7.49‒7.52 (m, 2H, Ph); 7.32‒7.34 (m, 
3H, Ph); 7.16 (dd, 4JHH = 2.10 Hz, 3JHH = 9.00 Hz, 1H, H‒6); 6.50 (br s, 1H, NH); 6.46 (d, 3JHH 
= 5.40 Hz, 1H, H‒3); 4.27‒4.33 (m, 2H, C5H3 & H‒11); 4.15‒4.20 (m, 2H, C5H3 & H‒11); 
4.09‒4.11 (m, 6H, C5H3 & C5H5); 3.75 (d, 3JHH = 12.60 Hz, 1H, H‒12); 3.44 (d, 3JHH = 12.60 
Hz, 1H, H‒12); 2.46 (d, 3JHH = 14.00 Hz, 1H, H‒13); 2.37 (d, 3JHH = 14.00 Hz, 1H, H‒13); 
0.34 (s, 6H, Si(CH3)2). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 151.5, 149.4, 148.7, 
136.9, 134.3, 133.2, 129.0, 128.0, 127.6, 124.6, 121.5, 117.1, 98.6 (CAr); 84.8, 82.9 (Fcquat.); 
70.0, 69.4, 68.7, 66.0 (Fc); 51.6, 41.6, 38.8 (CH2); ‒3.99 (Si(CH3)). FT‒IR (ATR, cm-1): ν = 
3298 (br, N‒H); 2948 (w, N‒H); 1609 (w, C=N); 1578 (s, C=C). EI+−MS (553.1396 g.mol-1): 
m/z 553.14 ([M]+, 12 %); 389.07 ([M‒NHCH2Si(CH3)2Ph]+, 39.5 %); 388.03 
([M‒H‒NHCH2Si(CH3)2Ph]+, 100 %). Elemental analysis for C30H32ClFeN3Si∙½H2O (562.14 
g.mol-1): Found C 63.79, H 5.87, N 7.38 %; Calculated C 64.04, H 5.92, N 7.47 %. 
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7.4  Ferrocenyl−Containing Aminobenzothiazoles 
6‒Chloro‒2‒iodobenzothiazole  (4.6) 
2-Amino-6-chlorobenzothiazole (0.325 g, 1.76 mmol) was 
dissolved in 3 M H2SO4 (25.0 mL) and cooled to 0˚C. Sodium 
nitrite (0.366 g, 5.30 mmol) was added to the yellow solution 
over 0.25 hr. Potassium iodide (0.332 g, 2.00 mmol) was added 
to the orange solution at 0˚C and allowed to stir at ambient temperature for 24 hr. The contents 
were diluted with H2O/Et2O (60.0 mL; 1:1), extracted using ethyl acetate (2 x 30.0 mL), 
collected the organic layer which was dried over Na2SO4 and the solvent was removed. The 
crude solid was purified using silica column chromatography [Ethyl acetate: Hexane (4:1)]. Rf 
= 0.88. Compound 4.6 was obtained as an orange solid (0.243 g, 47 %). m.p. 141.1‒143.4 ˚C. 
1H NMR (300.08 MHz, CDCl3): δ (ppm) = 7.94 (d, 3JHH = 8.70 Hz, 1H, H‒8); 7.84 (d, 3JHH = 
2.40 Hz, 1H, H‒5); 7.41 (dd, 4JHH = 2.40 Hz, 3JHH = 8.70 Hz, 1H, H‒7). 13C{1H} NMR 
(100.64 MHz, CDCl3): δ (ppm) = 152.8; 140.2; 132.1; 127.2; 123.2; 120.1; 105.8. FT‒IR 
(ATR, cm-1): ν = 1588 (s, C=N); 1546 (m, C=C). EI+−MS (294.8719 g.mol-1): m/z 294.82 
([M]+, 100 %). 
 
6‒Chloro‒N‒[(2‒(dimethylaminomethyl)ferrocenylmethylamino)benzo[d]thiazole  (4.7) 
2-[(N,N-dimethylamino)methyl]ferrocene-
methylamine (0.178 g, 0.652 mmol) was 
dissolved in THF (6.00 mL), followed by 
the addition K2CO3 and 2-iodo-6-chloro-
benzothiazole (0.158 g, 0.536 mmol). The orange solution was heated at 30 ˚C for 3 days, after 
which water (20.0 mL) was added. The compound was extracted using DCM (2 x 20.0 mL), 
the organic layer was collected and dried over Na2SO4. The crude product was purified using 
silica column chromatography: Initially flush with diethyl ether to remove unreacted 2-iodo-6-
chlorobenzothiazole, followed by the elution of compound 4.7 using Ethyl acetate: Hexane: 
Et3N (75: 20: 5). Rf = 0.43. Compound 4.7 was isolated as an orange hydroscopic solid (0.128 
g, 54 %). 1H NMR (300.08 MHz, CDCl3): δ (ppm) = 8.31 (br s, 1H, NH); 7.48 (d, 4JHH = 2.10 
Hz, 1H, H‒5); 7.45 (d, 3JHH = 8.70 Hz, 1H, H‒8); 7.22 (dd, 4JHH = 2.10 Hz, 3JHH = 8.70 Hz, 
1H, H‒7); 4.50 (br s, 2H, H‒10); 4.28 (t, 3JHH = 1.80 Hz, 1H, C5H3); 4.10‒4.12 (m, 6H, C5H3 
& C5H5); 4.04 (t, 3JHH = 2.70 Hz, 1H, C5H3); 3.80 (d, 3JHH = 12.60 Hz, 1H, H‒11); 2.84 (d, 
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3JHH = 12.60 Hz, 1H, H‒11); 2.23 (s, 6H, N(CH3)2). 13C{1H} NMR (100.64 MHz, CDCl3): δ 
(ppm) = 166.7, 151.6, 131.8, 126.3, 126.1, 120.3, 119.2 (CAr); 84.1, 83.8 (Fcquat.); 71.1, 70.3, 
69.2, 65.8 (Fc); 58.1 (CH2); 44.5 (N(CH3)2). FT‒IR (ATR, cm-1): ν = 3182 (br, N-H); 1597 (s, 
C=N); 1536 (s, C=C). EI+−MS (439.0566 g.mol-1): m/z 439.04 ([M]+, 86 %). LCMS for 
C21H22ClFeN3S (439.0566 g.mol-1): m/z 440.1 [M+H]+, tR = 3.832 min, > 99 %. 
 
N,N,N‒Trimethyl{2‒N’‒(6‒benzothiazolyl)aminomethyl}ferrocenylmethylammonium iodide 
(4.8) 
Compound 4.7 (0.172 g, 0.391 mmol) was 
dissolved in acetone (2.50 mL), followed by 
the addition of iodomethane. The contents 
were stirred at room temperature for 6 hr. 
The resulting solid was collected by suction filtration and washed with acetone. Compound 4.8 
was isolated as a yellow solid (0.0420 g, 18 %). m.p.: 181.3 ˚C (Decomp. w/o melting). 1H 
NMR (300.08 MHz, DMSO‒d6): δ (ppm) = 8.22 (t, 3JHH = 5.10 Hz, 1H, NH); 7.81 (d, 4JHH = 
2.10 Hz, 1H, H‒5); 7.40 (d, 3JHH = 8.70 Hz, 1H, H‒8); 7.26 (dd, 4JHH = 2.40 Hz, 3JHH = 8.70 
Hz, 1H, H‒7); 4.64 (d, 3JHH = 13.8 Hz, 1H, H‒10); 4.60‒4.61 (m, 1H, C5H3); 4.57‒4.58 (m, 
1H, C5H3); 4.39−4.55 (m, 4H, H‒10 & H‒11 & C5H3); 4.25 (s, 5H, C5H5); 2.96 (s, 9H, 
N(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 166.6, 151.7, 132.7, 126.2, 125.3, 
121.2, 119.4 (CAr); 87.2, 73.1 (Fcquat.); 72.8, 71.5, 70.3, 69.9 (Fc); 64.1 (CH2); 52.0(N(CH3)3); 
41.8 (CH2). FT‒IR (ATR, cm-1): ν = 3218 (m, N‒H); 1596 (s, C=N); 1558 (s, C=C). 
ESI+−HRMS (580.9845 g.mol-1): m/z 454.0808 ([M]+, 57 %), 395.0078 ([M−N(CH3)3, 100 
%). Elemental analysis for C22H25ClFeN3SI (580.97 g.mol-1): Found C 45.02, H 4.75, N 6.52 
%; Calculated C 45.44, H 4.34, N 7.23 %. 
 
General method for the synthesis of compounds 4.9−4.11 
The amine was added to the flask under N2, and dissolved in acetonitrile (15.0 mL). Compound 
4.8 and K2CO3 (3 eq.) was added to the amine solution and the contents refluxed for 48 hr 
(monitored by TLC). Reaction mixture was cooled to room temperature and H2O (30.0 mL) 
added. The compound was extracted using DCM (2 x 30.0 mL), the yellow organic layer 
collected and dried over Na2SO4. The compound was purified using silica column 
chromatography [ethyl acetate: petroleum ether: Et3N (7:2.5:0.5)]. The second yellow band 
was collected. 
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6-Chloro-2-[2-(N'-substituted aminomethyl)-N-ferrocenylmethyl(aminomethyl)trimethylsilane] 
benzo[d]thiazole  (4.9) 
Compound 4.8 (0.0867 g, 0.149 mmol); 
(aminomethyl)trimethylsilane (0.160 mL, 
1.19 mmol). Rf = 0.45. Compound 4.9 
was isolated as a yellow solid (0.0465 g, 
63 %). m.p.: 130.5−132.8 ˚C. 1H NMR 
(300.08 MHz, CDCl3): δ (ppm) = 7.83 (br s, 1H, NH); 7.50 (d, 3JHH = 1.80 Hz, 1H, H‒8); 7.46 
(d, 3JHH = 8.70 Hz, 1H, H‒5); 7.22 (dd, 4JHH = 2.10 Hz, 3JHH = 8.40 Hz, 1H, H‒7); 4.46−4.57 
(m, 2H, H‒10); 4.28−4.29 (m, 1H, C5H3); 4.16−4.17 (m, 1H, C5H3); 4.12 (s, 5H, C5H5); 4.06 (t, 
3JHH = 2.40 Hz, 1H, C5H3); 3.80 (d, 3JHH = 12.30 Hz, 1H, H‒11); 3.43 (d, 3JHH = 12.30 Hz, 1H, 
H‒11); 2.16 (d, 3JHH = 13.60 Hz, 1H, H‒12); 2.07 (d, 3JHH = 13.60 Hz, 1H, H‒12); 0.10 (s, 9H, 
Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ (ppm) = 166.3, 151.4, 131.8, 126.3, 126.1, 
120.3, 119.3 (CAr); 84.8, 83.9 (Fcquat.); 70.6, 70.1, 69.1, 66.0 (Fc); 52.6, 43.9, 40.2 (CH2); −2.31 
(Si(CH3)3). FT‒IR (ATR, cm-1): ν = 3185 (w, N-H); 1594 (w, C=N); 1557 (s, C=C). EI+−MS 
(497.0804 g.mol-1): m/z 497.01 ([M]+, 100 %). LCMS for C23H28ClFeN3SiS (497.05 g.mol-1): 
m/z 498.1 [M+H]+, tR = 4.340 min, > 99 %. 
 
6-Chloro-2-[2-(N'-substituted aminomethyl)-N-ferrocenylmethyl(amino-2,2’-dimethylpropyl)]- 
benzo[d]thiazole  (4.10) 
Compound 4.8 (0.0756 g, 0.130 mmol); 
2,2’dimethylpropan-1-amine (0.120 mL, 
1.02 mmol). Rf = 0.54. Compound 4.10 
was isolated as a yellow solid (0.0452 g, 
72 %). m.p.: 144.2−146.4 ˚C. 1H NMR 
(300.08 MHz, CDCl3): δ (ppm) = 7.70 (br s, 1H, NH); 7.48 (d, 3JHH = 2.10 Hz, 1H, H‒8); 7.46 
(d, 3JHH = 8.70 Hz, 1H, H‒5); 7.22 (dd, 4JHH = 2.10 Hz, 3JHH = 8.70 Hz, 1H, H‒7); 4.59 (d, 3JHH 
= 13.80 Hz, 1H, H‒10); 4.50 (d, 3JHH = 13.80 Hz, 1H, H‒10); 4.28−4.29 (m, 1H, C5H3); 
4.15−4.16 (m, 1H, C5H3); 4.12 (s, 5H, C5H5); 4.06 (t, 3JHH = 2.40 Hz, 1H, C5H3); 3.77 (d, 3JHH 
= 12.30 Hz, 1H, H‒11); 3.45 (d, 3JHH = 12.30 Hz, 1H, H‒11); 2.46 (d, 3JHH = 11.10 Hz, 1H, 
H‒12); 2.37 (d, 3JHH = 11.10 Hz, 1H, H‒12); 0.97 (s, 9H, C(CH3)3). 13C{1H} NMR (100.64 
MHz, CDCl3): δ (ppm) = 166.3, 151.4, 131.9, 126.3, 126.1, 120.3, 119.3 (CAr); 85.2, 83.9 
(Fcquat.); 70.5, 70.1, 69.1, 65.9 (Fc); 62.3, 49.0, 43.8 (CH2); 31.3 (C(CH3)3); 28.1 (C(CH3)3). 
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FT-IR (ATR, cm-1): ν = 3198 (br, N-H); 1597 (w, C=N); 1543 (s, C=C). EI+−MS (481.1034 
g.mol-1): m/z 481.08 ([M]+, 73 %). LCMS for C24H28ClFeN3S (481.1034 g.mol-1): m/z 482.1 
[M+H]+, tR = 4.207 min, > 99 %. 
 
6‒Chloro‒2‒[2‒(N'‒substituted aminomethyl)‒N‒ferrocenylmethyl(aminopropyl)trimethyl‒ 
silane]benzo[d]thiazole  (4.11) 
Compound 4.8 (0.0709 g, 0.122 
mmol); 3-aminopropyl(trimethyl)-
silane (0.180 mL, 1.07 mmol). Rf = 
0.66. Compound 4.11 was isolated 
as a yellow hydroscopic solid 
(0.0334 g, 52 %). 1H NMR (300.08 MHz, CDCl3): δ (ppm) = 8.42 (br s, 1H, NH); 7.49 (d, 
3JHH = 2.10 Hz, 1H, H−8); 7.45 (d, 3JHH = 8.40 Hz, 1H, H−5); 7.22 (dd, 4JHH = 2.10 Hz, 3JHH = 
8.40 Hz, 1H, H−7); 4.45−4.55 (m, 2H, H−10); 4.26−4.28 (m, 1H, C5H3); 4.11−4.14 (m, 6H, 
C5H3 & C5H5); 4.05 (t, 3JHH = 2.40 Hz, 1H, C5H3); 3.72 (d, 3JHH = 12.30 Hz, 1H, H−11); 3.48 
(d, 3JHH = 12.30 Hz, 1H, H−11); 2.56−2.71 (m, 2H, H−12); 1.49−1.60 (m, 2H, H−13); 0.51 (t, 
3JHH = 9.00 Hz, 2H, H−14); 0.017 (s, 9H, Si(CH3)3). 13C{1H} NMR (100.64 MHz, CDCl3): δ 
(ppm) = 166.3, 151.5, 131.8, 126.3, 126.1, 120.3, 119.2 (CAr); 85.1, 83.8 (Fcquat.); 70.4, 70.2, 
69.1, 65.9 (Fc); 52.6, 47.8, 43.9, 24.5, 14.3 (CH2); −1.68 (Si(CH3)3). FT−IR (ATR, cm-1): ν = 
3190 (br, N−H); 1597 (s, C=N); 1562 (s, C=C). EI+−MS (525.1116 g.mol-1): m/z 525.00 
([M]+, 93 %). LCMS for C25H32ClFeN3SiS (525.1116 g.mol-1): m/z 526.1 [M+H]+, tR = 4.710 
min, > 99 %. 
 
7.5  Ferrocenylamines 
General method for preparation of compounds 4.12 and 4.13 
The amine (1 eq.) was added to the Schlenk flask under N2, followed by the addition of 
ferrocenecarboxaldehyde and DCM (5.00 mL). The contents were heated at 35 ˚C for 5 hrs 
with the exclusion of light. The red solution was cooled to room temperature and MeOH (2.00 
mL) added. NaBH4 was slowly added to the solution, and the resulting orange solution was 
stirred at room temperature overnight. Water (20.0 mL) was added and the compound extracted 
using DCM (2 x 20.0 mL). The organic layer was collected, dried over Na2SO4 and the solvent 
removed.      
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N−(ferrocenylmethyl)−N−(trimethylsilyl)methanamine  (4.12) 
Ferrocenecarboxaldehyde (0.145 g, 0.678 mmol); 
(aminomethyl)trimethylsilane (0.100 mL, 0.747 mmol); 
NaBH4 (0.0509 g, 1.34 mmol). Compound 4.12 was isolated 
as a sticky orange solid (0.196 g, 96 %). 1H NMR (300.08 
MHz, CDCl3): δ (ppm) = 4.21 (t, 3JHH = 1.50 Hz, 2H, C5H4); 4.12 (s, 5H, C5H5); 4.11 (t, 3JHH 
= 1.50 Hz, 2H, C5H4); 3.52 (s, 2H, H‒1); 2.11 (s, 2H, H‒2); 0.057 (s, 9H, Si(CH3)3). 13C{1H} 
NMR (100.64 MHz, CDCl3): δ (ppm) = 87.1 (Fcquat.); 68.5, 68.3, 67.6 (Fc); 53.4, 40.0 (CH2); 
−2.51 (Si(CH3)3). FT−IR (ATR, cm-1): ν = 3093 (br, N−H). EI+−MS (301.0944 g.mol-1): m/z 
301.09 ([M]+, 73 %). Elemental analysis for C15H23FeNSi∙½H2O (307.04 g.mol-1): Found C 
58.75, H 7.55, N 4.19 %; Calculated C 58.62, H 7.77, N 4.56 %. 
 
N−(ferrocenylmethyl)−N−2,2−dimethylpropan−1−amine  (4.13) 
Ferrocenecarboxaldehyde (0.149 g, 0.696 mmol); 2,2’-
dimethylpropan-1-amine (0.0900 mL, 0.768 mmol); NaBH4 
(0.0578 g, 1.53 mmol). Compound 4.13 was isolated as an orange 
solid (0.188 g, 95 %). m.p.: 55.2−57.2 ˚C. 1H NMR (300.08 
MHz, CDCl3): δ (ppm) = 4.21 (t, 3JHH = 1.80 Hz, 2H, C5H4); 4.13 (s, 5H, C5H5); 4.11 (t, 3JHH 
= 1.80 Hz, 2H, C5H4); 3.52 (s, 2H, H‒1); 2.40 (s, 2H, H‒2); 0.93 (s, 9H, C(CH3)3). 13C{1H} 
NMR (100.64 MHz, CDCl3): δ (ppm) = 87.8 (Fcquat.); 68.4, 68.3, 67.5 (Fc); 62.2, 49.9 (CH2); 
31.5 (C(CH3)3); 27.8 (C(CH3)3). FT−IR (ATR, cm-1): ν = 3088 (br, N−H). EI+−MS (285.1174 
g.mol-1): m/z 285.02 ([M]+, 79 %). Elemental analysis for C16H23FeN∙⅕H2O (288.71 g.mol-1): 
Found C 66.83, H 8.46, N 4.63 %; Calculated C 66.50, H 8.17, N 4.85 %. 
 
7.6  DMSO and Aqueous Media Stability Studies 
A stability of the cyclopalladated complex 2.13 was monitored by NMR spectroscopy in 
DMSO−d6 and DMSO−d6:D2O (9:1, v/v) and the stability of the ferrocenyl−containing 
aminoquinoline 4.3 and aminobenzothiazole 4.11 was monitored in DMSO−d6:D2O (9:1, v/v). 
The 1H NMR spectra were recorded at 0 hr. The solution was warmed at 37 ˚C, and the 
stability monitored by 1H NMR spectroscopy at 24, 48 and 72 hr time intervals to confirm 
stability of compound during the in vitro assay time period. 
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7.7  Pharmacological Studies 
7.7.1  Antiplasmodial Assay 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were maintained 
using a modified method of Trager and Jensen.9 Quantitative assessment of antiplasmodial 
activity in vitro was determined via the parasite lactate dehydrogenase assay using a modified 
method described by Makler.10 Antiplasmodial assay was conducted according to previously 
published methods.10 A full dose-response was performed for all compounds to determine the 
concentration inhibiting 50% of parasite growth (IC50 value). Test samples were tested at a 
starting concentration of 100 μg/ml, which was then serially diluted 2-fold in complete medium 
to give 10 concentrations; with the lowest concentration being 0.2 μg/ml. Reference drugs were 
tested at a starting concentration of 1000 ng/ml. Active compounds were retested at starting 
concentrations of 10 μg/ml or 1000 ng/ml. The highest concentration of solvent to which the 
parasites were exposed had no measurable effect on the parasite viability (data not shown). The 
IC50 values were obtained using a non-linear dose-response curve fitting analysis via Graph 
Pad Prism v.4.0 software. 
 
7.7.2  Cytotoxicity Assay 
The MTT-assay is used as a colorimetric assay for cellular growth and survival, and compares 
well with other available assays.11,12 The test samples were tested in triplicate on one occasion. 
The same stock solutions prepared for the antiplasmodial activity testing were used for the 
cytotoxicity tests. Dilutions were prepared on the day of the experiment in complete medium. 
Emetine was used as the reference drug. The initial concentration of emetine was 100 μg/ml, 
which was serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, 
the lowest being 0.001 μg/ml. The same dilution technique was applied to the all test samples. 
The highest concentration of solvent to which the cells were exposed to had no measurable 
effect on the cell viability (data not shown). The IC50 values were obtained from full dose 
response curves, using a non-linear dose-response curve fitting analysis via GraphPad Prism 
v.4 software. 
 
7.7.3  β−Haematin Inhibition Assay  
The β-haematin inhibition assay was adapted from the method described by Wright and co-
workers.13 Compounds were prepared as a 10 mM stock solution in DMSO. The samples were 
tested at various concentrations between 5 and 500 μM. The stock solution was serially diluted 
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to give 12 concentrations in a 96 well flat-bottom assay plate. NP-40 detergent was added to 
mediate the formation of β-haematin (305.5 μM).  A 25 mM stock solution of haematin was 
prepared by dissolving haemin (16.3 mg) in dimethyl sulfoxide (1 mL). A 177.76 μL aliquot of 
haematin stock was suspended in 20 ml of a 2 M acetate buffer at pH 4.7. The suspension was 
then added to the plate to give a final haematin concentration of 100 μM. The plate was then 
incubated for 16 hours at 37°C. The assay was analysed using the pyridine-ferrochrome 
method developed by Ncokazi and Egan.14 32 μL of a solution of 50% pyridine, 20% acetone, 
20% water and 10% 2M HEPES buffer (pH 7.4) was added to each well. To this, 60 μL 
acetone was added to each well and mixed. The absorbance of the resulting complex was 
measured at 405 nm on a SpectraMax 340PC plate reader. The IC50 values were obtained using 
a non-linear dose-response curve fitting analysis via GraphPad Prism v.5.00 software. 
 
7.7.4  Metabolic Stability Study 
A single-point microsomal stability assay was conducted in 96-well format to determine the 
microsomal clearance of the compounds.17 Test compounds and controls were prepared from 
10 mM DMSO stock solutions. 0.40 mg protein/mL microsomes (pooled Human mixed 
gender, male Mouse BALB/c; Xenotech) were incubated with 1 µM test compound at 37 °C. 
Metabolic reactions were initiated by the addition of NADPH and the plates were incubated for 
30 min. The reactions were quenched with acetonitrile containing carbamazepine as internal 
standard. The centrifuged and filtered samples were analysed by HPLC–MS/MS and the 
analyte:internal standard ratio at T30 compared to that at T0 to determine % compound 
remaining. Control standards (midazolam and propranolol) were included in the assay to 
provide quality control and an indication of the metabolic capacity of the microsomes used. 
 
7.7.5  Antitrichomonal Assay 
Cultures of the G3 strain of T. vaginalis were grown in 5 ml complete TYM Diamond’s media 
in a 37 oC incubator for 24 hr. 50 mM stocks of the compounds were made by dissolving in 
DMSO and were screened against G3 strain of T. vaginalis. Untreated cells and those 
inoculated with 5 μl DMSO (0.1%) were used as controls. 5 μL of 50 mM stocks of the 
compound library were inoculated for a final concentration of 50 μM. Results were calculated 
based on cell counts utilising a haemocytometer after 24 hr. IC50 values were determined using 
serial dilution of the compounds and the calculated IC50 values confirmed using the same assay 
described above. 
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7.7.6  Antitumour Assay  
Cytotoxicity (WST-1) Assay 
Human A2780 and A2780cisR ovarian cancer cells and KMST‒6 human fibroblast skin cells 
were obtained from the European Collection of Cell Cultures (Salisbury, UK). A2780 and 
A2780cisR cells were grown routinely in RPMI−1640 medium and the KMST−6 cells in 
DMEM medium. Both media supplemented with 10% fetal calf serum (FCS) and antibiotics 
(Penicillin Streptomycin) at 37 °C and 5% CO2. Cytotoxicity was determined using the WST-1 
[(4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio)-1,3-benzene disulfonate] assay. Cells 
were seeded in 96-well plates as monolayers with 100 μL of cell solution (approximately 5 000 
cells) per well and pre‒incubated for 24 hr in medium supplemented with 10% FCS. 
Compounds were prepared as DMSO solutions, dissolved in the culture medium and serially 
diluted to the appropriate concentration, to give a final DMSO concentration of 0.5%. 100 μL 
of drug solution was added to each well and the plates were incubated for another 24 hr. 
Subsequently, WST-1 (10 μL solution) was added to the cells and the plates were incubated for 
a further 3 hr. The WST-1 tetrazolium salt is cleaved to a soluble formazan by a cellular 
mechanism, succinate-tetrazolium reductase system (EC 1.3.99.1), which occurs primarily at 
the cell surface. This bioreduction depends largely on the cellular production of NAD(P)H 
within metabolically intact and viable cells. The optical density, directly proportional to the 
number of surviving cells, was quantified at 450 nm, and background correction was 
performed at 600 nm, using a multiwell plate reader and the fraction of surviving cells was 
calculated from the absorbance of untreated control cells. Evaluation is based on means from 
three microcultures per concentration level and analysed via GraphPad Prism v.5.00 software. 
 
Cytotoxicity (MTT) Assay 
The oesophageal cancer cell‒line WHCO1, derived from a primary oesophageal squamous cell 
carcinoma, was provided by Professor Rob Veale (University of the Witwatersrand, 
Johannesburg, South Africa). IC50 determinations were carried out using an MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.15 3000 cells were seeded per 
well in 96‒well plates. Plates were incubated at 37 °C under 5% CO2 (24 hours), after which 
aqueous DMSO solutions of each compound (10 μL, with a constant final concentration of 
DMSO of 0.2%) were plated at various concentrations. After 48 hours incubation, observations 
were made, and MTT (10 μL) solution added to each well. After 4 hours of incubation, 
solubilisation solution (100 μL) was added to each well, and incubated overnight. Plates were 
Chapter 7: Experimental Section 
 
160 
 
read at 595 nm on a BioTek microplate reader, and IC50 values calculated using Graph Pad 
Prism v.4.0. Package of GraphPad Software, San Diego, USA. 
 
7.7.7 Plasmodium Berghei infected Mouse Model  
Ethics statement 
Animal experiments were performed at the animal unit of the PK laboratory of the University 
of Cape Town, division of clinical pharmacology following the grant of ethical approval from 
the Animal Research Ethics Committee of the Faculty of Health Sciences of the University of 
Cape Town (project no. 013/028). 
 
Environmental Conditions for the Animals 
Male C57BL/6 mice 12 to 16 weeks old, weighing 25 to 35 g were obtained from the 
University of Cape Town`s animal unit. They were kept in cages (a maximum of 5 mice per 
cage) in a temperature−controlled room with a 12 hr day/night light cycle. Ample dried food 
and water were supplied, and their sanitation was monitored daily. The animals were 
acclimatised to the test environment for 3 to 4 days before the experiment started. 
 
In Vivo Toxicity Evaluation 
Three healthy male C57BL/6 mice (massaverage = 35 g) were administered doses of compound 
2.13 which were prepared in HPMC:DMSO (9:1; v/v). Each mouse received the dosage via 
oral gavage at their respective dose concentration and volumes as shown below: 
 
M1: 270 μL of 50 mg/kg (6.47 mg/mL) 
M2: 280 μL of 30 mg/kg (3.81 mg/mL) 
M3: 250 μL of 10 mg/kg (1.40 mg/mL) 
 
The mice received the above specified dose four times (0, 24, 48 & 72 hr) during the course of 
the experiment, and the weight of the mice monitored throughout. 
 
In Vivo Efficacy Evaluation 
Plasmodium berghei transfected with green fluorescence protein (strain ANKA), a 
chloroquine−sensitive strain, was stored in liquid nitrogen. Parasites were thawed and 
administered intraperitoneally (IP) to infect two donor mice a week before the experiment 
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commenced. Then the parasite−infected red blood cells (RBCs) were collected into heparinised 
tubes by tail bleeding and the parasitaemia was determined using flow cytometry (≥ 15%). 
Finally, each of the test animals received 200 μl of the P. berghei−infected RBCs (1×107 per 
200μl PBS) IP to infect them with the parasite. There were three animals per dose group, and 
each of them received the dosage via oral gavage at their respective dose concentration and 
volumes as shown below:  
Group A: the negative control group received 200 μL of the drug vehicle alone (placebo). 
Group B: the test group received 200 μL of 50 mg/kg (6.33 mg/ml) of compound 2.13 in 
HPMC: DMSO (9:1; v/v). Average mass of mice = 25 g. 
Group C: the positive control group received 240 μL of 20 mg/kg CQ (2.50 mg/ml, free base) 
in H2O. Average mass of mice = 30 g. 
The volumes were adjusted relative to the weight of the mouse. 
The test compound was administered to the animals once a day for four days. The first dose 
was administered 2 hr after infection, followed by the second, third and fourth dose at intervals 
of 24 hr. Blood samples were collected via tail bleeding in tubes containing PBS on day 5, and 
% parasitaemia was determined with FACSCalibur™ using the software CellQuestPro.16 
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